Free fatty acid receptor 4 responds to endogenous fatty acids to protect the heart from pressure overload
On-Line Supplement

Katherine A. Murphy, PhD[1], Brian A. Harsch, MS[2], Chastity L. Healy, BS[1], Sonal S. Joshi, PhD[1], Shue Huang, PhD[2], Rachel E. Walker, PhD[2], Brandon M. Wagner, BA[1], Katherine M. Ernste, BA[1], Wei Huang, MS[3], Robert C. Block, MD, MPH[4], Casey D. Wright, PhD[5], Nathan Tintle, PhD[6], Brian C. Jensen, MD[3], Quinn S. Wells, MD, PharmD[7], Gregory C. Shearer, PhD[2,*], and Timot6hy D. O'Connell, PhD[1,*].

[1]Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN

[2]Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA

[3]Division of Cardiology and McAllister Heart Institute, University of North Carolina, Chapel Hill, NC

[4]Department of Public Health Sciences, University of Rochester, NY

[5]Inanovate Inc., Sioux Falls, SD

[6]Department of Statistics, Dordt University, Sioux Center, IA

[7]Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN

[*]Correspondence to:

Timothy D. O'Connell, PhD
Department of Integrative Biology and Physiology
University of Minnesota School of Medicine
3-141 CCRB
2231 6th Street SE
Minneapolis, MN 55414
Email: tdoconne@umn.edu

-and-

Gregory C Shearer, PhD
Department of Nutritional Sciences
110 Chandlee Laboratory
University Park, PA 16802
gcs13@psu.edu

Methods

Mice

For this study, all experimental mice were placed on a control diet (described below) at 8 weeks of age. At 12 weeks, male and female, WT and Ffar4KO mice were randomized and enrolled into the study. For all experimental analyses, data collection was done with investigator blinded to genotype and treatment.

Ffar4KO mice were generated from cryopreserved sperm from C57Bl/6N-*Ffar4*$^{tm1(KOMP)Vlcg}$ (Design ID: 15078; Project ID: VG15078) purchased from The KOMP Repository, UC-Davis (Davis, CA, USA). Cryo-recovery of the mouse line was performed at the UMN Mouse Genetics Laboratory through *in vitro* fertilization (IVF) using C57Bl/6J female recipients (#000664; The Jackson Laboratory, Bar Harbor ME, USA). The line was maintained by hemizygous breeding to C57Bl/6J for backcrossing. Homozygous mice were crossed to produce wild type and knock out offspring. Genotype was determined by PCR using the primer design provided by KOMP Repository:

Cassette Primers:	Reg-NeoF: GCAGCCTCTGTTCCACATACACTTCA
	Reg-LacF: ACTTGCTTTAAAAAACCTCCCACA
Gene Specific Primers:	Reg-Ffar4-wtR: TGGAAGCCCTCCTCTGTGTTCG
	Reg-Ffar4-wtF: TTACAGCCAGGTGGGACACAGG

Diet

Since fatty acids are known agonists of Ffar4, we sought to control the fatty acid profile of the diet by feeding mice a custom chow from Dyets, Inc (#180539; Bethlehem, PA, USA) beginning at 8 weeks of age. This chow is a modified version of the AIN-93M purified rodent diet used in our previous studies, with corn oil replacing soybean oil (diet composition is listed in Supplemental Table 1).[1, 2]

Transverse Aortic Constriction (TAC)

Transverse aortic constriction (TAC) surgery was performed as previously described.[1-5] Baseline measurements of cardiac function by echocardiography were collected prior to surgery. For surgery, mice were anesthetized with 3% isoflurane and maintained at 1.5% isoflurane without intubation. A small incision was made slightly left of the midline and above the left clavicle without entering the pleural cavity. The muscle tissue and lobes of the thymus were retracted to expose the aortic arch. A 7-0 surgical suture was threaded under the aortic arch and tied-off against a small piece of a blunt 28-gauge needle followed by immediate removal of

the needle. To close the original incision, the muscle layer and skin were secured separately with 4-0 continuous sutures. Buprenorphine (0.1 mg/kg IP) was administered for pain management during the first 24 hours post-surgery and as needed thereafter. Sham surgery was identical except for ligation of the aorta. Pulsed-wave Doppler by echocardiography was used to confirm pressure gradients by evaluating aortic flow velocity (AoV, Supplemental Tables 3B and 4B) 7-days post-surgery at the site of constriction. Exclusion criterion were established prior to the study and based on surgical success. Mice were excluded from the study if they did not obtain a significant pressure gradient post-TAC, based on Pulsed-wave Doppler by echocardiographic flow measurements at the constriction, which was considered a failed surgery due to inability to ligate the aorta, or mice were excluded if they failed to thrive following surgery and lost significant weight, which was considered as a failed surgery due to injury at surgery. Using these criteria, three WT and three Ffar4KO mice were excluded from the study.

Cardiac function

Echocardiography was performed before TAC (baseline), 7-days post-TAC to measure aortic velocity (AoV) to validate the TAC surgery, and 4 weeks post-TAC using the Vevo 2100 (FujiFilm VisualSonics Inc. Toronto, ON, Canada) with a MS550 transducer. For all measurements, mice were anesthetized with isoflurane, gently restrained in the supine position on the prewarmed monitoring pad, and echocardiographic images were captured as mice were recovering from anesthesia to achieve a target heart rate (HR) of 450 – 500 bpm. Parasternal long axis M-mode images of the left ventricle were captured to measure left ventricular wall thicknesses (LVPWs: systolic left ventricular posterior wall; LVPWd: diastolic left ventricular posterior wall), left ventricular internal diameters (LVIDs: systolic left ventricular internal diameter; LVIDd: diastolic left ventricular internal diameter), left ventricular volumes (ESV: end systolic volume, $(7.0/(2.4 + LVIDs))*LVIDs^3$; EDV: end diastolic volume, $(7.0/(2.4 + LVIDd))*LVIDd^3$), fractional shortening (FS: 100*((LVIDd – LVIDs)/LVIDd)), ejection fraction (EF: 100*((EDV – ESV)/EDV)), stroke volume (SV: EDV – ESV), and cardiac output (CO: SV*HR). Pulsed-wave Doppler images of the aortic arch were recorded at the site of constriction to measure peak aortic velocity (AoV) and pressure gradient (PG: $(4*AoV^2)/1000$). Pulsed-wave Doppler images of the apical four-chamber view were taken to measure mitral flow velocities (E wave and A wave to calculate E/A ratio) as well as mitral annulus tissue velocity (E/E': peak early transmitral flow velocity/peak early diastolic mitral annular velocity).

Erythrocyte FA composition

At the study endpoint, blood from the posterior vena cava was collected into EDTA tubes. Red blood cell fractions were separated and analyzed for fatty acid composition as previously described.[1, 2] Briefly, 50 µL of isolated erythrocytes were methylated with 14% boron trifluoride in methanol by incubation for 10 minutes at 100°C. Fatty acid methyl esters were extracted in hexane and analyzed by a GC-2010 gas chromatography system fitted with a QP2010 mass spectrometer (Shimadzu, Japan) using a Supelco SP-2560 fused silica column (Supelco, Bellefonte, PA). Area counts were obtained using Shimadzu GCMSolution software with multiple ion counts of characteristic fatty acids ions. Each fatty acid was quantified as mass percent of total fatty acids. In general, only minor differences in red blood cell fatty acid composition were detected between WT and Ffar4KO following TAC (Supplemental Table 2A and 2B).

Tissue histology

Four weeks after TAC surgery, hearts were arrested in diastole with 60mM KCl, excised, and weighed. Extracted hearts were cannulated and perfused with PBS with 60mM KCl, followed by 4% paraformaldehyde. The atria were removed from the fixed hearts prior to embedding in paraffin. Sectioning was performed by AML Laboratories (Jacksonville, FL) providing a transverse view of the ventricles. Lungs were also collected and lung weights were recorded.

Paraffin embedded ventricular sections were deparaffinized with xylene and rehydrated in ethanol. Sections were stained in 0.1% solution of Sirius red (direct red 80, Sigma-Aldrich, St Louis, MO) and fast green (Sigma-Aldrich) in 1.2% picric acid (Ricca Chemical Company, Arlington, TX), followed by dehydration in ethanol and xylene. Sections were imaged at 4x magnification. Ventricular fibrosis (as percent of total ventricular area) was quantified using Fiji software (NIH).[1, 2] Ventricular fibrosis was quantified using images captured at 4X magnification and included both the right and left ventricle. The threshold settings were adjusted to highlight and calculate the total tissue area or picrosirius red positively stained area.

Isolation and culture of adult cardiac myocytes

We previously described procedures for the isolation and culture of adult mouse cardiac myocytes.[6] Here, myocytes were isolated 3-days post-TAC from male WT and Ffar4KO, sham and TAC operated mice for analysis of myocyte transcriptomes, or were cultured from WT and Ffar4KO hearts for analysis of Ffar4 signaling. Briefly, mice were anesthetized with isoflurane

(3% for induction, 1.5% for maintenance), injected with heparin (100 IU/mL), the pleural cavity was opened and the heart removed, cannulated on a retrograde perfusion apparatus, and perfused with collagenase type II (Worthington Biochemical Corp, Lakewood, NJ) to dissociate ventricular myocytes. Isolated cardiac myocytes were plated at a density of 50 rod-shaped myocytes per square millimeter on laminin-coated culture dishes. Myocytes were cultured in MEM with Hank's Balanced Salt Solution, 1 mg/ml bovine serum albumin, 10 mM 2,3-butanedione monoxime, and 100 U/ml Penicillin in a 4.5% CO_2 incubator (%CO_2 determined empirically to maintain culture medium at pH 7.0) at 37°C. All reagents were purchased from Millipore Sigma (Burlington, MA, USA) unless otherwise specified. Full details of the buffers, enzymes, cell culture medium, all procedures for isolation and culturing of adult mouse ventricular myocytes (AMVM) and a detailed diagram of the perfusion apparatus were described in detail previously.[6] Based on our previous experience, myocyte isolation are ~95% pure, but we cannot exclude the possibility of minimal contamination with fibroblasts and endothelial cells.[6] Following plating, myocytes were counted at a magnification of 20X to determine cell viability, and myocytes were incubated in a 4.5% CO_2 incubator at 37°C overnight. For analysis of Ffar4 signaling, cardiac myocytes were treated with the Ffar4 agonist TUG-891(Cayman Chemical, MI, USA) (50 μM) for 0-60 minutes.

RNA-seq:

Three days after surgery, cardiac myocytes were isolated from WT sham (n=4), WT TAC (n=5), Ffar4KO sham (n=4) and Ffar4KO TAC (n=8) male mice. RNA was isolated using RNeasy Fibrous Tissue Mini Kit (Qiagen). Dual-indexed Clontech Pico Mammalian stranded RNA libraries were made. 125bp paired end sequencing was performed using the HiSeq 2500 sequencer (Illumina) by the University of Minnesota Genomics Center.

Data was analyzed by the University of Minnesota Informatics Institute. 2 X 125bp FastQ paired end reads (n=8.4 Million average per sample) were trimmed using Trimmomatic (v 0.33) enabled with the optional "-q" option; 3bp sliding-window trimming from 3' end requiring minimum Q30. Quality control on raw sequence data for each sample was performed with FastQC. Read mapping was performed via Hisat2 (v2.1.0) using the mouse genome (mm10) as reference. Gene quantification was done via Cuffquant for FPKM values and Feature Counts for raw read counts. Differentially expressed genes were identified using the edgeR (negative binomial) feature in CLC Genomics WorkBench (CLCGWB) (Qiagen, Redwood City, CA) using raw read counts. We filtered the generated list based on a minimum 1.7X Absolute Fold Change and FDR corrected $p < 0.05$. Two lists were generated of differentially expressed genes from 1.)

WT sham compared to WT TAC animals (2789 genes) and 2.) Ffar4KO sham compared to Ffar4KO TAC animals (1656 genes). The lists were compared to each other to identify genes that overlapped between the two lists to identify common genes (1409) and those genes that were unique to the WT mice (1380 genes) and Ffar4KO mice (247 genes). The genes were further annotated in CLCGW based on Gene Ontology (GO) terms for biological function from MGI. Genes were further sorted based on the indicated GO Terms into nine categories.

Principal component analyses used CPMs that were filtered based on gene size (excluding genes less than 200bp) and variance less than 1 in raw read counts. The actual cpm values are log2 transformed and plotted using the PCA function in R.

TUG-891 effects on cardiac gene expression

To assess the effects of Ffar4 on cardiac gene expression, 12-week-old male WT mice were injected IP with either TUG-891 (35 mg/kg) or DMSO vehicle once daily for three days. Twenty-four hours after the third injection, hearts were harvested, RNA was isolated using the RNeasy Fibrous Tissues Mini Kit (Qiagen). RNA was reverse transcribed with qScript cDNA SuperMix (Quantabio), and qRT-PCR was performed with Bio-Rad's iTaq Universal SYBR Green SuperMix and CFX96 Real-Time System.

Primer sequences used:
arg1 forward: CTCCAAGCCAAAGTCCTTAGAG
arg1 reverse: AGGAGCTGTCATTAGGGACATC

hmox1 forward: AAGCCGAGAATGCTGAGTTCA
hmox1 reverse: GCCGTGTAGATATGGTACAAGGA

ptgs2 forward: TGAGCAACTATTCCAAACCAGC
ptgs2 reverse: GCACGTAGTCTTCGATCACTATC

pik3r5 forward: TGCTCTGGAGCGATGCTTG
pik3r5 reverse: ACCTCTTGGGTCTTTTGTAGGA

cxcl5 fwd: TGCGTTGTGTTTGCTTAACCG
cxcl5 rvs: CTTCCACCGTAGGGCACTG

pak3 fwd: CTGAGGATGAACAGTAACAACCG
pak3 rvs: CTGGGAAGATAGAGCGAAGCC

il1rn fwd: GCTCATTGCTGGGTACTTACAA
il1rn rvs: CCAGACTTGGCACAAGACAGG

timp1 fwd: CGAGACCACCTTATACCAGCG
timp1 rvs: ATGACTGGGGTGTAGGCGTA

Oxylipins

Plasma lipoproteins were separated by FPLC followed by measurement of esterified oxylipin (HDL, LDL, and VLDL) or unesterified (albumin). 150 μL of mouse EDTA plasma was thawed and filtered by centrifugation at 10,000 g for 5 min using Ultrafree Durapore PVDF filter (pore-size 0.2 μM; Millipore, Bedford, MA). The filtrate was then injected onto an AKTA Purifier FPLC (Amersham Biosciences, Sweden) and run at a flow rate of 0.5 mL/min in 1mM EDTA, 0.9% NaCl saline solution, pH 7.4 using an additional 100 μL of phosphate buffer solution to fill injection loop. Elutions were monitored at a UV absorbance of 280 nm and lipoproteins were separated using a Superose-6 10/300 GL size exclusion column. Fractions were collected every 0.5 min using a Foxy 200 fraction collector and were pooled for each lipoprotein fraction and stored at -80 °C. VLDL, LDL, HDL, and albumin fractions (100 μL) were spiked with BHT/EDTA (0.2 mg/mL), four deuterated octadecanoid and eicosanoid surrogates (20 μL of 1000 nM concentration with final concentration of 50 nM after reconstitution) and subjected to liquid-liquid extraction to isolate lipid content. Samples were then hydrolyzed in 0.1 M methanolic sodium hydroxide to release ester-linked oxylipins and subjected to solid phase extraction using Chromabond HLB sorbent columns (Machery Nagel, Duren, Germany). Oxylipins were eluted with 0.5 mL of methanol with 0.1% acetic acid and 1 mL of ethyl acetate and dried under nitrogen stream and reconstituted in 200 μL methanol acetonitrile (1:1) with 100 nM of 1-cyclohexyluriedo-3-dodecanoic acid used as internal standard.

Samples were analyzed by liquid chromatography using a Waters Acquity UPLC coupled to Waters Xevo triple quadrupole mass spectrometer equipped with electrospray ionization source (Waters, Milford, MA). 5 μL of the extract was injected and separation was performed using a CORTECS UPLC C18 2.1 x 100 mm with 1.6 μM particle size column. Flow rate was set at 500 μL/min and consisted of a gradient run using water with 0.1% acetic acid (Solvent A) and acetonitrile isopropanol, 90:10 (Solvent B) for 15 minutes (0-12 min from 25% B to 95% B, 12-12.5 min 95% B, 12.5-15 min 25% B). Electrospray ionization operated in negative ion mode with capillary set at 2.7 kV, desolvation temperature set at 600 °C, and source temp set to 150°C. Optimal oxylipin MRM transitions were identified by direct injection of pure standards onto the mass spectrometer and using cone voltage and collision energy ramps to optimize detection and most prevalent daughter fragments. Calibration curves were generated prior to each run using standards for each oxylipin. Peak detection and integrations were achieved through Target Lynx (Waters, Milford, MA) and each peak inspected for accuracy and corrected when needed.

Cardiac myocyte cell death

Cardiac myocyte death was measured as described previously.[7] Cardiac myocytes were cultured overnight and treated with TUG-891 (10 μM) (Cayman Chemical, Ann Arbor, MI) or 18-HEPE (100 nM) (Cayman Chemical) as indicated. Cell death was induced with H_2O_2 (10 mM) (Sigma Aldrich, St. Louis, MO), as we described previously.[7] For each condition, at least 150 myocytes were counted in 5 randomly selected fields. Based on our prior studies, cell death was measured by comparing rod versus round morphology, as we have found that this replicates other measures of cell death, including annexin V/PI staining and staining with the mitochondrial membrane permeability stain JC-I.[4, 7-9]

RT-PCR for Ffar4 and Ffar1 expression in heart

Ventricular myocardium was obtained from non-failing and failing human hearts through the Duke Human Heart Repository (DHHR) as previously described.[10] Briefly, failing human myocardium was acquired from the left ventricular free wall of explanted hearts following cardiac transplantation. Non-failing left ventricular tissue was acquired from donors whose hearts were not utilized for transplant with permission from Carolina Donor Services. No HIPAA information was provided with any of the samples used in this study. Approximately 20-40 mg of human ventricular myocardium was homogenized in 1 mL of Trizol (Life Technologies #15596-026, Carlsbad, CA) with a TissueLyser LT (Qiagen N.V. #69980, Venlo, The Netherlands). The lysate centrifuged at 12,000g (15 min at 4°C) after the addition of chloroform (200 μL). Isopropanol (0.5 mL) was then added to the aqueous phase, centrifuged at 12,000 g (10 min at 4°C). The resulting RNA pellet was washed with 1 mL of 75% ethanol, then centrifuged at 7500 g (5 min at 4°C) and resuspended in RNase-free water.

Primers used to detect human Ffar4:

hFfar4: gctcatctggggctattcg

hFfar4: gcssstcgaaatttcctggt

(The above primers detected Ffar4S (NM_001195755.1) and Ffar4L (NM_181745.3).)

hFfar4 aagagctgtcgtgactcacagt (unique for Ffar4L, position 720 - 741)

hFfar4 aagagggtgcggaagagc

Note: Using these primers, PCR reactions will detect Ffar4S+Ffar4L or only Ffar4L, but not Ffar4S alone.

Genetic Proxy for FFAR4 Inhibition, Genotyping, and Human Echocardiography Cohort Development

We used the *FFAR4* R270H coding mutation (rs116454156) as a genetic proxy for Ffar4 inhibition. The R270H polymorphism has previously been associated with morbid obesity in a European population (OR [95% CI]: 1.62 [1.31, 2.00], P=8.00x10^{-6} [11]). Furthermore, functional analysis of Ffar4 R270H signaling in cell culture indicated that this polymorphism does not signal, and equimolar expression of the R270H with WT receptor to mimic haploinsufficiency reduced signaling by approximately 50%.[11]

Clinical and genotype information were derived from BioVU, the Vanderbilt University Medical Center (VUMC) biorepository that links de-identified electronic health records to DNA samples and genetic data.[12] Echocardiographic parameters were extracted from clinical transthoracic echocardiography (TTE).[13] Genotyping was performed using the Illumina HumanExome BeadChip array v.1.0 (http://genome.sph.umich.edu/wiki/Exome_Chip_Design) with standard quality control filters applied at both the individual and genotype level.[14] This platform contains ~250,000 single nucleotide polymorphisms (SNPs), including the *FFAR4* R270H variant.

The study cohort included adults of European ancestry who had undergone clinically indicated transthoracic echocardiography (TTE) and were previously genotyped as part of several BioVU research initiatives.

Statistics

Cardiac phenotyping was analyzed using an independent samples, Welch's t-test, comparing WT TAC mice to Ffar4KO TAC mice, to test the hypothesis that the Ffar4KO would have different cardiac phenotypes when under TAC, versus the WT, and to account for the unequal variances observed between the sham and TAC groups. Data from cell death experiments were analyzed with a two-way or three-way ANOVA followed by a Tukey post-hoc analysis as indicated. Where specified, principal components analysis (PCA) was used for dimension reduction of oxylipin matrices on log-transformed, standardized concentrations. Mixed models were used to account for within mouse time-dependent changes in oxylipins. Statistical significance was set at 0.05; Tukey's test was used to test for specified post-hoc differences using JMP version 13.2.1. Multiple linear regression was used to evaluate the association between *FFAR4* R270H and echocardiographic parameters adjusting for sex and age at echocardiogram. All subjects were of European descent. Bonferroni correction was applied to

account for multiple testing (two phenotypes), meaning that a *P* value less than 0.025 was considered statistically significant (0.05/2).

Study Approvals

Animal: All procedures on animals conformed to the NIH Guide for the Care and Use of Laboratory Animals and were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Minnesota.

Human: All tissue samples and data used in this study were deidentified. Heart tissue was collected by and subsequently obtained from the Duke Human Heart Repository and approved by the Duke University Institutional Review Board. All analyses of human derived echocardiographic data were approved by the Vanderbilt University Medical Center Institutional Review Board. The present study complies with the Declaration of Helsinki.

Additional compliance statements: For all surgeries, mice were anesthetized by induction with 3% isoflurane, and once anesthesia was induced, mice were maintained at 1.5% isoflurane, and verified by toe-pinch. Post-surgery, buprenorphine (0.1 mg/kg IP) was administered for pain management during the first 24 hours post-surgery and as needed thereafter. At the indicated time points post-surgery or for the isolation of cardiac myocytes, mice were anesthetized with 3% isoflurane, verified by toe-pinch, followed by removal of the heart in accordance with recommendations from the American Veterinary Medical Association. Finally, the data underlying this article are available in the article and in its online supplementary material.

References

1. Chen J, Shearer GC, Chen Q, Healy CL, Beyer AJ, Nareddy VB, Gerdes AM, Harris WS, O'Connell TD and Wang D. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. *Circulation*. 2011;123:584-93.
2. Eclov JA, Qian Q, Redetzke R, Chen Q, Wu SC, Healy CL, Ortmeier SB, Harmon E, Shearer GC and O'Connell TD. EPA, not DHA, prevents fibrosis in pressure overload induced heart failure; potential role of free fatty acid receptor 4. *J Lipid Res*. 2015;56:2297-2308.
3. O'Connell TD, Ishizaka S, Nakamura A, Swigart PM, Rodrigo MC, Simpson GL, Cotecchia S, Rokosh DG, Grossman W, Foster E and Simpson PC. The alpha(1A/C)- and alpha(1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. *J Clin Invest*. 2003;111:1783-1791.
4. O'Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turnbull L, Tecott LH, Baker AJ, Foster E, Grossman W and Simpson PC. Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. *J Clin Invest*. 2006;116:1005-15.
5. Nakamura A, Rokosh DG, Paccanaro M, Yee RR, Simpson PC, Grossman W and Foster E. LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. *Am J Physiol Heart Circ Physiol*. 2001;281:H1104-12.
6. O'Connell TD, Rodrigo MC and Simpson PC. Isolation and culture of adult mouse cardiac myocytes. *Methods Mol Biol*. 2007;357:271-96.
7. Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC and O'Connell TD. An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. *Circulation*. 2007;115:763-72.
8. Dahl EF, Wu SC, Healy CL, Perry J and O'Connell TD. ERK mediated survival signaling is dependent on the Gq-G-protein coupled receptor type and subcellular localization in adult cardiac myocytes. *J Mol Cell Cardiol*. 2018.
9. Huang Y, Wright CD, Kobayashi S, Healy CL, Elgethun M, Cypher A, Liang Q and O'Connell TD. GATA4 is a survival factor in adult cardiac myocytes but is not required for {alpha}1A-adrenergic receptor survival signaling. *Am J Physiol*. 2008;295:H699-707.
10. Schechter MA, Hsieh MK, Njoroge LW, Thompson JW, Soderblom EJ, Feger BJ, Troupes CD, Hershberger KA, Ilkayeva OR, Nagel WL, Landinez GP, Shah KM, Burns VA, Santacruz L, Hirschey MD, Foster MW, Milano CA, Moseley MA, Piacentino V, 3rd and

Bowles DE. Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure. *PLoS One*. 2014;9:e104157.

11. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, Kimura I, Leloire A, Liu N, Iida K, Choquet H, Besnard P, Lecoeur C, Vivequin S, Ayukawa K, Takeuchi M, Ozawa K, Tauber M, Maffeis C, Morandi A, Buzzetti R, Elliott P, Pouta A, Jarvelin MR, Korner A, Kiess W, Pigeyre M, Caiazzo R, Van Hul W, Van Gaal L, Horber F, Balkau B, Levy-Marchal C, Rouskas K, Kouvatsi A, Hebebrand J, Hinney A, Scherag A, Pattou F, Meyre D, Koshimizu TA, Wolowczuk I, Tsujimoto G and Froguel P. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. *Nature*. 2012;483:350-4.
12. Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR and Masys DR. Development of a large-scale de-identified DNA biobank to enable personalized medicine. *Clin Pharmacol Ther*. 2008;84:362-9.
13. Wells QS, Farber-Eger E and Crawford DC. Extraction of echocardiographic data from the electronic medical record is a rapid and efficient method for study of cardiac structure and function. *J Clin Bioinforma*. 2014;4:12.
14. Guo Y, He J, Zhao S, Wu H, Zhong X, Sheng Q, Samuels DC, Shyr Y and Long J. Illumina human exome genotyping array clustering and quality control. *Nat Protoc*. 2014;9:2643-62.

Supplemental Tables and Figures

Supplemental Figure 1: Ffar4 is not necessary for an adaptive respone to TAC in female mice.



Supplemental Figure 1. Four weeks following TAC or sham surgery, cardiac function was measured by echocardiography and mice were euthanized and hearts were collected for morphological analysis. All data shown are for female wild-type (WT) and Ffar4KO (KO) mice **A**, Heart weight (HW). **B,** Ventricular fibrosis quantified by fibrotic area (Sirius red)/total ventricular area (Fast green). **C,** Ejection fraction (EF, %). **D**, E/A ratio. **E,** end diastolic volume (EDV) **F,** end systolic volume (ESV) Data were compared by a Welch's two sample t test. Error bars represent the mean with SD.

Supplemental Figure 2: Cytoplasmic phospholipase $A_2\alpha$-dependent synthesis of enzymatically produced oxygenated fatty acids

A.



B.

	Cox	Lox	Cyp_{hyd}	Cyp_{epox}
EPA Anti-inflammatory	PG_3 HEPEs E-Resolvins (18-HEPE, AcCox)	HEPEs LTB_5	HEPEs EpETEs E-Resolvins	
DHA Anti-inflammatory	Protectins D-Resolvins 1-4	HDHAs Protectins D-Resolvins 1-6 Maresins	HDoHEs EpEPE, DiHDPE	
AA Pro-inflammatory	PG_2	HETEs LTB_4	HETEs EET	

Supplemental Figure 2. A. In cells, activation of cytoplasmic phospholipase $A_2\alpha$ facilitates the production of enzymatically-modified oxygenated fatty acids (FA), or oxylipins, with pro-inflammatory, anti-inflammatory, or pro-resolving effects. $cPLA_2\alpha$ is activated by upstream signaling cascades, in this example Ffar4. Upon activation $cPLA_2\alpha$ translocates to the nucleus and cleaves FAs from the sn-2 position of membrane phospholipids. Released FAs, most

commonly thought to be arachadonic acid (AA), but can be any FA, including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or linoleic acid (LA), can then be further oxidatively modified by cyclooxygenases (Cox), lipoxygenases (Lox), cytochrome P450 hydroxylases or cytochrome P450 epoxygenases. These oxygenated FAs, or oxylipins, can undergo one of four fates; 1. Sequestration back into cellular membranes, 2. Left free in the intracellular space to act as intracellular signaling molecules or be further enzymatically modified, for example the modification of 18-HEPE to produce E-resolvins; 3. Exported from the cell in lipoproteins, primarily HDL, 4. Exported as a free oxylipin. B. Oxylipins are classified by their parent FA (AA, EPA, DHA, …) and by the enzyme that produced each specific class of oxylipin. The table indicates oxylipin class defined by the parent FA.

Supplemental Figure 3: 18-HEPE is elevated in HDL from female versus male Ffar4KO mice, but significantly lower than 18-HEPE in HDL from WT mice.



Supplemental Figure 3. Plasma was collected 4 weeks following TAC or sham surgery, and 18-HEPE in HDL was detected by liquid chromatography/mass spectrometry. Fold-differences (95%CIs) are shown.

Supplemental Table 1. DYETS, Inc #180539 Chow Composition Table

Ingredient	kcal/gm	grams/kg	kcal/kg
Casein	3.58	140	501
Sucrose	4	100	400
Cornstarch	3.6	466	1676
Dyetrose	3.8	155	589
L-Cystine	4	1.8	7.2
Cellulose	0	50	0
Corn Oil	9	40	360
t-Butylhydroquinone	0	0.008	0
Mineral Mix #210050	0.84	35	29.4
Vitamin Mix #310025	3.87	10	38.7
Choline Bitartrate	0	2.5	0
TOTALS		**1000.00**	**3601**

Supplemental Table 2A. Male fatty acid levels 4 weeks post-TAC measured by mass spectrometry.

Fatty Acid (abbreviation)	WT Sham (12)	KO Sham (11)	WT TAC (24)	KO TAC (20)
C22:6n3 (DHA)	3.56 ± 0.76	3.59 ± 0.93	3.76 ± 0.74	3.71 ± 0.92
C22:5n3 (n3DPA)	0.27 ± 0.04	0.29 ± 0.05	0.31 ± 0.16	0.25 ± 0.08
C22:5n6 (n6DPA)	2.38 ± 0.70	1.92 ± 0.39	2.31 ± 0.57	2.21 ± 0.66
C22:4n6 (n6DTA)	2.17 ± 0.39	1.98 ± 0.43	2.10 ± 0.58	2.06 ± 0.63
C20:5n3 (EPA)	0.12 ± 0.07	0.13 ± 0.11	0.24 ± 0.25	0.13 ± 0.08*
C20:4n6 (AA)	12.91 ± 2.00	12.94 ± 2.91	12.40 ± 2.46	12.74 ± 2.94
C20:3n6 (dgLA)	1.42 ± 0.28	1.40 ± 0.39	1.49 ± 0.32	1.42 ± 0.43
C20:2n6 (EDA)	0.24 ± 0.05	0.21 ± 0.08	0.32 ± 0.21	0.20 ± 0.09
C18:3n3 (aLA)	0.12 ± 0.09	0.13 ± 0.11	0.14 ± 0.17	0.16 ± 0.09
C18:3n6 (gLA)	0.07 ± 0.06	0.10 ± 0.13	0.16 ± 0.38	0.14 ± 0.22
C18:2n6 (LA)	11.96 ± 1.11	11.26 ± 1.98	11.47 ± 1.63	11.59 ± 2.58
C20:1n9 (EA)	0.41 ± 0.14	0.33 ± 0.14	0.50 ± 0.14	0.39 ± 0.21
C24:0 (LgA)	0.22 ± 0.16	0.26 ± 0.15	0.33 ± 0.32	0.24 ± 0.16
C20:0 (ArcA)	0.18 ± 0.08	0.27 ± 0.26	0.32 ± 0.35	0.26 ± 0.19
C18:1n7 (VA)	2.04 ± 0.44	1.89 ± 0.33	2.36 ± 0.35	2.23 ± 0.59
C18:1n9 (OA)	12.55 ± 1.00	12.54 ± 1.22	13.21 ± 1.58	12.33 ± 1.69
C18:1n12	0.10 ± 0.05	0.10 ± 0.96	0.13 ± 0.12	0.14 ± 0.11
C18:1t (EIA)	0.24 ± 0.22	0.26 ± 0.27	0.23 ± 0.24	0.30 ± 0.27
C18:0 (SA)	14.58 ± 1.41	14.10 ± 1.66	13.68 ± 1.43	13.78 ± 1.89
C17:0	0.31 ± 0.05	0.51 ± 0.58	0.53 ± 0.78	0.52 ± 0.72
C16:1n7 (POA)	0.79 ± 0.25	0.95 ± 0.28	0.94 ± 0.25	1.09 ± 0.51
C16:0 (PA)	32.45 ± 2.26	33.69 ± 2.30	32.04 ± 1.88	33.13 ± 1.84*
C15:0	0.37 ± 0.49	0.24 ± 0.23	0.23 ± 0.17	0.27 ± 0.20
C14:0 (MA)	0.32 ± 0.16	0.39 ± 0.41	0.39 ± 0.32	0.35 ± 0.22
C12:0 (LA)	0.24 ± 0.28	0.50 ± 1.08	0.43 ± 1.06	0.62 ± 1.48

Data are presented as mean ± standard deviation for the number of mice indicated in parentheses. DHA, docosahexaenoic acid; n3DPA, n-3 docosapentaenoic acid (clupanodionic acid); n6DPA, n-6 docosapentaenoic acid (osbond acid); n6DTA, adrenic acid; EPA, eicosapentaenoic acid; AA, arachidonic acid; dgLA, dihomo-gamma-linolenic acid; EDA, eicosadienoic acid; aLA, alpha-linolenic acid; gLA, gamma-linolenic acid; LA, linoleic acid; EA, eicosenoic acid; LgA, lignoceric acid; ArcA, arachidic acid; VA, cis-vaccenic acid; OA, oleic acid; EIA, elaidic acid; SA, stearic acid; POA, palmitoleic acid; PA, palmitic acid; MA, myristic acid; LA, lauric acid. * Indicates $P<0.05$ vs WT TAC.

Supplemental Table 2B. Female fatty acid levels 4 weeks post-TAC measured by mass spectrometry.

Fatty Acid (abbreviation)	WT Sham (12)	KO Sham (12)	WT TAC (31)	KO TAC (25)
C22:6n3 (DHA)	4.59 ± 0.54	4.69 ± 0.50	4.19 ± 0.36	4.21 ± 0.89
C22:5n3 (n3DPA)	0.21 ± 0.05	0.22 ± 0.06	0.24 ± 0.07	0.26 ± 0.20
C22:5n6 (n6DPA)	2.34 ± 0.33	2.02 ± 0.45	2.46 ± 0.45	2.15 ± 0.54*
C22:4n6 (n6DTA)	2.56 ± 0.22	2.33 ± 0.48	2.42 ± 0.25	2.22 ± 0.49
C20:5n3 (EPA)	0.17 ± 0.14	0.10 ± 0.05	0.21 ± 0.15	0.13 ± 0.19
C20:4n6 (AA)	14.42 ± 1.60	14.73 ± 1.95	13.90 ± 1.41	13.87 ± 2.58
C20:3n6 (dgLA)	1.30 ± 0.20	1.21 ± 0.29	1.32 ± 0.19	1.16 ± 0.33*
C20:2n6 (EDA)	0.22 ± 0.07	0.16 ± 0.07	0.27 ± 0.07	0.21 ± 0.15
C18:3n3 (aLA)	0.10 ± 0.14	0.06 ± 0.04	0.08 ± 0.06	0.11 ± 0.19
C18:3n6 (gLA)	0.05 ± 0.03	0.03 ± 0.03	0.06 ± 0.06	0.07 ± 0.08
C18:2n6 (LA)	10.92 ± 1.34	10.56 ± 1.16	10.37 ± 0.96	10.37 ± 1.69
C20:1n9 (EA)	0.29 ± 0.11	0.18 ± 0.13	0.41 ± 0.09	0.23 ± 0.14*
C24:0 (LgA)	0.25 ± 0.12	0.20 ± 0.11	0.31 ± 0.19	0.27 ± 0.24
C20:0 (ArcA)	0.17 ± 0.09	0.12 ± 0.05	0.22 ± 0.12	0.17 ± 0.27
C18:1n7 (VA)	1.83 ± 0.28	1.40 ± 0.36	2.14 ± 0.32	1.86 ± 0.48*
C18:1n9 (OA)	13.42 ± 1.74	13.07 ± 0.62	14.12 ± 0.80	13.22 ± 1.92*
C18:1n12	0.09 ± 0.05	0.08 ± 0.03	0.12 ± 0.08	0.18 ± 0.35
C18:1t (EIA)	0.16 ± 0.12	0.14 ± 0.09	0.20 ± 0.14	0.23 ± 0.30
C18:0 (SA)	15.52 ± 1.36	15.68 ±1.51	15.39 ± 1.63	15.60 ± 2.49
C17:0	0.25 ± 0.05	0.25 ± 0.06	0.36 ± 0.21	0.29 ± 0.16
C16:1n7 (POA)	0.71 ± 0.20	0.50 ± 0.13	0.83 ± 0.46	0.65 ± 0.22
C16:0 (PA)	29.88 ± 1.70	31.84 ± 1.67	29.62 ± 1.78	31.73 ± 1.81*
C15:0	0.20 ± 0.20	0.12 ± 0.04	0.22 ± 0.18	0.19 ± 0.22
C14:0 (MA)	0.30 ± 0.10	0.22 ± 0.05	0.38 ± 0.28	0.39 ± 0.45
C12:0 (LA)	0.12 ± 0.11	0.10 ± 0.04	0.18 ± 0.16	0.28 ± 0.58

Data are presented as mean ± standard deviation for the number of mice indicated in parentheses. DHA, docosahexaenoic acid; n3DPA, n-3 docosapentaenoic acid (clupanodionic acid); n6DPA, n-6 docosapentaenoic acid (osbond acid); n6DTA, adrenic acid; EPA, eicosapentaenoic acid; AA, arachidonic acid; dgLA, dihomo-gamma-linolenic acid; EDA, eicosadienoic acid; aLA, alpha-linolenic acid; gLA, gamma-linolenic acid; LA, linoleic acid; EA, eicosenoic acid; LgA, lignoceric acid; ArcA, arachidic acid; VA, cis-vaccenic acid; OA, oleic acid; EIA, elaidic acid; SA, stearic acid; POA, palmitoleic acid; PA, palmitic acid; MA, myristic acid; LA, lauric acid. * Indicates $P<0.05$ vs WT TA

Supplemental Table 3A. **Male** morphological parameters 4 weeks post-TAC.

MORPHOLOGICAL	WT SHAM (12)	KO SHAM (11)	WT TAC (24)	KO TAC (20)
HW (mg)	142.3 ± 21.1	137.2 ± 12.8	196.6 ± 42.1	228.9 ± 45.8*
BW (g)	27.3 ± 2.2	27.1 ± 1.1	26.4 ± 1.3	26.3 ± 2.1
HW/BW (mg/g)	5.2 ± 0.7	5.1 ± 0.5	7.45 ± 1.6	8.2 ± 2.3*
LW (mg)	175.6 ± 13.1 (11)	175.0 ± 18.4	224.6 ± 101.8 (21)	293.0 ± 147.0
Fibrosis (%)	4.3 ± 1.7	3.3 ± 0.9	8.8 ± 6.1	8.7 ± 5.4

Data are presented as Mean ± standard deviation for the number of mice indicated in parentheses.
HR, heart rate; BW, body weight; LW, lung weight. * Indicates *P*<0.05 vs WT TAC

Supplemental Table 3B. **Male** cardiac function 4 weeks post-TAC measured by echocardiography.

CARDIAC FUNCTION	WT SHAM (12)	KO SHAM (11)	WT TAC (24)	KO TAC (20)
HR (bpm)	430 ± 52	423 ± 30	465 ± 67	473 ± 41
SV (μl)	28.5 ± 4.4	29.6 ± 4.4	23.8 ± 7.9	21.2 ± 9.6
EF (%)	43.4 ± 7.0	44.6 ± 6.0	35.7 ± 13.6	27.6 ± 12.2*
FS (%)	21.2 ± 4.1	21.8 ± 3.4	17.2 ± 7.3	12.9 ± 6.3*
EDV (μl)	66.3 ± 7.9	67.1 ± 10.2	70.4 ± 16.5	78.8 ± 17.0
ESV (μl)	37.7 ± 7.6	37.5 ± 8.3	46.6 ± 19.7	57.6 ± 18.1
CO (ml/min)	12.4 ± 2.8	12.5 ± 2.1	10.8 ± 3.4	10.0 ± 4.8
IVS;s (mm)	1.0 ± 0.2	1.0 ± 0.2	1.3 ± 0.2	1.3 ± 0.2
IVS;d (mm)	0.8 ± 0.1	0.8 ± 0.2	1.0 ± 0.2	1.1 ± 0.2
LVID;s (mm)	3.1 ± 0.2	3.1 ± 0.3	3.3 ± 0.6	3.7 ± 0.5*
LVID;d (mm)	3.9 ± 0.2	3.9 ± 0.3	4.0 ± 0.4	4.2 ± 0.4*
LVPW;s (mm)	1.1 ± 0.1	1.0 ± 0.1	1.2 ± 0.2	1.3 ± 0.2
LVPW;d (mm)	0.8 ± 0.1	0.8 ± 0.1	1.0 ± 0.2	1.1 ± 0.2
E/A	1.6 ± 0.2 (10)	1.95 ± 0.4	1.95 ± 0.7 (15)	3.23 ± 0.4 (14)*
E (mm/s)	496.2 ± 77.8 (11)	507.3 ± 75.8	647.8 ± 140.0	627.2 ± 137.5
E/E'	27.2 ± 4.2 (5)	27.7 ± 6.4 (4)	39.5 ± 12.2 (8)	47.0 ± 18.3 (5)
AOV (mm/s)	798 ± 130	750 ± 111	3298 ± 638	3429 ± 660

Data are presented as Mean ± standard deviation for the number of mice indicated in parentheses. HR, heart rate; SV, stroke volume; EF, ejection fraction; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; CO, cardiac output; IVS;s, interventricular septal thickness at systole; IVS;d, interventricular septal thickness at diastole; LVID;s, left ventricular internal diameter systole; LVID;d, left ventricular internal diameter diastole; LVPW;s, left ventricular posterior wall systole; LVPW;d, left ventricular posterior wall diastole; E/A, early mitral valve filling velocity/ late mitral valve filling velocity; E, early mitral valve filling velocity ; E/E', early mitral valve filling velocity/early mitral annular tissue velocity; AoV, peak aortic velocity. * Indicates *P*<0.05 vs WT TAC.

Supplemental Table 4A. Female morphological parameters 4 weeks post-TAC.

MORPHOLOGICAL	WT SHAM (13)	KO SHAM (12)	WT TAC (31)	KO TAC (25)
HW (mg)	114.7 ± 14.0	120.2 ± 10.8	181.0 ± 50.1	198.0 ± 46.9
BW (g)	21.3 ± 1.4	21.6 ± 1.4	21.4 ± 1.6	21.7 ± 2.3
HW/BW (mg/g)	5.4 ± 0.5	5.6 ± 0.4	8.5 ± 2.5	9.3 ± 3.0
LW (mg)	165.5 ± 16.5 (12)	163.2 ± 12.3	265.0 ± 150.4 (26)	311.1 ± 167.8
Fibrosis (%)	4.8 ± 1.6	4.1 ± 1.8	9.2 ± 6.1	6.9 ± 4.6

Data are presented as Mean ± standard deviation for the number of mice indicated in parentheses.
HR, heart rate; BW, body weight; LW, lung weight. * Indicates *P*<0.05 vs WT TAC

Supplemental Table 4B. Female cardiac function 4 weeks post-TAC measured by echocardiography.

CARDIAC FUNCTION	WT SHAM (13)	KO SHAM (12)	WT TAC (31)	KO TAC (25)
HR (bpm)	431 ± 64	431 ± 39	474 ± 70	486 ± 49
SV (μl)	25.2 ± 6.1	25.4 ± 6.1	19.9 ± 8.2	21.0 ± 6.4
EF (%)	49.8 ± 11.9	44.4 ± 11.1	34.3 ± 13.6	30.6 ± 11.8
FS (%)	25.1 ± 7.9	21.8 ± 6.4	16.3 ± 7.1	14.4 ± 6.0
EDV (μl)	51.5 ± 9.2	58.2 ± 8.4	60.4 ± 12.7	72.6 ± 17.5*
ESV (μl)	26.3 ± 8.2	32.8 ± 9.8	40.5 ± 15.6	51.6 ± 18.4*
CO (ml/min)	10.9 ± 3.3	10.9 ± 2.7	9.5 ± 4.3	10.2 ± 3.3
IVS;s (mm)	1.0 ± 0.2	1.0 ± 0.3	1.2 ± 0.2	1.2 ± 0.2
IVS;d (mm)	0.8 ± 0.1	0.8 ± 0.1	1.0 ± 0.2	1.0 ± 0.2
LVID;s (mm)	2.7 ± 0.4	2.9 ± 0.4	3.2 ± 0.5	3.5 ± 0.5*
LVID;d (mm)	3.5 ± 0.3	3.7 ± 0.2	3.8 ± 0.3	4.0 ± 0.4*
LVPW;s (mm)	1.1 ± 0.2	1.0 ± 0.1	1.2 ± 0.2	1.2 ± 0.2
LVPW;d (mm)	0.8 ± 0.1	0.7 ± 0.1	1.1 ± 0.2	1.0 ± 0.2
E/A	1.8 ± 0.6 (11)	2.1 ± 0.6 (11)	3.2 ± 1.5 (14)	2.6 ± 1.2 (9)
E (mm/s)	473 ± 153 (12)	473 ± 120	687 ± 159 (26)	638 ± 193
E/E’	23.7 ± 3.1 (3)	29.0 ± 10.0 (2)	63.9 ± 30.8 (10)	67.3 ± 30.5 (8)
AOV (mm/s)	736 ± 129	641 ± 108	3071 ± 683	3236 ± 491

Data are presented as Mean ± standard deviation for the number of mice indicated in parentheses. HR, heart rate; SV, stroke volume; EF, ejection fraction; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; CO, cardiac output; IVS;s, interventricular septal thickness at systole; IVS;d, interventricular septal thickness at diastole; LVID;s, left ventricular internal diameter systole; LVID;d, left ventricular internal diameter diastole; LVPW;s, left ventricular posterior wall systole; LVPW;d, left ventricular posterior wall diastole;E/A, E/A, early mitral valve filling velocity/ late mitral valve filling velocity; E, early mitral valve filling velocity ; E/E’, early mitral valve filling velocity/early mitral annular tissue velocity; AoV, peak aortic velocity. * Indicates *P*<0.05 vs WT TAC.

Supplemental Table 5. Cell Death Genes

GO Terms: Apoptosis, apoptotic, necrosis, necrotic, cell death

Genes Unique to FFAR4 KO Sham vs FFAR4 KO TAC: 22 increased, 6 decreased

Gene ID	Fold Change
Atf3	3.406
Cx3cl1	2.987
Igf1	2.787
Dcun1d3	2.125
Csrnp1	2.035
Cyba	2.019
Ero1l	1.889
Errfi1	1.882
Perp	1.867
G2e3	1.834
Ticam1	1.824
Mfge8	1.814
Nqo1	1.799
Ercc6	1.776
Trim27	1.769
Bcl2	1.768
Etv6	1.750
Gclc	1.747
Pnp	1.740
Ruvbl1	1.738
Ace	1.732
Sqstm1	1.706
Ndufc2	-1.708
Atg4d	-1.759
Fastk	-1.790
Ar	-1.853
Zfp346	-2.280
Bmp10	-8.321

Genes Unique to WT Sham vs WT TAC: 138 increased, 70 decreased

Gene ID	Fold Change
Il1rn	219.636
Adam8	117.349
Timp1	112.492
Spp1	85.235
Krt18	51.556
Ankrd2	47.887
Lrp8	37.091
Pak3	32.821
Sfn	30.744
Aldh1a2	26.354
Ccl2	25.129
Hmox1	24.043
Birc5	18.964
Cdk1	17.992
Gdf15	17.833
Hck	16.390
Ckap2	16.271
Star	16.221
Tpx2	15.257
Top2a	15.100
Ccr2	14.716
Crlf1	14.542
Lcn2	14.296
Inhba	13.724
Lgals3	13.711
Myc	13.703
Plk1	13.340
Ccl7	12.622
Cd24a	11.770
Gdf6	9.741

Genes Shared by FFAR4 KO Sham vs FFAR4 KO TAC and WT Sham vs WT TAC: 161 increased, 71 decreased

Gene ID	Fold Change KO	Fold Change WT
Lox	24.312	34.324
Serpine1	16.010	24.941
Ankrd1	10.962	6.718
Cd44	9.335	9.640
Tgfb2	8.828	10.745
Gadd45g	8.745	8.200
Dbn1	8.621	8.140
Fn1	7.686	8.424
Ier3	6.883	7.312
Thbs1	6.419	6.000
Tnfrsf12a	6.239	6.057
Nes	5.264	3.962
Hspb1	4.956	5.753
Ccl6	4.955	4.562
Phlda1	4.576	4.771
Ccl9	4.518	5.177
Tgm2	4.504	4.795
Emp1	4.430	5.579
Tspo	4.197	4.214
Ptprc	4.103	4.334
Fcgr3	3.993	3.074
Dynll1	3.938	3.725
Clu	3.867	4.239
Prelid1	3.718	3.329
Ncam1	3.705	3.728
Creb3l1	3.704	4.160
Adcyap1r1	3.613	4.621
Prmt2	3.606	2.954
Adamts12	3.453	3.580
Lgals1	3.446	4.017

Ect2	9.516	Plscr1	3.381	2.523
Havcr2	9.472	Mmp3	3.340	2.805
Angptl4	9.421	Sfrp1	3.307	3.030
Bub1b	8.822	Otulin	3.303	2.893
Plaur	7.858	G6pdx	3.290	3.119
Ptgs2	7.153	Ctsz	3.283	3.126
C5ar1	7.009	Ifi204	3.274	2.803
Pdpn	6.605	Tgfb3	3.271	2.029
Brca1	6.587	Dap	3.227	3.250
Pak1	6.585	Gba	3.173	2.411
Sphk1	6.439	Tmbim1	3.161	3.685
Nlrc3	6.282	Fndc1	3.103	2.449
Kif14	6.185	Cfl1	3.086	3.469
Cit	5.892	Cttn	2.980	3.271
Cd84	5.723	Ptprf	2.946	3.562
Fcer1g	5.635	Anxa1	2.922	2.855
Socs3	5.425	Shb	2.914	2.708
Tnfrsf23	5.322	Slc25a24	2.828	2.192
Pf4	5.217	Col18a1	2.799	3.149
Siglec1	4.901	Mllt11	2.797	3.626
Clec5a	4.882	Prkcd	2.795	2.078
Ccr5	4.734	Mal	2.792	3.251
Cd14	4.651	Adam9	2.775	2.992
Ncf2	4.636	Arid5a	2.752	2.228
Asns	4.630	Bak1	2.750	3.150
Ncf1	4.390	Lmna	2.742	3.030
Hells	4.317	Sox9	2.653	2.948
Fcgr2b	4.140	Dab2	2.596	2.801
Nckap1l	4.056	Syk	2.586	3.022
Il33	4.052	Gpx1	2.585	2.557
Coro1a	3.957	Nol12	2.579	2.751
Itgb3	3.912	Ptgis	2.577	2.278
Ripk3	3.867	Cd248	2.557	2.515
Phlda3	3.835	Txnrd1	2.544	2.756
Ptpn6	3.746	P4hb	2.540	2.835
Gpnmb	3.711	Usp53	2.527	3.426
Tlr2	3.624	Creb3	2.514	2.240
Egr3	3.598	Txndc5	2.483	2.393
Rad18	3.589	Fam129b	2.472	2.698
Sdf2l1	3.551	Cdkn1a	2.459	2.314

Nek6	3.546	Bin1	2.452	2.310
Tox3	3.545	Actn4	2.450	2.105
Frzb	3.515	Lgmn	2.442	2.530
Bnc2	3.414	Ilk	2.436	2.613
Ada	3.300	Eef1a1	2.411	2.414
Shq1	3.275	Lpar1	2.370	2.072
Met	3.273	Flna	2.316	2.414
Srpx	3.268	Ptk2b	2.311	2.958
Pik3cg	3.245	Cryab	2.295	2.313
Mlkl	3.236	Plk2	2.294	2.215
Inhbb	3.229	Gclm	2.284	2.564
Spi1	3.141	Anxa5	2.281	2.446
Dhcr24	3.043	Hcls1	2.274	2.609
Blm	2.997	Sulf1	2.265	2.514
Casp3	2.931	Itga4	2.244	2.883
Cx3cr1	2.848	Itgb1	2.223	2.307
Rassf5	2.806	Mical1	2.222	2.817
Pla2g4a	2.787	Tnfrsf1a	2.209	2.301
Tmem173	2.787	Plcg2	2.198	1.956
Src	2.752	Trp53	2.166	2.165
Cd300ld	2.739	Sigmar1	2.155	1.800
Bcl3	2.694	Ppp1r15a	2.133	1.933
Tnfrsf11a	2.666	Ecscr	2.132	2.271
Tnfrsf10b	2.651	Hdac6	2.132	2.373
Eef1e1	2.600	Tlr4	2.125	2.071
Clip3	2.563	Hmgb2	2.122	2.469
Arrb2	2.484	Csf1r	2.121	1.942
Robo1	2.443	Emp2	2.111	2.255
Pik3cd	2.349	Hif1a	2.108	2.022
Prkcb	2.113	Lsp1	2.106	2.371
Cib1	2.066	Ptprj	2.104	1.777
Bax	2.038	Cybb	2.100	2.584
Hax1	2.033	Por	2.086	2.004
Katnb1	2.029	Dlg5	2.072	2.097
Myd88	2.010	Tnfrsf1b	2.067	2.151
Npm1	1.969	Arf4	2.061	1.837
Anxa6	1.964	Mt1	2.053	2.537
Mapk7	1.950	Sra1	2.030	1.811
Fgfr1	1.934	Capn2	2.015	2.061
Map1s	1.918	Abcc1	2.004	1.837

Atad5	1.912	Arf6	2.001	2.160
Brms1	1.894	Sgpl1	1.982	2.148
Cpne1	1.885	Rnf4	1.977	1.764
Atf4	1.883	Ltbr	1.963	2.180
Casp8	1.881	Ywhaz	1.958	2.058
Rpl11	1.877	Pde1a	1.957	1.750
Zmat3	1.868	Hmgcr	1.955	1.999
Apex1	1.850	Ywhah	1.951	1.874
Gadd45b	1.848	Xbp1	1.935	1.979
Eif5a	1.843	Shisa5	1.935	2.218
Map2k1	1.839	Rpl10	1.929	2.058
Stambp	1.834	Emp3	1.922	2.850
Bad	1.833	Lrp1	1.916	1.889
Pigt	1.829	F2r	1.915	2.004
Clptm1l	1.827	Fem1b	1.912	1.836
Stat3	1.817	Cxcl16	1.906	2.152
Ctsc	1.815	Inpp5d	1.903	2.647
Ppp1r13l	1.799	Pa2g4	1.890	1.892
Ucp2	1.792	Anp32b	1.882	1.709
Noc2l	1.786	Rassf2	1.881	1.773
Nup62	1.780	Mcm2	1.862	2.489
Ufm1	1.777	Hk1	1.858	2.066
Unc5b	1.761	Hyal2	1.853	1.806
Slc9a3r1	1.753	Axl	1.849	2.011
Gnai2	1.739	Mydgf	1.849	2.087
Cidea	1.723	Pea15a	1.849	1.775
Ptpn2	1.707	Actr3	1.840	2.003
Dnmt1	1.703	Fmr1	1.834	1.908
Hsf1	-1.702	Chst11	1.834	1.836
Opa1	-1.707	Dapk3	1.833	1.719
Aldh2	-1.721	Itgav	1.831	1.859
Asah2	-1.724	Tgfb1	1.830	1.963
Rarg	-1.731	Grk5	1.827	2.082
Ndufs3	-1.741	Tgfbr1	1.826	1.858
Gstp1	-1.766	Pak4	1.804	1.918
Lims1	-1.767	Chmp4b	1.803	1.785
Rora	-1.767	B4galt1	1.792	2.046
Flcn	-1.783	Plvap	1.789	2.024
Pde3a	-1.798	Rrp1b	1.787	1.710
Itpkb	-1.808	Ctsb	1.785	2.093

Tek	-1.816	Prnp	1.777	1.799
Erbb4	-1.844	Txn1	1.763	2.159
Akt2	-1.847	Ralb	1.762	1.903
Cep63	-1.848	Rara	1.750	1.728
Txnip	-1.849	Crip1	1.743	2.134
Chchd10	-1.867	Gli3	1.738	2.298
Ypel3	-1.874	Gatad2a	1.732	1.816
Jmy	-1.881	Ptpn1	1.729	2.025
Rapgef2	-1.888	Plscr3	1.726	1.934
Endog	-1.889	Pmp22	1.714	1.736
Tbx3	-1.895	Shc1	1.709	2.106
Pde5a	-1.902	Pcnt	-1.708	-2.008
Alkbh7	-1.918	Slc25a4	-1.709	-1.835
Kcnb1	-1.924	Sort1	-1.710	-1.915
Hint2	-1.935	Gpam	-1.714	-2.049
Rnf146	-1.940	Mavs	-1.722	-1.791
Sh3kbp1	-1.968	Abcb1a	-1.728	-2.190
Prkd1	-1.973	Wdr92	-1.730	-1.893
Sncaip	-1.974	Xdh	-1.731	-1.825
Rassf3	-1.976	Dpep1	-1.735	-2.188
Zbtb16	-1.991	Cecr2	-1.753	-2.072
Six4	-1.994	Nsmaf	-1.755	-2.085
Pnpla8	-2.032	Optn	-1.760	-2.252
Aamdc	-2.040	Bcl2l11	-1.769	-2.251
Col4a3	-2.048	Cyfip2	-1.769	-2.076
Map3k5	-2.062	Acaa2	-1.772	-1.909
Kdr	-2.126	Cdkn1b	-1.774	-1.813
Irf1	-2.133	Phlpp1	-1.779	-1.766
Epha7	-2.138	Smpd2	-1.791	-1.964
Zc3h8	-2.141	Msh2	-1.794	-1.867
Rrm2b	-2.142	Jun	-1.810	-1.759
Sept4	-2.144	Pdcd4	-1.823	-1.795
Bmp6	-2.148	Tnfaip8	-1.856	-2.613
Egr1	-2.284	Ube2b	-1.858	-2.316
Ackr3	-2.301	Nmnat1	-1.862	-2.469
Tnfsf10	-2.362	Sod2	-1.863	-2.121
Id1	-2.367	Fgf13	-1.864	-1.703
Tmc8	-2.456	Agtr1a	-1.868	-1.727
Tnfrsf21	-2.496	Rgcc	-1.878	-2.006
Plekhf1	-2.527	Apbb1	-1.896	-1.712

Camk2b	-2.688		Ago4	-1.916	-2.475
Rapsn	-2.692		Gm20594	-1.936	-2.822
Dll1	-2.711		Lims2	-1.938	-1.930
Wnt5a	-2.734		Ndufs1	-1.943	-2.387
Gata2	-2.748		Tgfbr3	-1.947	-1.725
Cd28	-2.776		Ivns1abp	-1.971	-2.709
Ceacam1	-2.786		Pink1	-1.974	-2.209
Cradd	-2.800		Mapt	-1.975	-2.059
Tpd52l1	-3.067		Ahr	-2.000	-2.165
Ccdc3	-3.084		Vegfb	-2.001	-2.218
Map2k6	-3.425		Mitf	-2.008	-1.789
Gzmm	-3.537		Lifr	-2.033	-2.257
Gadd45a	-3.622		Stat5b	-2.034	-1.833
Prkcq	-3.793		Thrb	-2.035	-2.350
Ung	-3.926		Ndnf	-2.038	-1.973
Atcay	-5.338		Sema6a	-2.086	-1.958
Ntf3	-5.417		Pdk2	-2.103	-2.685
Ptgfr	-5.664		Mtfp1	-2.104	-2.379
			Camk2a	-2.117	-1.759
			Fbxo32	-2.129	-2.753
			Sox7	-2.140	-2.402
			Nqo2	-2.199	-2.352
			F3	-2.209	-2.642
			Foxo3	-2.219	-2.307
			Ccng1	-2.229	-2.336
			Ank2	-2.232	-2.457
			Egln1	-2.240	-2.352
			Rps6ka2	-2.251	-2.898
			Abcc8	-2.273	-2.690
			Slc2a4	-2.297	-2.415
			Ddt	-2.305	-2.024
			Pik3r1	-2.401	-2.446
			Adamts7	-2.457	-2.723
			Ppargc1a	-2.536	-3.388
			Cd274	-2.549	-3.672
			G0s2	-2.563	-2.086
			Apip	-2.620	-2.852
			Aqp1	-2.678	-3.200
			Dusp1	-2.695	-3.057
			Gsn	-2.718	-3.531

Herpud1	-2.751	-3.134
Angpt1	-4.454	-4.113

Supplemental Table 6. Inflammation Genes

GO Terms: monocyte, dendritic cell, macrophage, myeloid, B cell, T cell, lymph, interferon, interleukin, inflammatory, lymphocyte, leukocyte, chemokine, cytokine, immune

Genes Unique to FFAR4 KO Sham vs FFAR4 KO TAC: 23 increased, 3 decreased		Genes Unique to WT Sham vs WT TAC: 166 increased, 73 decreased		Genes Shared by FFAR4 KO Sham vs FFAR4 KO TAC and WT Sham vs WT TAC: 168 increased, 56 decreased		
Gene ID	Fold Change	Gene ID	Fold Change	Gene ID	Fold Change KO	Fold Change WT
Cx3cl1	2.987	Ereg	240.348	Serpine1	16.010	24.941
Igf1	2.787	Il1rn	219.636	Postn	15.162	13.826
Il2rg	2.152	Chil3	211.386	Serpina3n	13.726	16.369
Klf6	2.127	Adam8	117.349	Ankrd1	10.962	6.718
Ahcy	2.055	Timp1	112.492	Col3a1	10.165	9.226
Cyba	2.019	Arg1	94.628	Itgam	9.947	10.004
Trove2	1.970	Ankrd2	47.887	Cd44	9.335	9.640
Maf	1.964	Lrp8	37.091	Tgfb2	8.828	10.745
Ssc5d	1.963	Cxcl5	30.522	Gadd45g	8.745	8.200
Errfi1	1.882	Aldh1a2	26.354	Nppb	8.688	5.931
Flnb	1.843	Ccl2	25.129	Loxl3	8.357	14.007
Ticam1	1.824	Hmox1	24.043	Fn1	7.686	8.424
Ifitm3	1.805	Serpina3i	22.500	Ier3	6.883	7.312
Elf4	1.792	Anln	22.149	Itga5	6.523	7.683
Trim27	1.769	Ccnb2	19.624	Thbs1	6.419	6.000
Bcl2	1.768	Birc5	18.964	Fyb	6.236	5.579
Smad1	1.757	Cxcr6	18.350	Prg4	6.235	6.559
Pnp	1.740	Hck	16.390	Ctss	6.082	6.240
Ace	1.732	Ckap2	16.271	Sbno2	5.549	5.008
Eif2ak4	1.724	Star	16.221	Capg	5.358	5.617
Tinagl1	1.720	Ccr2	14.716	Lcp1	5.083	6.470
Prex1	1.716	Lcn2	14.296	Il4ra	5.027	4.673
Sqstm1	1.706	Lgals3	13.711	Hspb1	4.956	5.753
Ndufc2	-1.708	Myc	13.703	Ccl6	4.955	4.562
Hdac9	-1.759	Plk1	13.340	Msn	4.820	5.174
Jam3	-1.792	Ccl7	12.622	Rhoc	4.626	4.705
		Msr1	12.445	Mmp14	4.608	5.418
		Cd24a	11.770	Ccl9	4.518	5.177
		Csf2rb	11.085	Tgm2	4.504	4.795

Runx1	10.581	Emilin1	4.265	4.364
Gpr35	10.420	Ptprc	4.103	4.334
Ccr1	9.871	Litaf	4.072	3.362
Racgap1	9.775	Vim	4.049	3.986
Ect2	9.516	Fcgr3	3.993	3.074
Havcr2	9.472	Soat1	3.896	3.758
Lat2	9.451	Ldlr	3.813	4.756
Itgb2	9.094	Prelid1	3.718	3.329
Cd180	9.072	Trim16	3.681	4.547
Prc1	8.639	Rnf19b	3.642	4.003
Kif23	8.412	Tuba1b	3.497	3.072
Dok1	8.142	Adamts12	3.453	3.580
Pik3ap1	8.033	Lgals1	3.446	4.017
Kif4	7.863	Plscr1	3.381	2.523
Ptx3	7.589	Ifi30	3.347	3.281
Tlr13	7.379	Pla2g7	3.332	4.630
Myo1g	7.226	Sfrp1	3.307	3.030
Ptgs2	7.153	Otulin	3.303	2.893
Kif20a	7.039	G6pdx	3.290	3.119
C5ar1	7.009	Osmr	3.278	3.525
Sele	6.769	Ifi204	3.274	2.803
Pdpn	6.605	Tgfb3	3.271	2.029
Sphk1	6.439	Klhl6	3.194	2.011
Pirb	6.345	Gba	3.173	2.411
Nlrc3	6.282	Masp1	3.107	2.701
C3ar1	6.280	Cfl1	3.086	3.469
Csf2rb2	6.265	Ppp1r14b	2.963	2.678
Kif14	6.185	Adcy7	2.959	2.815
Vav1	5.911	Enpp1	2.956	3.722
Cit	5.892	Ptprf	2.946	3.562
Kif20b	5.861	Sdc1	2.941	4.236
Slc11a1	5.774	Anxa1	2.922	2.855
Cd84	5.723	Shb	2.914	2.708
Il17ra	5.718	Nme1	2.889	3.359
Fcer1g	5.635	Zyx	2.880	2.798
Fcgr1	5.594	Ctps	2.861	3.016
Tyrobp	5.482	C1qa	2.831	2.521
Socs3	5.425	Cblb	2.830	2.564
Pf4	5.217	Adgre1	2.830	3.153
Siglec1	4.901	Bcr	2.803	2.980

Clec5a	4.882	Nppa	2.800	4.948
Myo1f	4.761	Prkcd	2.795	2.078
Ccr5	4.734	Apbb1ip	2.779	4.058
Cd14	4.651	Adam9	2.775	2.992
Panx1	4.538	Rpl3	2.761	2.997
Ncf1	4.390	Arid5a	2.752	2.228
Hells	4.317	Bak1	2.750	3.150
Alox5ap	4.293	Unc93b1	2.747	2.081
E2f8	4.272	C1qb	2.736	3.385
Fcgr2b	4.140	Myh9	2.705	2.344
Ptprn	4.104	C1qc	2.665	2.601
Nckap1l	4.056	Sox9	2.653	2.948
Il33	4.052	Mrc1	2.649	2.420
Dock2	4.017	Ctla2a	2.635	2.344
Clec12a	3.989	Dab2	2.596	2.801
Nusap1	3.957	Syk	2.586	3.022
Coro1a	3.957	Gpx1	2.585	2.557
Ly86	3.942	Ptgis	2.577	2.278
Itgb3	3.912	Cd248	2.557	2.515
Fermt3	3.897	P4hb	2.540	2.835
Ripk3	3.867	Actg1	2.531	2.528
Blk	3.841	Nt5e	2.521	1.947
Ptpn6	3.746	Anxa4	2.517	2.602
Gpnmb	3.711	Creb3	2.514	2.240
Thy1	3.651	Stab1	2.502	2.184
Nfam1	3.632	Serpinf1	2.488	2.428
Cfp	3.626	Iqgap1	2.488	2.517
Tlr2	3.624	Cdkn1a	2.459	2.314
Hist1h2bg	3.605	Lgmn	2.442	2.530
Egr3	3.598	Rras	2.397	2.153
Incenp	3.347	Myo1c	2.360	2.894
Ada	3.300	Sdc4	2.343	2.329
Met	3.273	Ptk2b	2.311	2.958
Nfkbiz	3.249	Vcam1	2.304	2.086
Pik3cg	3.245	Plk2	2.294	2.215
Spi1	3.141	Bcar1	2.279	1.778
Numbl	3.043	Hcls1	2.274	2.609
Lcp2	3.022	Itga4	2.244	2.883
Blm	2.997	Itgb1	2.223	2.307
Sept5	2.991	Tnfrsf1a	2.209	2.301

Casp3	2.931	Sept11	2.201	1.849
Ikzf1	2.902	Plcg2	2.198	1.956
Cx3cr1	2.848	Fkbp1a	2.197	2.456
Dhx58	2.843	Trp53	2.166	2.165
Alcam	2.796	Cspg4	2.148	2.136
Pla2g4a	2.787	Hsp90aa1	2.144	2.216
Tmem173	2.787	Tlr4	2.125	2.071
Src	2.752	Hmgb2	2.122	2.469
Cd300ld	2.739	Csf1r	2.121	1.942
Cdc25b	2.733	Ptms	2.120	2.073
Chst3	2.732	Emp2	2.111	2.255
Themis2	2.703	Hif1a	2.108	2.022
Bcl3	2.694	Lsp1	2.106	2.371
Tnfrsf11a	2.666	Ptprj	2.104	1.777
Arrb2	2.484	Cybb	2.100	2.584
Robo1	2.443	Dlg5	2.072	2.097
D1Ertd622e	2.416	Tnfrsf1b	2.067	2.151
Lxn	2.378	Ddx21	2.036	1.879
Rab7b	2.371	Cd151	2.033	2.030
Cmtm3	2.353	Skap2	2.026	3.448
Pik3cd	2.349	Lrrc32	2.022	1.833
Irf8	2.246	Gprc5b	2.020	1.770
Hist1h2be	2.212	Capn2	2.015	2.061
Mapk11	2.199	Nras	2.013	2.256
Prkcb	2.113	Arf6	2.001	2.160
Cfb	2.075	Il1r1	1.999	1.782
Bax	2.038	Ltbr	1.963	2.180
Hax1	2.033	Dysf	1.936	2.127
Gcnt1	2.029	Myo9b	1.935	1.994
Relb	2.022	Xbp1	1.935	1.979
Polr3g	2.014	Lrp1	1.916	1.889
Myd88	2.010	F2r	1.915	2.004
Csf2ra	2.002	Cxcl16	1.906	2.152
Susd2	1.987	Inpp5d	1.903	2.647
Ecm1	1.966	Nfil3	1.880	2.121
Mapk7	1.950	Mcm2	1.862	2.489
Atad5	1.912	Hk1	1.858	2.066
Casp8	1.881	Hyal2	1.853	1.806
Nfkb2	1.866	Axl	1.849	2.011
Stambp	1.834	Actr3	1.840	2.003

Bad	1.833	Calr	1.837	1.886
Stat3	1.817	Dapk3	1.833	1.719
Ctsc	1.815	Itgav	1.831	1.859
Rps6ka4	1.808	Tgfb1	1.830	1.963
Atic	1.804	Slc7a2	1.803	2.109
Rpl39	1.787	Csk	1.803	1.709
Noc2l	1.786	Chmp4b	1.803	1.785
Nup62	1.780	Cdk6	1.801	1.781
Dhx33	1.773	B4galt1	1.792	2.046
Apobec3	1.765	Prnp	1.777	1.799
Map2k3	1.763	Tmem176b	1.774	2.331
Arhgef5	1.746	Dbnl	1.754	2.002
Adam15	1.726	Rara	1.750	1.728
Cidea	1.723	Ddost	1.744	1.901
Ptpn2	1.707	Gli3	1.738	2.298
Impdh2	1.703	Rpl13a	1.722	1.813
Zbtb7b	1.700	Pmp22	1.714	1.736
Parp14	-1.705	Fam49b	1.712	1.800
Slc39a3	-1.706	Pvr	1.708	1.864
Rarg	-1.731	Btnl9	-1.701	-2.683
Flt1	-1.746	Gpam	-1.714	-2.049
Gstp1	-1.766	Mavs	-1.722	-1.791
Rora	-1.767	Lpl	-1.737	-2.346
Alox5	-1.779	Rab12	-1.760	-1.747
Flcn	-1.783	Optn	-1.760	-2.252
Klf2	-1.791	Bcl2l11	-1.769	-2.251
H2-Q4	-1.807	Phlpp1	-1.779	-1.766
Itpkb	-1.808	Msh2	-1.794	-1.867
Tek	-1.816	Siae	-1.799	-1.804
Mr1	-1.834	Jun	-1.810	-1.759
Cfh	-1.879	Gbp5	-1.815	-2.163
Rapgef2	-1.888	Pdcd4	-1.823	-1.795
Kif16b	-1.898	Prox1	-1.826	-2.173
Pde5a	-1.902	Irgm2	-1.828	-2.669
Irf2bp2	-1.925	Il10rb	-1.831	-2.017
Cd300lg	-1.928	Ephx2	-1.832	-1.951
Gbp3	-1.938	Tnfaip8	-1.856	-2.613
Il15ra	-1.954	Wfdc1	-1.862	-2.771
Kdm5d	-1.958	Agtr1a	-1.868	-1.727
Rarres2	-1.969	Map4k2	-1.872	-2.778

Prkd1	-1.973		Rgcc	-1.878	-2.006
Dll4	-1.979		Klhl21	-1.884	-1.824
Tmem204	-1.980		Itgb6	-1.918	-2.285
Tspan2	-1.987		Trpm4	-1.936	-1.708
Zbtb16	-1.991		Tgfbr3	-1.947	-1.725
Kat8	-1.993		Igf2	-1.950	-1.939
C1s1	-2.009		Alad	-1.970	-2.073
Map3k5	-2.062		Gbp4	-1.984	-2.377
Gbp9	-2.071		Gbp7	-1.997	-2.989
Pdgfd	-2.100		Ahr	-2.000	-2.165
Kdr	-2.126		Crhr2	-2.026	-1.926
Irf1	-2.133		Lifr	-2.033	-2.257
Zc3h8	-2.141		Stat5b	-2.034	-1.833
Sept4	-2.144		Mylk3	-2.041	-2.546
Bmp6	-2.148		Vtn	-2.045	-3.620
Abcd2	-2.278		Igtp	-2.048	-1.735
Klhl13	-2.282		Timp4	-2.087	-2.694
Egr1	-2.284		Ccbe1	-2.092	-2.587
Adgrf5	-2.285		F3	-2.209	-2.642
Ackr3	-2.301		Iigp1	-2.287	-2.244
Fzd8	-2.320		Cd200	-2.288	-2.106
Tnfsf10	-2.362		Ddt	-2.305	-2.024
Tnfrsf21	-2.496		Pik3r1	-2.401	-2.446
Ccrl2	-2.506		Gbp6	-2.453	-4.015
Slc26a6	-2.548		Adamts7	-2.457	-2.723
Prdm1	-2.648		Pde4d	-2.497	-2.374
Dll1	-2.711		Nr1d2	-2.518	-2.834
Wnt5a	-2.734		Cd274	-2.549	-3.672
Gata2	-2.748		Ppara	-2.614	-2.691
Cd28	-2.776		Dusp1	-2.695	-3.057
Ceacam1	-2.786		Gsn	-2.718	-3.531
Colec11	-2.848		Lpin1	-2.759	-2.924
P2ry14	-2.855		Mlf1	-2.995	-3.053
Enpp2	-3.196		Efnb3	-4.012	-3.701
Rps6ka5	-3.390		Angpt1	-4.454	-4.113
Cxcl9	-3.448				
Gzmm	-3.537				
Tgtp2	-3.550				
Aqp4	-3.555				
Prkcq	-3.793				

Dpp4	-3.837
F830016B08Rik	-3.931
Gbp10	-4.311
Tgtp1	-5.041
Mme	-5.251
Ptgfr	-5.664
Cdkn1c	-5.729
Pla2g5	-5.822
Il15	-5.997
Cyp26b1	-23.267

Supplementary Table 7. Oxidation-Reduction Genes
GO Terms: Oxidation-Reduction

Genes Unique to FFAR4 KO Sham vs FFAR4 KO TAC: 5 increased, 8 decreased

Gene ID	Fold Change
Cyba	2.019
Me2	1.948
Ero1l	1.889
Nqo1	1.799
Pxdn	1.723
Ndufc2	-1.708
Aldh1b1	-1.729
Cyp4b1	-1.803
Hibadh	-1.816
Cpox	-1.834
Cyp2u1	-1.855
Scd1	-1.872
Oxnad1	-2.146

Genes Unique to WT Sham vs WT TAC: 25 increased, 38 decreased

Gene ID	Fold Change
P4ha3	101.497
Aldh1a2	26.354
Hmox1	24.043
Kcnab2	9.746
Loxl4	9.535
Steap2	8.543
Ptgs2	7.153
Mthfd1l	6.998
Akr1b8	6.829
Rrm2	5.633
Tbxas1	4.509
Gpx7	3.552
Mthfd2	3.175
Dhcr24	3.043
Frrs1	2.982
Sqle	2.946
Rdh11	2.879
Msmo1	2.459
Pycr2	2.241
Cyb561a3	2.088
Gpx3	2.069
Sod3	1.974
Sardh	1.934
Cbr2	1.894
Impdh2	1.703
Decr1	-1.703
Ndufa9	-1.710

Genes Shared by FFAR4 KO Sham vs FFAR4 KO TAC and WT Sham vs WT TAC: 34 increased, 58 decreased

Gene ID	Fold Change KO	Fold Change WT
Lox	24.312	34.324
Loxl3	8.357	14.007
Loxl2	7.354	7.545
Qsox1	4.180	4.329
Srxn1	3.987	4.193
Loxl1	3.785	3.452
Ifi30	3.347	3.281
G6pdx	3.290	3.119
Fads3	2.738	3.250
Aldh18a1	2.617	2.458
Gpx1	2.585	2.557
Ptgis	2.577	2.278
Mical2	2.544	2.742
Txnrd1	2.544	2.756
Plod3	2.509	2.553
P3h1	2.506	2.958
Vat1	2.370	3.094
Pgd	2.293	2.786
Cyb561	2.241	1.753
Mical1	2.222	2.817
Ugdh	2.200	2.476
Cyb5r3	2.137	2.432
Cybb	2.100	2.584
Por	2.086	2.004
Hsd17b12	2.070	3.062
P3h3	2.044	2.019
Hmgcr	1.955	1.999

Uqcrc2	-1.713	Tyw1	1.919	2.191
Aldh2	-1.721	Mthfr	1.906	1.858
Pdpr	-1.727	Fads1	1.812	1.754
Ndufb10	-1.730	Cyb5r1	1.789	2.294
Acadsb	-1.735	Txn1	1.763	2.159
Ndufs3	-1.741	Cyp20a1	1.749	1.781
Cyp27a1	-1.751	Rrm1	1.749	2.313
Ndufb2	-1.756	Ndufa5	-1.724	-1.806
Acadvl	-1.760	Xdh	-1.731	-1.825
Idh3g	-1.776	Tecrl	-1.746	-1.709
Alox5	-1.779	Hadha	-1.757	-2.090
Cbr4	-1.783	Phyh	-1.774	-1.885
Me3	-1.783	L2hgdh	-1.779	-2.155
Ndufs7	-1.791	Etfb	-1.791	-1.949
Sdhb	-1.820	Sdha	-1.798	-2.039
Dhrs11	-1.843	Dld	-1.817	-2.102
Dhrs4	-1.860	Ndufs8	-1.836	-1.900
Ogdh	-1.870	Aldh5a1	-1.853	-2.780
Acads	-1.875	Mdh1	-1.854	-1.866
Ptgr2	-1.876	Sod2	-1.863	-2.121
Ndufb9	-1.879	Dhrs7	-1.878	-2.120
Pdha1	-1.887	Ivd	-1.885	-2.559
Ndufs2	-1.893	Ndufs4	-1.885	-2.218
Alkbh7	-1.918	Sdr39u1	-1.903	-1.854
Kdm5d	-1.958	Hsdl2	-1.907	-2.324
Fmo2	-1.972	Rtn4ip1	-1.915	-1.720
Bckdha	-2.123	Ldhd	-1.915	-2.858
Rrm2b	-2.142	Etfdh	-1.923	-2.156
Hadhb	-2.290	Pdhb	-1.930	-1.888
Akr1c14	-2.631	Aaed1	-1.933	-2.274
Adh1	-2.687	Akr7a5	-1.935	-2.387
Sord	-2.704	Ndufs1	-1.943	-2.387
Cyb5rl	-3.342	Idh2	-1.945	-2.544
Tet1	-3.817	Fmo5	-1.948	-2.579
Cyb5r2	-4.230	Ldhb	-1.951	-2.318
Cyp26b1	-23.267	C330018D20Rik	-1.967	-2.099
		Rdh14	-1.976	-2.129
		Retsat	-1.995	-2.013
		Nnt	-2.000	-2.393
		Adi1	-2.046	-1.921

Etfa	-2.081	-2.236
Kdm1b	-2.087	-1.961
Dhrs3	-2.123	-2.663
Fmo1	-2.138	-2.131
Bckdhb	-2.142	-2.406
Gcdh	-2.145	-2.427
Acadm	-2.161	-2.786
Sesn1	-2.162	-3.090
Ddo	-2.185	-2.191
Nqo2	-2.199	-2.352
Dpyd	-2.238	-2.337
Egln1	-2.240	-2.352
Msrb2	-2.267	-2.275
Fam213a	-2.302	-3.059
Aldh6a1	-2.323	-3.012
Hadh	-2.364	-2.757
Dhdh	-2.382	-2.864
Aldh4a1	-2.434	-3.223
D2hgdh	-2.435	-3.526
Acad11	-2.509	-2.647
Adhfe1	-2.676	-2.376
Tecr	-2.723	-2.728
Maob	-2.808	-3.146
Selenbp1	-2.935	-3.139
Dhrs7c	-4.965	-7.365

Supplemental Table 8. Contractile Function Genes

GO Terms: Heart contraction, cardiac muscle cell contraction, sarcomere, heart rate, ryanodine, sarcoplasmic reticulum, cardiac muscle cell action potential involved in contraction, cardiac contraction

Genes Unique to FFAR4 KO Sham vs FFAR4 KO TAC: 2 increased, 2 decreased

Gene ID	Fold Change
Myh7	2.484
Ace	1.732
Kcnj5	-1.897
Bmp10	-8.321

Genes Unique to WT Sham vs WT TAC: 10 increased, 15 decreased

Gene ID	Fold Change
Tnnt3	6.630
Ccr5	4.734
Ada	3.300
Met	3.273
Kcne4	2.899
Atp1b1	1.927
Pkp2	1.886
Ppp1r13l	1.799
Map2k3	1.763
Gnai2	1.739
Gaa	-1.711
Taz	-1.722
Ctnna3	-1.798
Myom2	-1.843
Tnni3k	-1.889
Pde5a	-1.902
Hcn4	-1.993
Six4	-1.994
Epas1	-2.109
Tnnt1	-2.132
Kcna5	-2.157
Map2k6	-3.425
Cacna2d2	-3.520
Sln	-6.103
Scn4b	-8.311

Genes Shared by FFAR4 KO Sham vs FFAR4 KO TAC and WT Sham vs WT TAC: 20 increased, 31 decreased

Gene ID	Fold Change KO	Fold Change WT
Hbegf	12.860	11.692
Tgfb2	8.828	10.745
Synpo2l	5.543	4.979
Xirp1	3.534	3.189
Ankrd23	3.449	2.536
Cav3	3.100	3.035
Klhl41	3.026	2.837
Nppa	2.800	4.948
Gpx1	2.585	2.557
Wdr1	2.581	2.653
Actg1	2.531	2.528
Bin1	2.452	2.310
Itgb1	2.223	2.307
Csrp3	2.219	2.003
Fkbp1a	2.197	2.456
Sri	2.008	1.881
Tmem38b	1.900	2.004
Gnao1	1.861	2.401
Popdc2	1.815	1.864
Slc8a1	1.727	1.886
Trdn	-1.740	-1.799
Tmem38a	-1.815	-2.108
Prox1	-1.826	-2.173
Tnni3	-1.927	-2.143
Trpm4	-1.936	-1.708
Vegfb	-2.001	-2.218

Crhr2	-2.026	-1.926
Atp2a2	-2.035	-2.385
Thrb	-2.035	-2.350
Myh6	-2.039	-2.507
Cacna1g	-2.040	-1.762
Mylk3	-2.041	-2.546
Sp4	-2.043	-2.230
Myl2	-2.057	-2.436
Atp1a2	-2.207	-2.710
Ank2	-2.232	-2.457
Hopx	-2.233	-3.247
Rps6ka2	-2.251	-2.898
Pik3r1	-2.401	-2.446
Pln	-2.439	-2.656
Adra1b	-2.439	-2.145
Pde4d	-2.497	-2.374
Gstm7	-2.611	-2.433
Kcnh2	-2.618	-2.107
Tcap	-2.645	-2.400
Myl4	-2.994	-3.758
Kcnj2	-3.256	-3.366
Rgs2	-3.313	-3.246
Hrc	-3.466	-5.100
Adra1a	-3.544	-3.681
Dhrs7c	-4.965	-7.365

Supplemental Table 9. Angiogenesis Genes
GO Terms: Angiogenesis

Genes Unique to FFAR4 KO Sham vs FFAR4 KO TAC: 5 increased, 2 decreased

Gene ID	Fold Change
Cx3cl1	2.987
Mfge8	1.814
Adamts9	1.760
Smad1	1.757
Ace	1.732
Hdac9	-1.759
Jam3	-1.792

Genes Unique to WT Sham vs WT TAC: 39 increased, 31 decreased

Gene ID	Fold Change
Ereg	240.348
Adam8	117.349
Adam12	38.177
Ccl2	25.129
Hmox1	24.043
Ccr2	14.716
Lgals3	13.711
Runx1	10.581
Angptl4	9.421
Itgb2	9.094
Ptgs2	7.153
C5ar1	7.009
Pdpn	6.605
Brca1	6.587
Sphk1	6.439
C3ar1	6.280
Mmp19	5.480
Pf4	5.217
Bmper	4.639
E2f8	4.272
Itgb3	3.912
Thy1	3.651
Egr3	3.598
Plau	3.321
Pik3cg	3.245
Cx3cr1	2.848
Robo1	2.443
Prkcb	2.113

Genes Shared by FFAR4 KO Sham vs FFAR4 KO TAC and WT Sham vs WT TAC: 58 increased, 18 decreased

Gene ID	Fold Change KO	Fold Change WT
Rtn4	17.020	17.496
Serpine1	16.010	24.941
Hbegf	12.860	11.692
Col8a1	9.567	9.110
Tgfb2	8.828	10.745
Fn1	7.686	8.424
Loxl2	7.354	7.545
Itga5	6.523	7.683
Thbs1	6.419	6.000
Tnfrsf12a	6.239	6.057
Anxa2	5.166	6.442
Hspb1	4.956	5.753
Srpx2	4.921	4.422
Adamts1	4.522	4.112
Emilin1	4.265	4.364
Creb3l1	3.704	4.160
Sparc	3.700	3.853
Otulin	3.303	2.893
Col4a1	3.301	3.032
Anxa1	2.922	2.855
Shb	2.914	2.708
Ddah1	2.803	3.495
Col18a1	2.799	3.149
Col4a2	2.797	2.674
Myh9	2.705	2.344
Syk	2.586	3.022
Gpx1	2.585	2.557
Ptgis	2.577	2.278

Cib1	2.066		Stab1	2.502	2.184
Ecm1	1.966		Serpinf1	2.488	2.428
Mapk7	1.950		Anxa3	2.469	2.291
Fgfr1	1.934		Rras	2.397	2.153
Casp8	1.881		Amot	2.347	1.769
Kctd10	1.863		Flna	2.316	2.414
Stat3	1.817		Ptk2b	2.311	2.958
Hs6st1	1.793		Plk2	2.294	2.215
Unc5b	1.761		Sulf1	2.265	2.514
Hgs	1.755		Itgb1	2.223	2.307
Adam15	1.726		Tnfrsf1a	2.209	2.301
Tie1	-1.705		Cspg4	2.148	2.136
Dcn	-1.738		Ecscr	2.132	2.271
Flt1	-1.746		Mcam	2.131	1.882
Ptprm	-1.763		Emp2	2.111	2.255
Synj2bp	-1.764		Hif1a	2.108	2.022
Rora	-1.767		Cybb	2.100	2.584
Flcn	-1.783		Rnh1	2.067	2.098
Klf2	-1.791		Parva	2.013	1.962
Ptprb	-1.804		Nras	2.013	2.256
Foxo4	-1.804		Glul	1.998	1.937
Tek	-1.816		Dysf	1.936	2.127
Cd59a	-1.832		Xbp1	1.935	1.979
Prkd1	-1.973		Clic4	1.871	1.906
Dll4	-1.979		Mydgf	1.849	2.087
Reck	-2.041		Itgav	1.831	1.859
Col4a3	-2.048		Tgfbr1	1.826	1.858
Epas1	-2.109		Pak4	1.804	1.918
Kdr	-2.126		B4galt1	1.792	2.046
Plxdc1	-2.205		Shc1	1.709	2.106
Ackr3	-2.301		Gtf2i	-1.754	-1.711
Fzd8	-2.320		Jun	-1.810	-1.759
Id1	-2.367		Prox1	-1.826	-2.173
Smoc2	-2.392		Agtr1a	-1.868	-1.727
Fgf9	-2.474		Rgcc	-1.878	-2.006
Dll1	-2.711		Ppp1r16b	-1.902	-2.501
Wnt5a	-2.734		Igf2	-1.950	-1.939
Gata2	-2.748		Vegfb	-2.001	-2.218
Ceacam1	-2.786		Crhr2	-2.026	-1.926
Enpp2	-3.196		Ndnf	-2.038	-1.973

Egf	-4.469	Col4a4	-2.072	-2.081
Ephb1	-5.173	Sema6a	-2.086	-1.958
		Ccbe1	-2.092	-2.587
		F3	-2.209	-2.642
		Egln1	-2.240	-2.352
		Abcc8	-2.273	-2.690
		Aqp1	-2.678	-3.200
		Angpt1	-4.454	-4.113

Supplemental Table 10. Fibrosis Genes

GO Terms: Collagen, metallopeptidase, extracellular matrix, fibroblast, matrix, fibrosis

Genes Unique to FFAR4 KO Sham vs FFAR4 KO TAC: 10 increased, 3 decreased

Gene ID	Fold Change
Igf1	2.787
Vwa1	2.072
Ero1l	1.889
Errfi1	1.882
Ccdc80	1.882
Bcl2	1.768
Adamts9	1.760
Ruvbl1	1.738
Pxdn	1.723
Lum	1.722
Adamts3	-1.755
Dnajc19	-1.763
Jam3	-1.792

Genes Unique to WT Sham vs WT TAC: 43 increased, 25 decreased

Gene ID	Fold Change
Ereg	240.348
Adam8	117.349
Timp1	112.492
Arg1	94.628
Pak3	32.821
Ccl2	25.129
Col11a1	17.389
Ccna2	14.460
Lgals3	13.711
Myc	13.703
Loxl4	9.535
Itgb2	9.094
Ubash3b	7.652
Ptx3	7.589
Ptgs2	7.153
Pdpn	6.605
Pak1	6.585
Sphk1	6.439
Nlrc3	6.282
Il17ra	5.718
Mmp19	5.480
Fbn2	5.043
Tgif1	4.348
Itgb3	3.912
Thy1	3.651
Egr3	3.598
Plau	3.321
Pik3cg	3.245
Itga11	3.174

Genes Shared by FFAR4 KO Sham vs FFAR4 KO TAC and WT Sham vs WT TAC: 98 increased, 26 decreased

Gene ID	Fold Change KO	Fold Change WT
Lox	24.312	34.324
Serpine1	16.010	24.941
Postn	15.162	13.826
Col1a1	11.043	11.083
Col12a1	10.283	11.121
Col3a1	10.165	9.226
Col5a2	9.968	9.928
Col8a1	9.567	9.110
Cd44	9.335	9.640
Tgfb2	8.828	10.745
Loxl3	8.357	14.007
Col1a2	8.165	7.647
Fn1	7.686	8.424
Loxl2	7.354	7.545
Col5a1	6.935	6.841
Thbs1	6.419	6.000
Ctss	6.082	6.240
Fbn1	5.625	5.364
Anxa2	5.166	6.442
Lcp1	5.083	6.470
Mrc2	4.616	3.066
Mmp14	4.608	5.418
Col16a1	4.513	3.752
Emilin1	4.265	4.364
Vim	4.049	3.986
Creb3l1	3.704	4.160
Adamts2	3.608	3.687
Fbln2	3.515	3.839
Tgfbi	3.493	3.399

Bcl3	2.694		Sh3pxd2b	3.486	3.501
Col27a1	2.693		Adamts12	3.453	3.580
Pdgfc	2.636		Cd63	3.435	3.194
Arrb2	2.484		Ifi30	3.347	3.281
Tram2	2.447		Mmp3	3.340	2.805
Mmp23	2.431		Sfrp1	3.307	3.030
D1Ertd622e	2.416		Col4a1	3.301	3.032
Cib1	2.066		Tgfb3	3.271	2.029
Bax	2.038		Col15a1	3.191	2.929
Fgfr1	1.934		Aebp1	3.139	3.664
Gpm6b	1.905		Eln	2.913	2.003
Nfkb2	1.866		Zyx	2.880	2.798
Sulf2	1.768		Col14a1	2.859	2.153
Adam15	1.726		Serpinh1	2.807	2.799
Dpt	-1.722		Col5a3	2.805	2.260
Fzd4	-1.750		Col18a1	2.799	3.149
Gstp1	-1.766		Col4a2	2.797	2.674
Lims1	-1.767		Prkcd	2.795	2.078
Tek	-1.816		Fosl2	2.782	3.120
Cd59a	-1.832		Adam9	2.775	2.992
Gpc1	-1.893		Rcn3	2.772	3.552
Kif16b	-1.898		Bak1	2.750	3.150
Dll4	-1.979		Sox9	2.653	2.948
Abi3bp	-1.980		Syk	2.586	3.022
Reck	-2.041		Fscn1	2.554	1.949
Col4a3	-2.048		Plod3	2.509	2.553
Pdgfd	-2.100		P3h1	2.506	2.958
Dand5	-2.293		Iqgap1	2.488	2.517
Id1	-2.367		Cdkn1a	2.459	2.314
Smoc2	-2.392		Mfap4	2.445	2.813
Fgf9	-2.474		Ilk	2.436	2.613
Has3	-2.573		Sdc4	2.343	2.329
Fuz	-2.725		Ddr1	2.343	3.180
Wnt5a	-2.734		Ptk2b	2.311	2.958
Tcf15	-2.877		Vcam1	2.304	2.086
Enpp2	-3.196		Col4a5	2.301	1.958
Dpp4	-3.837		Sulf1	2.265	2.514
Egf	-4.469		Itga4	2.244	2.883
Fgf12	-5.785		Itgb1	2.223	2.307
			Tnfrsf1a	2.209	2.301

Olfml2b	2.201	2.322
Trp53	2.166	2.165
Rcc2	2.146	2.043
Vps33b	2.137	1.953
Emp2	2.111	2.255
Hif1a	2.108	2.022
Ptprj	2.104	1.777
Hsd17b12	2.070	3.062
Tnfrsf1b	2.067	2.151
P3h3	2.044	2.019
Nras	2.013	2.256
Lamc1	2.000	1.813
Sgpl1	1.982	2.148
F2r	1.915	2.004
Tmem38b	1.900	2.004
Itgbl1	1.869	1.986
Hyal2	1.853	1.806
Actr3	1.840	2.003
Itgav	1.831	1.859
Tgfb1	1.830	1.963
Csgalnact1	1.827	1.919
Tgfbr1	1.826	1.858
Cdk6	1.801	1.781
Colgalt1	1.798	1.726
B4galt1	1.792	2.046
Ctsb	1.785	2.093
Coro1c	1.759	1.843
Slc8a1	1.727	1.886
Pmp22	1.714	1.736
Clasp2	-1.723	-1.728
Clasp1	-1.751	-2.046
Bcl2l11	-1.769	-2.251
Pex6	-1.773	-2.500
Jun	-1.810	-1.759
Pdcd4	-1.823	-1.795
Sod2	-1.863	-2.121
Rgcc	-1.878	-2.006
Ndufs4	-1.885	-2.218
Apbb1	-1.896	-1.712
Dach1	-1.897	-2.799

Itgb6	-1.918	-2.285
Tnxb	-1.937	-3.175
Idh2	-1.945	-2.544
Tgfbr3	-1.947	-1.725
Ecm2	-2.033	-2.536
Ndnf	-2.038	-1.973
Vtn	-2.045	-3.620
Col4a4	-2.072	-2.081
Fbln1	-2.080	-2.386
Mmp15	-2.237	-2.565
Cd200	-2.288	-2.106
Pik3r1	-2.401	-2.446
Timm21	-2.440	-1.991
Egflam	-2.554	-2.092
Aqp1	-2.678	-3.200

Supplemental Table 11. GPR Genes
GO Terms: G-protein

Genes Unique to FFAR4 KO Sham vs FFAR4 KO TAC: 4 increased, 0 decreased		Genes Unique to WT Sham vs WT TAC: 23 increased, 27 decreased		Genes Shared by FFAR4 KO Sham vs FFAR4 KO TAC and WT Sham vs WT TAC: 19 increased, 17 decreased		
Gene ID	Fold Change	Gene ID	Fold Change	Gene ID	Fold Change KO	Fold Change WT
Cx3cl1	2.987	Ccl2	25.129	Ccl6	4.955	4.562
Adgrd1	2.575	Cxcr6	18.350	Ccl9	4.518	5.177
Akap12	2.225	Ccr2	14.716	Tgm2	4.504	4.795
Prex1	1.716	Ccl7	12.622	Adcyap1r1	3.613	4.621
		Gpr35	10.420	Adcy7	2.959	2.815
		Pik3r5	10.221	Anxa1	2.922	2.855
		Ccr1	9.871	Adgre1	2.830	3.153
		C5ar1	7.009	Syk	2.586	3.022
		Plek	6.558	Lpar1	2.370	2.072
		C3ar1	6.280	Bcar1	2.279	1.778
		Vav1	5.911	Itgb1	2.223	2.307
		Pf4	5.217	Gprc5b	2.020	1.770
		Ccr5	4.734	Lrp1	1.916	1.889
		Itgb3	3.912	F2r	1.915	2.004
		P2ry6	3.282	Gnao1	1.861	2.401
		Pik3cg	3.245	Gpr153	1.852	2.554
		S1pr2	3.129	Grk5	1.827	2.082
		Cx3cr1	2.848	Usp20	1.795	2.179
		Fzd2	2.615	Fzd1	1.728	2.331
		Arrb2	2.484	Sort1	-1.710	-1.915
		Rgs10	2.307	Palm	-1.805	-1.909
		Adgra3	2.035	Ano1	-1.849	-2.281
		Gnai2	1.739	Agtr1a	-1.868	-1.727
		Adgrl4	-1.714	Gpr157	-1.896	-2.042
		Mgrn1	-1.726	Lgr6	-1.908	-2.249
		Gpsm1	-1.735	Grm1	-1.938	-2.100
		Fzd4	-1.750	Npr3	-1.957	-2.357
		Rgs3	-1.772	Crhr2	-2.026	-1.926
		Rapgef2	-1.888	Rgs6	-2.082	-1.826
		Pde5a	-1.902	Ric8b	-2.130	-2.509

Gkap1	-1.945		Rgs5	-2.151	-2.708
Prex2	-1.984		Adra1b	-2.439	-2.145
Dgke	-2.003		Rgs2	-3.313	-3.246
Adgrf5	-2.285		Adra1a	-3.544	-3.681
Ackr3	-2.301		P2ry1	-4.190	-5.821
Fzd8	-2.320		Gpr22	-6.708	-6.137
Kctd12b	-2.449				
Ccrl2	-2.506				
Camk2b	-2.688				
Wnt5a	-2.734				
P2ry14	-2.855				
Rgs17	-3.355				
Adcy1	-3.363				
Celsr2	-3.647				
Rgs7bp	-3.920				
Akap5	-4.109				
Gnb3	-5.439				
Ptgfr	-5.664				
Mrgprh	-7.156				
Celsr3	-17.699				

Supplemental Table 12. Fatty Acid Metabolism Genes

GO Terms: Fatty acid

Genes Unique to FFAR4 KO Sham vs FFAR4 KO TAC: 0 increased, 4 decreased

Gene ID	Fold Change
Prkab2	1.747
Mlxipl	-1.737
Aig1	-1.869
Scd1	-1.872

Genes Unique to WT Sham vs WT TAC: 11 increased, 17 decreased

Gene ID	Fold Change
Ptgs2	7.153
Brca1	6.587
Tbxas1	4.509
Aacs	3.760
Tlr2	3.624
Hpgds	3.154
Pdk3	2.571
Hacd4	2.187
Acsl4	2.043
Lpin2	2.023
Plin2	1.801
Decr1	-1.703
Asah2	-1.724
Acadsb	-1.735
Echdc2	-1.741
Irs1	-1.748
Acadvl	-1.760
Cbr4	-1.783
Echs1	-1.816
Akt2	-1.847
Acads	-1.875
Alkbh7	-1.918
Hibch	-2.002
Pnpla8	-2.032
Abcd2	-2.278
Acot1	-3.193
Ucp3	-4.553
Acsm5	-5.715

Genes Shared by FFAR4 KO Sham vs FFAR4 KO TAC and WT Sham vs WT TAC: 15 increased, 40 decreased

Gene ID	Fold Change KO	Fold Change WT
Thbs1	6.419	6.000
Ldlr	3.813	4.756
Myo5a	3.745	2.816
Ankrd23	3.449	2.536
Fads3	2.738	3.250
Ptgis	2.577	2.278
Eif6	2.466	3.325
Elovl1	2.273	2.978
Nucb2	2.250	2.253
Tlr4	2.125	2.071
Por	2.086	2.004
Abcc1	2.004	1.837
Sgpl1	1.982	2.148
Xbp1	1.935	1.979
Fads1	1.812	1.754
Gpam	-1.714	-2.049
Lpl	-1.737	-2.346
Lipe	-1.738	-1.839
Abcd3	-1.744	-1.814
Tecrl	-1.746	-1.709
Hadha	-1.757	-2.090
Acat1	-1.762	-2.006
Acot11	-1.764	-1.847
Acaa2	-1.772	-1.909
Phyh	-1.774	-1.885
Auh	-1.775	-1.982
Etfb	-1.791	-1.949
Aldh5a1	-1.853	-2.780
Ivd	-1.885	-2.559

Crat	-1.899	-2.050
Etfdh	-1.923	-2.156
Tnxb	-1.937	-3.175
Acot2	-1.965	-2.003
Eci1	-1.981	-2.429
Cpt2	-2.030	-2.238
Etfa	-2.081	-2.236
Hadhb	-2.095	-2.290
Gcdh	-2.145	-2.427
Acadm	-2.161	-2.786
Ech1	-2.223	-2.511
Acacb	-2.284	-2.644
Hadh	-2.364	-2.757
Plin5	-2.386	-2.429
Mlycd	-2.415	-2.520
Ptgds	-2.433	-3.263
Acad11	-2.509	-2.647
Ppargc1a	-2.536	-3.388
C1qtnf9	-2.573	-3.581
Ppara	-2.614	-2.691
Acsl1	-2.638	-3.018
Tecr	-2.723	-2.728
Acsl6	-2.754	-3.114
Lpin1	-2.759	-2.924
Dgat2	-2.763	-2.645
Ces1d	-6.513	-9.549

Supplemental Table 13. Hypertrophy Genes

GO Terms: Hypertrophy, cell growth involved in cardiac muscle cell

Genes Unique to FFAR4 KO Sham vs FFAR4 KO TAC: 4 increased, 3 decreased

Gene ID	Fold Change
Igf1	2.787
Myh7	2.484
Cyba	2.019
Errfi1	1.882
Ar	-1.853
Adra1b	-2.439
Bmp10	-8.321

Genes Unique to WT Sham vs WT TAC: 1 increased, 2 decreased

Gene ID	Fold Change
Pak1	6.585
Pde5a	-1.902
Trpc3	-2.778

Genes Shared by FFAR4 KO Sham vs FFAR4 KO TAC and WT Sham vs WT TAC: 16 increased, 10 decreased

Gene ID	Fold Change KO	Fold Change WT
Nppb	8.688	5.931
Lmcd1	3.848	3.012
G6pdx	3.290	3.119
Cav3	3.100	3.035
Col14a1	2.859	2.153
Nppa	2.800	4.948
Lmna	2.742	3.030
Sorbs2	2.727	2.767
Sox9	2.653	2.948
Mtpn	2.397	2.763
Csrp3	2.219	2.003
Tnfrsf1a	2.209	2.301
Tnfrsf1b	2.067	2.151
Pdlim5	2.037	2.390
Twf1	1.876	1.737
Ctdp1	1.718	2.013
Slc25a4	-1.709	-1.835
Akap1	-1.714	-1.871
Atp2a2	-2.035	-2.385
Myh6	-2.039	-2.507
Klf15	-2.116	-2.747
Fbxo32	-2.129	-2.753
Ppara	-2.614	-2.691
Tcap	-2.645	-2.400
Rgs2	-3.313	-3.246
Adra1a	-3.544	-3.681

Supplemental Table 14 LC/MS/MS detection and quantitation of oxylipins.

COMPOUND	PRECURSOR ION	PRODUCT ION	DWELL TIME (SEC)	RETENTION TIME (MINS)	CONE (V)	CE (EV)	LOD (NM)	LOQ (NM)	INTERNAL STANDARD
9-HOTRE	293.1	171.1	0.08	6.37	36	16	0.29	0.89	9-HODE d4
9-KODE	293.1	185.1	0.02	7.43	34	16	0.49	1.48	9-HODE d4
13-KODE	293.1	195.1	0.02	7.29	34	16	0.39	1.18	9-HODE d4
13-HOTRE	293.1	195.2	0.08	6.46	36	16	0.38	1.14	9-HODE d4
9-HODE	295.1	171.1	0.02	7.07	34	14	0.14	0.43	9-HODE d4
9(10)-EPOME	295.1	171.1	0.03	7.99	35	14	0.27	0.81	9(10)-EpOME d4
13-HODE	295.1	195.1	0.03	7.03	34	14	0.10	0.31	9-HODE d4
12(13)-EPOME	295.1	195.1	0.03	7.93	35	14	0.16	0.48	9(10)-EpOME d4
9-HODE D4	299.1	172.1	0.02	7.04	34	16	0.33	0.99	-
9(10)-EPOME D4	299.2	172.1	0.03	7.95	35	14	0.43	1.31	-
9(10)-DIHOME	313.1	201.1	0.05	5.79	28	8	2.07	6.28	9(10)-EpOME d4
15-KETE	317.1	113.1	0.02	7.34	34	14	0.27	0.81	12-HETE d8
5-HEPE	317.1	115.1	0.04	6.92	28	16	0.60	1.81	12-HETE d8
11-HEPE	317.1	121.1	0.05	6.67	28	16	0.46	1.39	12-HETE d8
8-HEPE	317.1	127.1	0.05	6.74	28	16	0.79	2.39	12-HETE d8
9-HEPE	317.1	149.1	0.04	6.81	28	16	0.34	1.02	12-HETE d8
12-HEPE	317.1	179.1	0.05	6.77	28	16	0.27	0.81	12-HETE d8
5-KETE	317.1	203.1	0.03	7.8	34	14	0.42	1.27	12-HETE d8
11(12)-EPETE	317.1	208.1	0.02	7.45	32	10	0.41	1.23	14,15-EET d11
15-HEPE	317.1	219.1	0.05	6.63	28	16	0.49	1.49	12-HETE d8
17(18)-EPETE	317.1	259.4	0.02	7.2	32	10	1.88	5.71	14,15-EET d11
12-KETE	317.1	273.2	0.02	7.54	34	14	0.63	1.90	12-HETE d8
8(9)-EPETE	317.1	299.1	0.02	7.49	32	10	1.15	3.48	14,15-EET d11
18-HEPE	317.2	215.2	0.08	6.46	34	12	0.20	0.60	12-HETE d8
14(15)-EPETE	317.2	247.3	0.02	7.4	32	10	1.15	3.47	14,15-EET d11
12-HETE	319.0	179.1	0.02	7.43	32	14	0.63	1.89	12-HETE d8
5-HETE	319.1	114.9	0.08	7.64	32	14	0.29	0.88	12-HETE d8
9-HETE	319.1	123.0	0.02	7.54	32	14	0.22	0.67	12-HETE d8
15-HETE	319.1	219.0	0.02	7.17	32	14	0.26	0.79	12-HETE d8
8(9)-EPETRE	319.1	155.1	0.20	8.23	30	10	0.09	0.28	14,15-EET d11
11(12)-EPETRE	319.1	208.1	0.03	8.16	30	10	0.48	1.44	14,15-EET d11
14(15)-EPETRE	319.1	219.1	0.03	7.93	30	10	0.43	1.29	14,15-EET d11
12-HETE D8	327.2	184.1	0.02	7.38	35	14	3.35	10.15	-
14,15-EET D11	330.1	219.0	0.03	7.88	30	10	0.35	1.05	-
12-HPETE	335.1	153.1	0.02	7.54	20	8	0.64	1.94	12-HETE d8
15-HPETE	335.1	219.1	0.02	7.33	20	6	0.58	1.77	12-HETE d8
11(12)-DIHETE	335.2	167.2	0.05	5.53	25	8	2.53	7.66	14,15-EET d11
14(15)-DIHETE	335.2	207.2	0.05	5.46	25	8	0.07	0.21	14,15-EET d11
17(18)-DIHETE	335.2	247.2	0.11	5.29	25	8	0.54	1.62	14,15-EET d11
8(9)-DIHETE	335.2	317.2	0.05	5.61	25	8	1.58	4.78	14,15-EET d11
8(9)-DIHETRE	337.1	127.1	0.08	6.38	28	8	1.21	3.68	14,15-EET d11
11(12)-DIHETRE	337.1	167.1	0.08	6.19	28	8	1.83	5.54	14,15-EET d11
14(15)-DIHETRE	337.1	207.1	0.16	5.96	28	8	0.64	1.95	14,15-EET d11
CUDA	340.2	214.1	0.05	5.82	34	12	-	-	-
7(8)-EPDPE	343.1	189.1	0.03	8.18	34	10	1.41	4.27	12-HETE d8
13(14)-EPDPE	343.1	193.1	0.03	8.05	34	10	0.58	1.77	12-HETE d8
16(17)-EPDPE	343.1	233.1	0.03	8.02	34	10	0.21	0.62	12-HETE d8
19(20)-EPDPE	343.1	281.1	0.03	7.81	34	10	0.28	0.85	12-HETE d8
10(11)-EPDPE	343.1	299.1	0.03	8.18	34	10	0.74	2.26	12-HETE d8
4-HDOHE	343.2	101.1	0.03	7.81	35	10	0.54	1.65	12-HETE d8
8-HDOHE	343.2	109.1	0.02	7.56	35	10	0.15	0.47	12-HETE d8
7-HDOHE	343.2	141.1	0.02	7.51	35	10	0.59	1.78	12-HETE d8
11-HDOHE	343.2	149.1	0.02	7.45	35	10	0.59	1.80	12-HETE d8
10-HDOHE	343.2	181.1	0.02	7.37	35	10	0.74	2.24	12-HETE d8
14-HDOHE	343.2	205.1	0.02	7.36	35	10	0.23	0.70	12-HETE d8
13-HDOHE	343.2	221.1	0.02	7.3	35	10	0.45	1.36	12-HETE d8
16-HDOHE	343.2	233.1	0.02	7.22	35	12	0.85	2.58	12-HETE d8
20-HDOHE	343.2	241.1	0.02	7.06	35	12	0.43	1.30	12-HETE d8
17-HDOHE	343.2	245.1	0.02	7.24	35	12	0.27	0.83	12-HETE d8
22-HDOHE	343.2	281.1	0.04	6.96	35	12	0.66	2.00	12-HETE d8
RESOLVIN D1	375.1	141.1	0.16	4.15	34	16	0.06	0.20	14,15-EET d11

Supplemental Table 15. Time dependent changes in myocyte oxylipins, by pool.

						Myocytes		*Interaction*	*Test for difference at each time*	
Fraction	**Compartment**	**pFA**	**Chemistry**	**Oxylipin**	**Time**	**WT (CI)**	**KO (CI)**	**Prob>|t|**	**%Difference (CI)**	**Prob>|t|**
Esterified	Cell	LA	Alcohol	9-HODE	0	15 (8, 25)	12 (7, 21)	0.76	-17% (-74, 159)	>0.80
Esterified	Cell	LA	Alcohol	9-HODE	15	20 (12, 34)	16 (10, 27)		-20% (-69, 109)	>0.80
Esterified	Cell	LA	Alcohol	9-HODE	30	26 (15, 43)	20 (12, 33)		-23% (-69, 94)	>0.80
Esterified	Cell	LA	Alcohol	9-HODE	60	28 (16, 50)	20 (11, 36)		-28% (-80, 155)	>0.80
NEOx	Cell	LA	Alcohol	9-HODE	0	1.15 (0.63, 2.11)	1.02 (0.56, 1.88)	>0.80	-11% (-75, 217)	>0.80
NEOx	Cell	LA	Alcohol	9-HODE	15	1.13 (0.69, 1.86)	0.97 (0.59, 1.6)		-14% (-68, 129)	>0.80
NEOx	Cell	LA	Alcohol	9-HODE	30	1.12 (0.66, 1.88)	0.93 (0.55, 1.56)		-17% (-66, 107)	>0.80
NEOx	Cell	LA	Alcohol	9-HODE	60	1.1 (0.57, 2.11)	0.86 (0.45, 1.65)		-22% (-82, 237)	>0.80
Esterified	Media	LA	Alcohol	9-HODE	0	5.01 (3.09, 8.11)	4.02 (2.48, 6.51)	>0.80	-20% (-70, 114)	>0.80
Esterified	Media	LA	Alcohol	9-HODE	15	4.85 (3.02, 7.78)	3.91 (2.44, 6.27)		-19% (-67, 95)	>0.80
Esterified	Media	LA	Alcohol	9-HODE	30	4.9 (3.06, 7.84)	3.97 (2.48, 6.35)		-19% (-66, 91)	>0.80
Esterified	Media	LA	Alcohol	9-HODE	60	5.65 (3.45, 9.25)	4.63 (2.83, 7.58)		-18% (-71, 135)	>0.80
NEOx	Media	LA	Alcohol	9-HODE	0	0.6 (0.31, 1.15)	0.52 (0.27, 1)	>0.80	-13% (-78, 239)	>0.80
NEOx	Media	LA	Alcohol	9-HODE	15	0.86 (0.48, 1.55)	0.73 (0.41, 1.31)		-15% (-73, 161)	>0.80
NEOx	Media	LA	Alcohol	9-HODE	30	1.04 (0.58, 1.89)	0.86 (0.47, 1.55)		-18% (-72, 140)	>0.80
NEOx	Media	LA	Alcohol	9-HODE	60	0.9 (0.45, 1.78)	0.7 (0.35, 1.39)		-22% (-83, 256)	>0.80
Esterified	Cell	LA	Alcohol	13-HODE	0	18 (11, 31)	15 (9, 25)	0.53	-19% (-74, 149)	>0.80
Esterified	Cell	LA	Alcohol	13-HODE	15	23 (14, 39)	18 (11, 29)		-24% (-71, 96)	>0.80
Esterified	Cell	LA	Alcohol	13-HODE	30	28 (17, 46)	20 (12, 33)		-29% (-72, 77)	>0.80
Esterified	Cell	LA	Alcohol	13-HODE	60	32 (19, 57)	20 (11, 35)		-38% (-82, 113)	>0.80
NEOx	Cell	LA	Alcohol	13-HODE	0	1.67 (0.94, 2.96)	1.24 (0.7, 2.19)	0.39	-26% (-77, 141)	>0.80
NEOx	Cell	LA	Alcohol	13-HODE	15	1.76 (1.19, 2.6)	1.13 (0.77, 1.68)		-36% (-71, 41)	0.54
NEOx	Cell	LA	Alcohol	13-HODE	30	1.93 (1.25, 2.99)	1.08 (0.7, 1.67)		-44% (-72, 11)	0.13
NEOx	Cell	LA	Alcohol	13-HODE	60	2.62 (1.39, 4.93)	1.11 (0.59, 2.09)		-58% (-90, 75)	0.45
Esterified	Media	LA	Alcohol	13-HODE	0	6.14 (3.53, 10.69)	5.25 (3.02, 9.14)	0.61	-15% (-71, 148)	>0.80
Esterified	Media	LA	Alcohol	13-HODE	15	5.57 (3.18, 9.76)	4.9 (2.8, 8.59)		-12% (-68, 144)	>0.80
Esterified	Media	LA	Alcohol	13-HODE	30	5.46 (3.12, 9.53)	4.94 (2.83, 8.64)		-9% (-67, 149)	>0.80
Esterified	Media	LA	Alcohol	13-HODE	60	6.6 (3.79, 11.48)	6.34 (3.64, 11.03)		-4% (-68, 188)	>0.80
NEOx	Media	LA	Alcohol	13-HODE	0	0.45 (0.25, 0.83)	0.92 (0.5, 1.69)	0.35	105% (-38, 572)	0.46
NEOx	Media	LA	Alcohol	13-HODE	15	0.94 (0.69, 1.28)	1.6 (1.17, 2.18)		71% (-5, 206)	0.08
NEOx	Media	LA	Alcohol	13-HODE	30	1.43 (0.95, 2.15)	2.04 (1.36, 3.06)		43% (0, 103)	0.05
NEOx	Media	LA	Alcohol	13-HODE	60	1.33 (0.67, 2.65)	1.32 (0.66, 2.63)		-1% (-78, 349)	>0.80
Esterified	Cell	aLA	Alcohol	9-HOTrE	0	0.48 (0.22, 1.04)	0.15 (0.07, 0.33)	0.18	-68% (-93, 51)	0.24
Esterified	Cell	aLA	Alcohol	9-HOTrE	15	0.66 (0.42, 1.04)	0.29 (0.19, 0.46)		-56% (-82, 9)	0.09
Esterified	Cell	aLA	Alcohol	9-HOTrE	30	0.73 (0.42, 1.27)	0.45 (0.26, 0.77)		-39% (-70, 23)	0.28
Esterified	Cell	aLA	Alcohol	9-HOTrE	60	0.46 (0.19, 1.09)	0.53 (0.22, 1.26)		16% (-83, 692)	>0.80
NEOx	Cell	aLA	Alcohol	9-HOTrE	0	0.17 (0.07, 0.44)	0.12 (0.05, 0.31)	>0.80	-29% (-90, 410)	>0.80
NEOx	Cell	aLA	Alcohol	9-HOTrE	15	0.15 (0.07, 0.34)	0.11 (0.05, 0.25)		-26% (-85, 259)	>0.80
NEOx	Cell	aLA	Alcohol	9-HOTrE	30	0.15 (0.07, 0.34)	0.12 (0.05, 0.27)		-22% (-82, 243)	>0.80
NEOx	Cell	aLA	Alcohol	9-HOTrE	60	0.2 (0.07, 0.54)	0.17 (0.06, 0.46)		-14% (-91, 706)	>0.80
Esterified	Media	aLA	Alcohol	9-HOTrE	0	0.5 (0.23, 1.1)	0.21 (0.1, 0.47)	0.34	-57% (-91, 114)	0.60
Esterified	Media	aLA	Alcohol	9-HOTrE	15	0.52 (0.31, 0.88)	0.28 (0.17, 0.47)		-47% (-81, 51)	0.45
Esterified	Media	aLA	Alcohol	9-HOTrE	30	0.54 (0.3, 0.98)	0.36 (0.2, 0.65)		-34% (-73, 61)	0.74
Esterified	Media	aLA	Alcohol	9-HOTrE	60	0.57 (0.24, 1.37)	0.59 (0.25, 1.41)		3% (-85, 627)	>0.80
NEOx	Media	aLA	Alcohol	9-HOTrE	0	0.26 (0.14, 0.51)	0.2 (0.1, 0.38)	0.56	-25% (-81, 189)	>0.80
NEOx	Media	aLA	Alcohol	9-HOTrE	15	0.21 (0.13, 0.35)	0.17 (0.11, 0.29)		-18% (-69, 121)	>0.80
NEOx	Media	aLA	Alcohol	9-HOTrE	30	0.18 (0.11, 0.31)	0.17 (0.1, 0.28)		-9% (-63, 123)	>0.80
NEOx	Media	aLA	Alcohol	9-HOTrE	60	0.18 (0.09, 0.37)	0.2 (0.1, 0.41)		12% (-77, 446)	>0.80
Esterified	Cell	aLA	Alcohol	13-HOTrE	0	0.6 (0.22, 1.63)	0.39 (0.14, 1.05)	>0.80	-35% (-92, 428)	>0.80
Esterified	Cell	aLA	Alcohol	13-HOTrE	15	0.64 (0.29, 1.41)	0.41 (0.19, 0.91)		-36% (-87, 208)	>0.80
Esterified	Cell	aLA	Alcohol	13-HOTrE	30	0.69 (0.3, 1.59)	0.44 (0.19, 1.02)		-36% (-85, 169)	>0.80
Esterified	Cell	aLA	Alcohol	13-HOTrE	60	0.8 (0.27, 2.38)	0.51 (0.17, 1.51)		-36% (-94, 633)	>0.80
NEOx	Cell	aLA	Alcohol	13-HOTrE	0	0.56 (0.23, 1.34)	0.39 (0.16, 0.94)	0.15	-29% (-89, 342)	>0.80
NEOx	Cell	aLA	Alcohol	13-HOTrE	15	0.41 (0.2, 0.86)	0.21 (0.1, 0.44)		-48% (-88, 119)	0.75
NEOx	Cell	aLA	Alcohol	13-HOTrE	30	0.4 (0.19, 0.86)	0.15 (0.07, 0.33)		-62% (-90, 46)	0.26
NEOx	Cell	aLA	Alcohol	13-HOTrE	60	0.91 (0.36, 2.32)	0.18 (0.07, 0.47)		-80% (-98, 64)	0.21
Esterified	Media	aLA	Alcohol	13-HOTrE	0	0.35 (0.16, 0.72)	0.2 (0.09, 0.41)	0.33	-43% (-88, 168)	>0.80
Esterified	Media	aLA	Alcohol	13-HOTrE	15	0.46 (0.25, 0.87)	0.31 (0.17, 0.58)		-33% (-80, 128)	>0.80
Esterified	Media	aLA	Alcohol	13-HOTrE	30	0.53 (0.28, 1.02)	0.43 (0.22, 0.82)		-20% (-74, 151)	>0.80
Esterified	Media	aLA	Alcohol	13-HOTrE	60	0.44 (0.2, 0.96)	0.5 (0.22, 1.09)		14% (-81, 571)	>0.80
NEOx	Media	aLA	Alcohol	13-HOTrE	0	0.14 (0.05, 0.36)	0.38 (0.14, 1.01)	0.29	179% (-64, 2042)	0.65
NEOx	Media	aLA	Alcohol	13-HOTrE	15	0.15 (0.07, 0.35)	0.33 (0.15, 0.76)		117% (-57, 986)	0.70
NEOx	Media	aLA	Alcohol	13-HOTrE	30	0.18 (0.08, 0.42)	0.31 (0.13, 0.72)		69% (-63, 665)	>0.80
NEOx	Media	aLA	Alcohol	13-HOTrE	60	0.28 (0.1, 0.79)	0.29 (0.1, 0.81)		3% (-90, 951)	>0.80
Esterified	Cell	AA	Alcohol	5-HETE	0	15 (7, 32)	11 (5, 23)	0.57	-27% (-85, 253)	>0.80
Esterified	Cell	AA	Alcohol	5-HETE	15	20 (9, 42)	14 (6, 29)		-31% (-83, 185)	>0.80
Esterified	Cell	AA	Alcohol	5-HETE	30	25 (12, 53)	16 (7, 34)		-36% (-84, 157)	>0.80
Esterified	Cell	AA	Alcohol	5-HETE	60	31 (14, 69)	17 (8, 38)		-44% (-90, 197)	>0.80
NEOx	Cell	AA	Alcohol	5-HETE	0	0.15 (0.1, 0.24)	0.13 (0.08, 0.2)	0.46	-16% (-67, 119)	>0.80
NEOx	Cell	AA	Alcohol	5-HETE	15	0.19 (0.13, 0.29)	0.15 (0.1, 0.23)		-22% (-64, 72)	>0.80
NEOx	Cell	AA	Alcohol	5-HETE	30	0.22 (0.15, 0.34)	0.16 (0.11, 0.24)		-27% (-65, 54)	>0.80
NEOx	Cell	AA	Alcohol	5-HETE	60	0.22 (0.14, 0.36)	0.14 (0.09, 0.23)		-37% (-78, 83)	0.79
Esterified	Media	AA	Alcohol	5-HETE	0	0.42 (0.2, 0.88)	0.33 (0.16, 0.69)	>0.80	-21% (-83, 256)	>0.80
Esterified	Media	AA	Alcohol	5-HETE	15	0.4 (0.2, 0.81)	0.31 (0.15, 0.63)		-23% (-79, 190)	>0.80
Esterified	Media	AA	Alcohol	5-HETE	30	0.41 (0.2, 0.83)	0.31 (0.15, 0.63)		-24% (-79, 174)	>0.80
Esterified	Media	AA	Alcohol	5-HETE	60	0.51 (0.24, 1.09)	0.38 (0.18, 0.81)		-26% (-86, 285)	>0.80
NEOx	Media	AA	Alcohol	5-HETE	0	0.16 (0.09, 0.26)	0.13 (0.08, 0.22)	0.27	-14% (-70, 142)	>0.80
NEOx	Media	AA	Alcohol	5-HETE	15	0.16 (0.1, 0.26)	0.15 (0.09, 0.24)		-5% (-62, 139)	>0.80
NEOx	Media	AA	Alcohol	5-HETE	30	0.16 (0.1, 0.25)	0.16 (0.1, 0.27)		5% (-57, 157)	>0.80
NEOx	Media	AA	Alcohol	5-HETE	60	0.15 (0.09, 0.26)	0.2 (0.12, 0.33)		27% (-58, 289)	>0.80

Esterified	Cell	AA	Alcohol	9-HETE	0	1.02 (0.38, 2.75)	0.6 (0.22, 1.62)	0.65	-41% (-93, 362)	>0.80
Esterified	Cell	AA	Alcohol	9-HETE	15	0.89 (0.42, 1.89)	0.47 (0.22, 0.99)		-48% (-88, 133)	0.79
Esterified	Cell	AA	Alcohol	9-HETE	30	0.96 (0.43, 2.15)	0.45 (0.2, 1)		-53% (-88, 80)	0.53
Esterified	Cell	AA	Alcohol	9-HETE	60	2.1 (0.72, 6.16)	0.77 (0.26, 2.27)		-63% (-97, 313)	>0.80
NEOx	Cell	AA	Alcohol	9-HETE	0	0.32 (0.18, 0.59)	0.3 (0.16, 0.55)	0.62	-6% (-73, 221)	>0.80
NEOx	Cell	AA	Alcohol	9-HETE	15	0.48 (0.33, 0.71)	0.41 (0.28, 0.61)		-14% (-60, 86)	>0.80
NEOx	Cell	AA	Alcohol	9-HETE	30	0.61 (0.39, 0.95)	0.48 (0.31, 0.75)		-21% (-59, 49)	>0.80
NEOx	Cell	AA	Alcohol	9-HETE	60	0.6 (0.3, 1.17)	0.39 (0.2, 0.77)		-34% (-85, 195)	>0.80
Esterified	Media	AA	Alcohol	9-HETE	0	0.4 (0.21, 0.76)	0.41 (0.21, 0.77)	0.07	1% (-73, 283)	>0.80
Esterified	Media	AA	Alcohol	9-HETE	15	0.48 (0.26, 0.87)	0.38 (0.21, 0.69)		-21% (-75, 150)	>0.80
Esterified	Media	AA	Alcohol	9-HETE	30	0.54 (0.3, 1)	0.34 (0.19, 0.62)		-38% (-79, 88)	>0.80
Esterified	Media	AA	Alcohol	9-HETE	60	0.63 (0.32, 1.23)	0.24 (0.12, 0.47)		-61% (-91, 66)	0.36
NEOx	Media	AA	Alcohol	9-HETE	0	0.35 (0.16, 0.76)	0.39 (0.18, 0.84)	>0.80	11% (-78, 452)	>0.80
NEOx	Media	AA	Alcohol	9-HETE	15	0.4 (0.19, 0.83)	0.44 (0.21, 0.93)		12% (-72, 356)	>0.80
NEOx	Media	AA	Alcohol	9-HETE	30	0.39 (0.19, 0.83)	0.45 (0.21, 0.94)		14% (-71, 343)	>0.80
NEOx	Media	AA	Alcohol	9-HETE	60	0.27 (0.12, 0.61)	0.32 (0.14, 0.71)		17% (-80, 580)	>0.80
Esterified	Cell	AA	Alcohol	12-HETE	0	0.85 (0.39, 1.89)	0.51 (0.23, 1.14)	0.77	-40% (-89, 218)	>0.80
Esterified	Cell	AA	Alcohol	12-HETE	15	1.05 (0.53, 2.09)	0.67 (0.34, 1.33)		-36% (-83, 142)	>0.80
Esterified	Cell	AA	Alcohol	12-HETE	30	1.2 (0.59, 2.42)	0.8 (0.4, 1.63)		-33% (-81, 137)	>0.80
Esterified	Cell	AA	Alcohol	12-HETE	60	1.22 (0.53, 2.85)	0.92 (0.39, 2.13)		-25% (-89, 394)	>0.80
NEOx	Cell	AA	Alcohol	12-HETE	0	0.41 (0.26, 0.65)	0.36 (0.23, 0.57)	0.39	-13% (-65, 120)	>0.80
NEOx	Cell	AA	Alcohol	12-HETE	15	0.47 (0.3, 0.74)	0.43 (0.27, 0.68)		-7% (-60, 116)	>0.80
NEOx	Cell	AA	Alcohol	12-HETE	30	0.49 (0.31, 0.77)	0.48 (0.31, 0.76)		-2% (-57, 125)	>0.80
NEOx	Cell	AA	Alcohol	12-HETE	60	0.43 (0.27, 0.68)	0.47 (0.3, 0.75)		11% (-58, 195)	>0.80
Esterified	Media	AA	Alcohol	12-HETE	0	0.41 (0.27, 0.61)	0.36 (0.24, 0.53)	0.66	-13% (-61, 93)	>0.80
Esterified	Media	AA	Alcohol	12-HETE	15	0.45 (0.3, 0.66)	0.38 (0.25, 0.56)		-16% (-60, 77)	>0.80
Esterified	Media	AA	Alcohol	12-HETE	30	0.48 (0.32, 0.72)	0.4 (0.27, 0.59)		-18% (-60, 70)	>0.80
Esterified	Media	AA	Alcohol	12-HETE	60	0.54 (0.36, 0.81)	0.42 (0.28, 0.64)		-22% (-67, 83)	>0.80
NEOx	Media	AA	Alcohol	12-HETE	0	0.51 (0.32, 0.8)	0.36 (0.23, 0.57)	0.63	-29% (-71, 78)	>0.80
NEOx	Media	AA	Alcohol	12-HETE	15	0.49 (0.31, 0.78)	0.36 (0.23, 0.58)		-26% (-69, 72)	>0.80
NEOx	Media	AA	Alcohol	12-HETE	30	0.48 (0.3, 0.76)	0.36 (0.23, 0.58)		-24% (-67, 75)	>0.80
NEOx	Media	AA	Alcohol	12-HETE	60	0.47 (0.29, 0.74)	0.38 (0.24, 0.6)		-20% (-69, 110)	>0.80
Esterified	Cell	AA	Alcohol	15-HETE	0	1.13 (0.31, 4.1)	1.19 (0.33, 4.31)	>0.80	5% (-93, 1460)	>0.80
Esterified	Cell	AA	Alcohol	15-HETE	15	1.21 (0.39, 3.76)	1.29 (0.41, 4.01)		7% (-88, 857)	>0.80
Esterified	Cell	AA	Alcohol	15-HETE	30	1.3 (0.41, 4.12)	1.41 (0.44, 4.48)		9% (-86, 768)	>0.80
Esterified	Cell	AA	Alcohol	15-HETE	60	1.51 (0.38, 5.89)	1.69 (0.43, 6.62)		12% (-95, 2260)	>0.80
NEOx	Cell	AA	Alcohol	15-HETE	0	0.33 (0.15, 0.73)	0.3 (0.14, 0.65)	0.61	-11% (-82, 337)	>0.80
NEOx	Cell	AA	Alcohol	15-HETE	15	0.29 (0.14, 0.61)	0.28 (0.13, 0.58)		-4% (-77, 289)	>0.80
NEOx	Cell	AA	Alcohol	15-HETE	30	0.27 (0.13, 0.57)	0.28 (0.13, 0.59)		3% (-74, 300)	>0.80
NEOx	Cell	AA	Alcohol	15-HETE	60	0.31 (0.14, 0.69)	0.37 (0.17, 0.81)		18% (-79, 565)	>0.80
Esterified	Media	AA	Alcohol	15-HETE	0	0.22 (0.13, 0.38)	0.18 (0.1, 0.31)	0.42	-19% (-74, 154)	>0.80
Esterified	Media	AA	Alcohol	15-HETE	15	0.26 (0.16, 0.42)	0.19 (0.12, 0.31)		-27% (-71, 85)	>0.80
Esterified	Media	AA	Alcohol	15-HETE	30	0.31 (0.19, 0.51)	0.21 (0.13, 0.34)		-34% (-73, 59)	0.72
Esterified	Media	AA	Alcohol	15-HETE	60	0.5 (0.28, 0.9)	0.27 (0.15, 0.49)		-46% (-85, 97)	0.71
NEOx	Media	AA	Alcohol	15-HETE	0	0.19 (0.1, 0.39)	0.23 (0.12, 0.47)	0.53	21% (-71, 404)	>0.80
NEOx	Media	AA	Alcohol	15-HETE	15	0.21 (0.11, 0.39)	0.23 (0.12, 0.44)		11% (-68, 278)	>0.80
NEOx	Media	AA	Alcohol	15-HETE	30	0.23 (0.12, 0.43)	0.23 (0.12, 0.44)		2% (-69, 232)	>0.80
NEOx	Media	AA	Alcohol	15-HETE	60	0.3 (0.15, 0.62)	0.26 (0.13, 0.54)		-14% (-82, 314)	>0.80
Esterified	Cell	EPA	Alcohol	5-HEPE	0	0.89 (0.24, 3.26)	0.86 (0.23, 3.18)	0.21	-2% (-93, 1305)	>0.80
Esterified	Cell	EPA	Alcohol	5-HEPE	15	1.12 (0.32, 3.99)	0.82 (0.23, 2.91)		-27% (-93, 680)	>0.80
Esterified	Cell	EPA	Alcohol	5-HEPE	30	1.61 (0.45, 5.69)	0.88 (0.25, 3.1)		-46% (-95, 447)	>0.80
Esterified	Cell	EPA	Alcohol	5-HEPE	60	4.71 (1.24, 17.92)	1.43 (0.38, 5.45)		-70% (-98, 444)	>0.80
NEOx	Cell	EPA	Alcohol	5-HEPE	0	0.34 (0.21, 0.54)	0.26 (0.16, 0.42)	>0.80	-23% (-70, 99)	>0.80
NEOx	Cell	EPA	Alcohol	5-HEPE	15	0.31 (0.2, 0.5)	0.24 (0.15, 0.39)		-22% (-67, 83)	>0.80
NEOx	Cell	EPA	Alcohol	5-HEPE	30	0.32 (0.2, 0.51)	0.25 (0.16, 0.4)		-22% (-66, 81)	>0.80
NEOx	Cell	EPA	Alcohol	5-HEPE	60	0.45 (0.28, 0.73)	0.36 (0.22, 0.57)		-21% (-71, 119)	>0.80
Esterified	Media	EPA	Alcohol	5-HEPE	0	0.36 (0.23, 0.58)	0.28 (0.17, 0.44)	0.14	-24% (-71, 99)	>0.80
Esterified	Media	EPA	Alcohol	5-HEPE	15	0.32 (0.2, 0.5)	0.28 (0.18, 0.43)		-13% (-62, 102)	>0.80
Esterified	Media	EPA	Alcohol	5-HEPE	30	0.29 (0.19, 0.46)	0.29 (0.19, 0.45)		-1% (-56, 124)	>0.80
Esterified	Media	EPA	Alcohol	5-HEPE	60	0.28 (0.17, 0.45)	0.36 (0.22, 0.58)		29% (-55, 269)	>0.80
NEOx	Media	EPA	Alcohol	5-HEPE	0	0.39 (0.22, 0.69)	0.2 (0.11, 0.34)	0.001	-50% (-84, 51)	0.41
NEOx	Media	EPA	Alcohol	5-HEPE	15	0.31 (0.18, 0.55)	0.21 (0.12, 0.37)		-34% (-77, 88)	>0.80
NEOx	Media	EPA	Alcohol	5-HEPE	30	0.26 (0.15, 0.47)	0.24 (0.13, 0.41)		-11% (-68, 147)	>0.80
NEOx	Media	EPA	Alcohol	5-HEPE	60	0.23 (0.13, 0.41)	0.37 (0.21, 0.66)		59% (-51, 411)	>0.80
Esterified	Cell	EPA	Alcohol	8-HEPE	0	1.15 (0.71, 1.86)	0.54 (0.33, 0.87)	0.08	-53% (-83, 28)	0.22
Esterified	Cell	EPA	Alcohol	8-HEPE	15	0.94 (0.63, 1.4)	0.55 (0.37, 0.82)		-42% (-73, 28)	0.31
Esterified	Cell	EPA	Alcohol	8-HEPE	30	0.83 (0.55, 1.26)	0.6 (0.4, 0.91)		-28% (-65, 51)	0.78
Esterified	Cell	EPA	Alcohol	8-HEPE	60	0.83 (0.49, 1.38)	0.93 (0.55, 1.55)		12% (-65, 256)	>0.80
NEOx	Cell	EPA	Alcohol	8-HEPE	0	0.55 (0.29, 1.03)	0.38 (0.2, 0.72)	0.77	-30% (-82, 164)	>0.80
NEOx	Cell	EPA	Alcohol	8-HEPE	15	0.57 (0.32, 1.01)	0.41 (0.23, 0.73)		-28% (-76, 117)	>0.80
NEOx	Cell	EPA	Alcohol	8-HEPE	30	0.61 (0.34, 1.08)	0.46 (0.25, 0.81)		-25% (-74, 115)	>0.80
NEOx	Cell	EPA	Alcohol	8-HEPE	60	0.72 (0.37, 1.4)	0.59 (0.3, 1.14)		-18% (-82, 263)	>0.80
Esterified	Media	EPA	Alcohol	8-HEPE	0	0.44 (0.22, 0.89)	0.52 (0.26, 1.05)	0.66	17% (-72, 392)	>0.80
Esterified	Media	EPA	Alcohol	8-HEPE	15	0.5 (0.25, 1)	0.56 (0.28, 1.12)		11% (-69, 305)	>0.80
Esterified	Media	EPA	Alcohol	8-HEPE	30	0.54 (0.27, 1.07)	0.57 (0.29, 1.13)		6% (-70, 273)	>0.80
Esterified	Media	EPA	Alcohol	8-HEPE	60	0.51 (0.25, 1.04)	0.48 (0.24, 0.99)		-5% (-80, 345)	>0.80
NEOx	Media	EPA	Alcohol	8-HEPE	0	0.6 (0.35, 1.03)	0.59 (0.34, 1)	>0.80	-2% (-68, 196)	>0.80
NEOx	Media	EPA	Alcohol	8-HEPE	15	0.59 (0.36, 0.97)	0.58 (0.35, 0.97)		-1% (-62, 158)	>0.80
NEOx	Media	EPA	Alcohol	8-HEPE	30	0.55 (0.33, 0.9)	0.55 (0.33, 0.91)		1% (-60, 153)	>0.80
NEOx	Media	EPA	Alcohol	8-HEPE	60	0.4 (0.23, 0.69)	0.41 (0.24, 0.72)		4% (-69, 251)	>0.80
Esterified	Cell	EPA	Alcohol	11-HEPE	0	0.39 (0.25, 0.6)	0.46 (0.3, 0.72)	0.08	20% (-53, 206)	>0.80
Esterified	Cell	EPA	Alcohol	11-HEPE	15	0.36 (0.24, 0.53)	0.36 (0.24, 0.52)		-1% (-53, 112)	>0.80
Esterified	Cell	EPA	Alcohol	11-HEPE	30	0.37 (0.25, 0.55)	0.31 (0.21, 0.46)		-17% (-60, 68)	>0.80
Esterified	Cell	EPA	Alcohol	11-HEPE	60	0.58 (0.36, 0.94)	0.33 (0.21, 0.53)		-43% (-80, 64)	0.59
NEOx	Cell	EPA	Alcohol	11-HEPE	0	0.28 (0.15, 0.52)	0.26 (0.14, 0.49)	0.32	-6% (-74, 238)	>0.80

NEOx	Cell	EPA	Alcohol	11-HEPE	15	0.32 (0.19, 0.54)	0.26 (0.15, 0.44)		-18% (-71, 132)	>0.80
NEOx	Cell	EPA	Alcohol	11-HEPE	30	0.36 (0.21, 0.62)	0.26 (0.15, 0.44)		-29% (-73, 91)	>0.80
NEOx	Cell	EPA	Alcohol	11-HEPE	60	0.46 (0.24, 0.89)	0.25 (0.13, 0.48)		-46% (-87, 130)	>0.80
Esterified	Media	EPA	Alcohol	11-HEPE	0	0.29 (0.16, 0.51)	0.23 (0.13, 0.4)	0.7	-22% (-76, 153)	>0.80
Esterified	Media	EPA	Alcohol	11-HEPE	15	0.36 (0.22, 0.6)	0.27 (0.16, 0.45)		-25% (-72, 97)	>0.80
Esterified	Media	EPA	Alcohol	11-HEPE	30	0.39 (0.23, 0.65)	0.28 (0.17, 0.46)		-29% (-72, 80)	>0.80
Esterified	Media	EPA	Alcohol	11-HEPE	60	0.28 (0.15, 0.5)	0.18 (0.1, 0.33)		-35% (-83, 141)	>0.80
NEOx	Media	EPA	Alcohol	11-HEPE	0	0.34 (0.23, 0.51)	0.22 (0.15, 0.33)	0.7	-36% (-73, 50)	0.61
NEOx	Media	EPA	Alcohol	11-HEPE	15	0.32 (0.22, 0.48)	0.21 (0.14, 0.32)		-34% (-68, 38)	0.54
NEOx	Media	EPA	Alcohol	11-HEPE	30	0.31 (0.21, 0.46)	0.21 (0.14, 0.31)		-32% (-67, 39)	0.58
NEOx	Media	EPA	Alcohol	11-HEPE	60	0.3 (0.19, 0.46)	0.22 (0.14, 0.33)		-28% (-71, 82)	>0.80
Esterified	Cell	EPA	Alcohol	12-HEPE	0	0.36 (0.16, 0.78)	0.24 (0.11, 0.53)	>0.80	-32% (-87, 250)	>0.80
Esterified	Cell	EPA	Alcohol	12-HEPE	15	0.33 (0.17, 0.68)	0.23 (0.12, 0.47)		-30% (-82, 171)	>0.80
Esterified	Cell	EPA	Alcohol	12-HEPE	30	0.34 (0.17, 0.7)	0.25 (0.12, 0.51)		-28% (-80, 162)	>0.80
Esterified	Cell	EPA	Alcohol	12-HEPE	60	0.48 (0.21, 1.09)	0.37 (0.16, 0.83)		-23% (-88, 380)	>0.80
NEOx	Cell	EPA	Alcohol	12-HEPE	0	0.37 (0.22, 0.62)	0.19 (0.11, 0.33)	0.34	-48% (-82, 57)	0.48
NEOx	Cell	EPA	Alcohol	12-HEPE	15	0.33 (0.22, 0.5)	0.2 (0.13, 0.3)		-41% (-74, 37)	0.42
NEOx	Cell	EPA	Alcohol	12-HEPE	30	0.3 (0.19, 0.47)	0.2 (0.13, 0.32)		-33% (-69, 46)	0.64
NEOx	Cell	EPA	Alcohol	12-HEPE	60	0.27 (0.15, 0.47)	0.23 (0.13, 0.41)		-14% (-76, 206)	>0.80
Esterified	Media	EPA	Alcohol	12-HEPE	0	0.33 (0.23, 0.48)	0.24 (0.16, 0.35)	0.04	-28% (-67, 59)	>0.80
Esterified	Media	EPA	Alcohol	12-HEPE	15	0.26 (0.19, 0.37)	0.23 (0.17, 0.32)		-12% (-53, 65)	>0.80
Esterified	Media	EPA	Alcohol	12-HEPE	30	0.23 (0.16, 0.32)	0.24 (0.17, 0.34)		7% (-41, 93)	>0.80
Esterified	Media	EPA	Alcohol	12-HEPE	60	0.22 (0.14, 0.32)	0.34 (0.23, 0.51)		58% (-36, 290)	0.65
NEOx	Media	EPA	Alcohol	12-HEPE	0	0.3 (0.14, 0.67)	0.17 (0.08, 0.38)	0.17	-44% (-88, 162)	>0.80
NEOx	Media	EPA	Alcohol	12-HEPE	15	0.26 (0.12, 0.59)	0.17 (0.08, 0.38)		-36% (-85, 175)	>0.80
NEOx	Media	EPA	Alcohol	12-HEPE	30	0.24 (0.11, 0.53)	0.18 (0.08, 0.39)		-27% (-83, 208)	>0.80
NEOx	Media	EPA	Alcohol	12-HEPE	60	0.23 (0.1, 0.51)	0.22 (0.1, 0.48)		-6% (-81, 366)	>0.80
Esterified	Cell	EPA	Alcohol	18-HEPE	0	0.19 (0.11, 0.32)	0.15 (0.09, 0.25)	0.004	-22% (-72, 122)	>0.80
Esterified	Cell	EPA	Alcohol	18-HEPE	15	0.37 (0.29, 0.49)	0.17 (0.13, 0.22)		**-55% (-73, -26)**	**0.001**
Esterified	Cell	EPA	Alcohol	18-HEPE	30	0.6 (0.42, 0.86)	0.16 (0.11, 0.22)		**-74% (-81, -66)**	**<0.0001**
Esterified	Cell	EPA	Alcohol	18-HEPE	60	0.82 (0.45, 1.5)	0.07 (0.04, 0.13)		**-91% (-98, -68)**	**0.0002**
NEOx	Cell	EPA	Alcohol	18-HEPE	0	0.12 (0.08, 0.19)	0.08 (0.06, 0.13)	0.0005	-33% (-72, 62)	0.76
NEOx	Cell	EPA	Alcohol	18-HEPE	15	0.26 (0.18, 0.37)	0.11 (0.08, 0.16)		**-56% (-78, -13)**	**0.01**
NEOx	Cell	EPA	Alcohol	18-HEPE	30	0.43 (0.3, 0.62)	0.12 (0.08, 0.18)		**-72% (-85, -46)**	**0.0001**
NEOx	Cell	EPA	Alcohol	18-HEPE	60	0.61 (0.39, 0.95)	0.07 (0.05, 0.11)		**-88% (-96, -67)**	**<0.0001**
Esterified	Media	EPA	Alcohol	18-HEPE	0	0.32 (0.18, 0.55)	0.17 (0.1, 0.3)	0.09	-46% (-83, 68)	0.57
Esterified	Media	EPA	Alcohol	18-HEPE	15	0.34 (0.2, 0.56)	0.15 (0.09, 0.25)		-56% (-83, 16)	0.13
Esterified	Media	EPA	Alcohol	18-HEPE	30	0.37 (0.22, 0.61)	0.13 (0.08, 0.22)		**-64% (-86, -8)**	**0.03**
Esterified	Media	EPA	Alcohol	18-HEPE	60	0.47 (0.27, 0.84)	0.12 (0.07, 0.21)		**-75% (-93, -13)**	**0.02**
NEOx	Media	EPA	Alcohol	18-HEPE	0	0.14 (0.07, 0.27)	0.14 (0.07, 0.29)	0.14	6% (-75, 344)	>0.80
NEOx	Media	EPA	Alcohol	18-HEPE	15	0.15 (0.08, 0.29)	0.13 (0.07, 0.25)		-14% (-75, 195)	>0.80
NEOx	Media	EPA	Alcohol	18-HEPE	30	0.17 (0.09, 0.32)	0.12 (0.06, 0.23)		-30% (-79, 130)	>0.80
NEOx	Media	EPA	Alcohol	18-HEPE	60	0.19 (0.09, 0.4)	0.09 (0.04, 0.19)		-53% (-90, 125)	0.69
Esterified	Cell	DHA	Alcohol	4-HDoHE	0	23.7 (10.5, 53.3)	24.4 (10.9, 54.9)	0.6	3% (-81, 447)	>0.80
Esterified	Cell	DHA	Alcohol	4-HDoHE	15	30.9 (14.2, 67.4)	29.5 (13.5, 64.3)		-5% (-78, 313)	>0.80
Esterified	Cell	DHA	Alcohol	4-HDoHE	30	38.1 (17.5, 83.1)	33.7 (15.5, 73.4)		-12% (-79, 266)	>0.80
Esterified	Cell	DHA	Alcohol	4-HDoHE	60	48.6 (21.1, 112.2)	36.8 (16, 84.8)		-24% (-88, 365)	>0.80
NEOx	Cell	DHA	Alcohol	4-HDoHE	0	0.57 (0.36, 0.89)	0.39 (0.25, 0.62)	>0.80	-30% (-72, 73)	>0.80
NEOx	Cell	DHA	Alcohol	4-HDoHE	15	0.64 (0.4, 1)	0.44 (0.28, 0.7)		-30% (-70, 61)	0.80
NEOx	Cell	DHA	Alcohol	4-HDoHE	30	0.67 (0.43, 1.05)	0.47 (0.3, 0.74)		-30% (-69, 59)	0.79
NEOx	Cell	DHA	Alcohol	4-HDoHE	60	0.62 (0.39, 0.97)	0.43 (0.27, 0.68)		-30% (-73, 83)	>0.80
Esterified	Media	DHA	Alcohol	4-HDoHE	0	0.5 (0.25, 0.99)	0.59 (0.3, 1.18)	0.39	19% (-72, 406)	>0.80
Esterified	Media	DHA	Alcohol	4-HDoHE	15	0.76 (0.42, 1.38)	0.79 (0.43, 1.44)		4% (-67, 232)	>0.80
Esterified	Media	DHA	Alcohol	4-HDoHE	30	1.01 (0.55, 1.86)	0.91 (0.49, 1.68)		-9% (-70, 171)	>0.80
Esterified	Media	DHA	Alcohol	4-HDoHE	60	1.15 (0.55, 2.39)	0.79 (0.38, 1.64)		-31% (-87, 253)	>0.80
NEOx	Media	DHA	Alcohol	4-HDoHE	0	0.55 (0.36, 0.83)	0.54 (0.36, 0.82)	0.65	-1% (-56, 123)	>0.80
NEOx	Media	DHA	Alcohol	4-HDoHE	15	0.53 (0.35, 0.8)	0.53 (0.35, 0.81)		1% (-52, 116)	>0.80
NEOx	Media	DHA	Alcohol	4-HDoHE	30	0.5 (0.33, 0.76)	0.52 (0.35, 0.79)		4% (-51, 119)	>0.80
NEOx	Media	DHA	Alcohol	4-HDoHE	60	0.46 (0.3, 0.69)	0.5 (0.33, 0.76)		9% (-54, 157)	>0.80
Esterified	Cell	DHA	Alcohol	7-HDoHE	0	1.1 (0.37, 3.22)	1.56 (0.53, 4.58)	0.51	42% (-85, 1263)	>0.80
Esterified	Cell	DHA	Alcohol	7-HDoHE	15	1.49 (0.57, 3.88)	1.81 (0.69, 4.71)		21% (-81, 669)	>0.80
Esterified	Cell	DHA	Alcohol	7-HDoHE	30	1.93 (0.73, 5.11)	2 (0.75, 5.29)		3% (-82, 496)	>0.80
Esterified	Cell	DHA	Alcohol	7-HDoHE	60	2.77 (0.89, 8.68)	2.09 (0.67, 6.53)		-25% (-94, 858)	>0.80
NEOx	Cell	DHA	Alcohol	7-HDoHE	0	0.55 (0.37, 0.82)	0.55 (0.37, 0.83)	0.12	1% (-57, 135)	>0.80
NEOx	Cell	DHA	Alcohol	7-HDoHE	15	0.64 (0.46, 0.9)	0.56 (0.4, 0.78)		-14% (-55, 68)	>0.80
NEOx	Cell	DHA	Alcohol	7-HDoHE	30	0.73 (0.51, 1.04)	0.54 (0.38, 0.76)		-26% (-60, 37)	0.68
NEOx	Cell	DHA	Alcohol	7-HDoHE	60	0.83 (0.54, 1.27)	0.45 (0.29, 0.69)		-46% (-79, 42)	0.39
Esterified	Media	DHA	Alcohol	7-HDoHE	0	0.7 (0.37, 1.33)	0.45 (0.24, 0.85)	0.34	-36% (-82, 125)	>0.80
Esterified	Media	DHA	Alcohol	7-HDoHE	15	0.69 (0.37, 1.32)	0.48 (0.25, 0.91)		-31% (-79, 124)	>0.80
Esterified	Media	DHA	Alcohol	7-HDoHE	30	0.67 (0.36, 1.28)	0.5 (0.27, 0.95)		-25% (-77, 138)	>0.80
Esterified	Media	DHA	Alcohol	7-HDoHE	60	0.6 (0.32, 1.14)	0.53 (0.28, 1)		-13% (-77, 227)	>0.80
NEOx	Media	DHA	Alcohol	7-HDoHE	0	0.57 (0.28, 1.16)	0.5 (0.25, 1.01)	0.68	-13% (-78, 246)	>0.80
NEOx	Media	DHA	Alcohol	7-HDoHE	15	0.57 (0.28, 1.15)	0.51 (0.25, 1.04)		-10% (-75, 232)	>0.80
NEOx	Media	DHA	Alcohol	7-HDoHE	30	0.56 (0.28, 1.14)	0.53 (0.26, 1.07)		-7% (-74, 238)	>0.80
NEOx	Media	DHA	Alcohol	7-HDoHE	60	0.57 (0.28, 1.16)	0.57 (0.28, 1.16)		0% (-76, 319)	>0.80
Esterified	Cell	DHA	Alcohol	8-HDoHE	0	3.92 (1.86, 8.27)	2.98 (1.41, 6.3)	>0.80	-24% (-84, 262)	>0.80
Esterified	Cell	DHA	Alcohol	8-HDoHE	15	7.73 (4.39, 13.63)	6.02 (3.42, 10.61)		-22% (-75, 140)	>0.80
Esterified	Cell	DHA	Alcohol	8-HDoHE	30	11.82 (6.44, 21.7)	9.41 (5.13, 17.27)		-20% (-71, 121)	>0.80
Esterified	Cell	DHA	Alcohol	8-HDoHE	60	12.81 (5.67, 28.94)	10.65 (4.71, 24.07)		-17% (-87, 420)	>0.80
NEOx	Cell	DHA	Alcohol	8-HDoHE	0	0.61 (0.36, 1.02)	0.49 (0.29, 0.83)	0.17	-19% (-73, 138)	>0.80
NEOx	Cell	DHA	Alcohol	8-HDoHE	15	0.97 (0.59, 1.59)	0.68 (0.42, 1.12)		-30% (-72, 78)	>0.80
NEOx	Cell	DHA	Alcohol	8-HDoHE	30	1.26 (0.77, 2.07)	0.77 (0.47, 1.26)		-39% (-75, 50)	0.56
NEOx	Cell	DHA	Alcohol	8-HDoHE	60	1.13 (0.66, 1.94)	0.52 (0.3, 0.89)		-54% (-86, 50)	0.36
NEOx	Media	DHA	Alcohol	8-HDoHE	0	0.97 (0.55, 1.7)	0.76 (0.43, 1.33)	0.62	-22% (-75, 144)	>0.80
NEOx	Media	DHA	Alcohol	8-HDoHE	15	0.77 (0.44, 1.34)	0.63 (0.36, 1.09)		-18% (-71, 130)	>0.80

NEOx	Media	DHA	Alcohol	8-HDoHE	30	0.68 (0.39, 1.18)	0.58 (0.33, 1.01)		-15% (-69, 135)	>0.80
NEOx	Media	DHA	Alcohol	8-HDoHE	60	0.75 (0.42, 1.33)	0.7 (0.39, 1.23)		-7% (-72, 211)	>0.80
Esterified	Cell	DHA	Alcohol	10-HDoHE	0	1.29 (0.45, 3.7)	0.99 (0.34, 2.84)	>0.80	-23% (-91, 586)	>0.80
Esterified	Cell	DHA	Alcohol	10-HDoHE	15	1.84 (0.68, 4.96)	1.47 (0.55, 3.96)		-20% (-88, 423)	>0.80
Esterified	Cell	DHA	Alcohol	10-HDoHE	30	2.43 (0.9, 6.56)	2.01 (0.74, 5.45)		-17% (-86, 408)	>0.80
Esterified	Cell	DHA	Alcohol	10-HDoHE	60	3.28 (1.1, 9.82)	2.95 (0.98, 8.82)		-10% (-92, 900)	>0.80
NEOx	Cell	DHA	Alcohol	10-HDoHE	0	1.16 (0.61, 2.21)	0.72 (0.38, 1.37)	0.44	-38% (-84, 139)	>0.80
NEOx	Cell	DHA	Alcohol	10-HDoHE	15	0.81 (0.48, 1.39)	0.57 (0.34, 0.98)		-30% (-75, 100)	>0.80
NEOx	Cell	DHA	Alcohol	10-HDoHE	30	0.7 (0.4, 1.22)	0.56 (0.32, 0.97)		-20% (-70, 111)	>0.80
NEOx	Cell	DHA	Alcohol	10-HDoHE	60	0.98 (0.49, 1.96)	1 (0.5, 1.99)		1% (-78, 375)	>0.80
Esterified	Media	DHA	Alcohol	10-HDoHE	0	0.67 (0.36, 1.26)	0.71 (0.38, 1.34)	0.49	7% (-71, 294)	>0.80
Esterified	Media	DHA	Alcohol	10-HDoHE	15	0.62 (0.34, 1.11)	0.6 (0.33, 1.08)		-2% (-68, 197)	>0.80
Esterified	Media	DHA	Alcohol	10-HDoHE	30	0.64 (0.36, 1.16)	0.57 (0.32, 1.04)		-11% (-69, 161)	>0.80
Esterified	Media	DHA	Alcohol	10-HDoHE	60	1.02 (0.53, 1.96)	0.76 (0.4, 1.47)		-25% (-82, 219)	>0.80
NEOx	Media	DHA	Alcohol	10-HDoHE	0	0.65 (0.38, 1.13)	0.72 (0.42, 1.25)	0.4	11% (-64, 245)	>0.80
NEOx	Media	DHA	Alcohol	10-HDoHE	15	0.64 (0.38, 1.05)	0.64 (0.39, 1.06)		1% (-61, 163)	>0.80
NEOx	Media	DHA	Alcohol	10-HDoHE	30	0.6 (0.36, 0.99)	0.55 (0.33, 0.91)		-8% (-64, 130)	>0.80
NEOx	Media	DHA	Alcohol	10-HDoHE	60	0.48 (0.27, 0.84)	0.36 (0.2, 0.64)		-24% (-78, 166)	>0.80
Esterified	Cell	DHA	Alcohol	13-HDoHE	0	0.73 (0.39, 1.35)	0.69 (0.37, 1.28)	>0.80	-5% (-74, 249)	>0.80
Esterified	Cell	DHA	Alcohol	13-HDoHE	15	1.2 (0.71, 2.03)	1.13 (0.67, 1.91)		-6% (-66, 161)	>0.80
Esterified	Cell	DHA	Alcohol	13-HDoHE	30	1.74 (1.02, 2.99)	1.64 (0.95, 2.81)		-6% (-64, 143)	>0.80
Esterified	Cell	DHA	Alcohol	13-HDoHE	60	2.48 (1.28, 4.81)	2.29 (1.18, 4.45)		-7% (-79, 310)	>0.80
NEOx	Cell	DHA	Alcohol	13-HDoHE	0	0.61 (0.36, 1.03)	0.41 (0.25, 0.69)	0.52	-33% (-77, 97)	>0.80
NEOx	Cell	DHA	Alcohol	13-HDoHE	15	0.61 (0.38, 1)	0.44 (0.27, 0.72)		-28% (-72, 82)	>0.80
NEOx	Cell	DHA	Alcohol	13-HDoHE	30	0.64 (0.39, 1.04)	0.49 (0.3, 0.8)		-23% (-69, 88)	>0.80
NEOx	Cell	DHA	Alcohol	13-HDoHE	60	0.76 (0.44, 1.3)	0.66 (0.39, 1.13)		-13% (-73, 183)	>0.80
Esterified	Media	DHA	Alcohol	13-HDoHE	0	0.65 (0.4, 1.05)	0.56 (0.34, 0.92)	0.55	-13% (-68, 134)	>0.80
Esterified	Media	DHA	Alcohol	13-HDoHE	15	0.69 (0.42, 1.12)	0.57 (0.35, 0.93)		-17% (-66, 104)	>0.80
Esterified	Media	DHA	Alcohol	13-HDoHE	30	0.73 (0.45, 1.18)	0.58 (0.36, 0.93)		-21% (-67, 92)	>0.80
Esterified	Media	DHA	Alcohol	13-HDoHE	60	0.76 (0.46, 1.25)	0.55 (0.33, 0.91)		-28% (-75, 108)	>0.80
NEOx	Media	DHA	Alcohol	13-HDoHE	0	0.68 (0.43, 1.06)	0.57 (0.36, 0.88)	>0.80	-17% (-66, 107)	>0.80
NEOx	Media	DHA	Alcohol	13-HDoHE	15	0.54 (0.35, 0.83)	0.45 (0.29, 0.69)		-16% (-63, 88)	>0.80
NEOx	Media	DHA	Alcohol	13-HDoHE	30	0.48 (0.31, 0.75)	0.4 (0.26, 0.62)		-16% (-62, 85)	>0.80
NEOx	Media	DHA	Alcohol	13-HDoHE	60	0.56 (0.36, 0.89)	0.47 (0.3, 0.75)		-16% (-68, 125)	>0.80
Esterified	Cell	DHA	Alcohol	14-HDoHE	0	2.2 (0.83, 5.79)	1.29 (0.49, 3.41)	>0.80	-41% (-92, 347)	>0.80
Esterified	Cell	DHA	Alcohol	14-HDoHE	15	2.68 (1.24, 5.8)	1.61 (0.74, 3.49)		-40% (-87, 177)	>0.80
Esterified	Cell	DHA	Alcohol	14-HDoHE	30	3.52 (1.56, 7.94)	2.16 (0.96, 4.87)		-39% (-85, 150)	>0.80
Esterified	Cell	DHA	Alcohol	14-HDoHE	60	7.6 (2.67, 21.65)	4.86 (1.71, 13.86)		-36% (-94, 574)	>0.80
NEOx	Cell	DHA	Alcohol	14-HDoHE	0	0.42 (0.22, 0.81)	0.37 (0.19, 0.71)	0.55	-12% (-78, 248)	>0.80
NEOx	Cell	DHA	Alcohol	14-HDoHE	15	0.41 (0.22, 0.76)	0.34 (0.18, 0.62)		-19% (-75, 160)	>0.80
NEOx	Cell	DHA	Alcohol	14-HDoHE	30	0.44 (0.24, 0.81)	0.33 (0.18, 0.61)		-25% (-75, 129)	>0.80
NEOx	Cell	DHA	Alcohol	14-HDoHE	60	0.64 (0.32, 1.27)	0.41 (0.2, 0.81)		-36% (-86, 192)	>0.80
Esterified	Media	DHA	Alcohol	14-HDoHE	0	0.42 (0.23, 0.78)	0.42 (0.23, 0.78)	>0.80	-1% (-73, 259)	>0.80
Esterified	Media	DHA	Alcohol	14-HDoHE	15	0.5 (0.29, 0.85)	0.5 (0.29, 0.85)		0% (-65, 183)	>0.80
Esterified	Media	DHA	Alcohol	14-HDoHE	30	0.54 (0.31, 0.94)	0.55 (0.32, 0.95)		1% (-62, 170)	>0.80
Esterified	Media	DHA	Alcohol	14-HDoHE	60	0.52 (0.27, 1)	0.54 (0.28, 1.03)		2% (-76, 337)	>0.80
NEOx	Media	DHA	Alcohol	14-HDoHE	0	0.57 (0.3, 1.08)	0.49 (0.26, 0.94)	0.27	-13% (-76, 221)	>0.80
NEOx	Media	DHA	Alcohol	14-HDoHE	15	0.41 (0.22, 0.79)	0.4 (0.21, 0.77)		-2% (-70, 220)	>0.80
NEOx	Media	DHA	Alcohol	14-HDoHE	30	0.35 (0.19, 0.67)	0.38 (0.2, 0.73)		9% (-66, 249)	>0.80
NEOx	Media	DHA	Alcohol	14-HDoHE	60	0.39 (0.2, 0.75)	0.53 (0.28, 1.02)		36% (-66, 445)	>0.80
Esterified	Cell	DHA	Alcohol	17-HDoHE	0	3.31 (1.19, 9.18)	5.75 (2.07, 15.96)	0.31	74% (-80, 1379)	>0.80
Esterified	Cell	DHA	Alcohol	17-HDoHE	15	2.93 (1.27, 6.75)	3.92 (1.7, 9.04)		34% (-74, 591)	>0.80
Esterified	Cell	DHA	Alcohol	17-HDoHE	30	3.5 (1.46, 8.37)	3.61 (1.51, 8.62)		3% (-77, 372)	>0.80
Esterified	Cell	DHA	Alcohol	17-HDoHE	60	12.28 (4.09, 36.85)	7.5 (2.5, 22.5)		-39% (-95, 621)	>0.80
NEOx	Cell	DHA	Alcohol	17-HDoHE	0	1.18 (0.69, 2.02)	0.73 (0.43, 1.24)	>0.80	-38% (-79, 84)	0.78
NEOx	Cell	DHA	Alcohol	17-HDoHE	15	1.09 (0.65, 1.82)	0.67 (0.4, 1.12)		-39% (-77, 62)	0.65
NEOx	Cell	DHA	Alcohol	17-HDoHE	30	1.03 (0.61, 1.72)	0.63 (0.37, 1.05)		-39% (-76, 57)	0.61
NEOx	Cell	DHA	Alcohol	17-HDoHE	60	1 (0.58, 1.72)	0.6 (0.35, 1.04)		-40% (-82, 98)	>0.80
Esterified	Media	DHA	Alcohol	17-HDoHE	0	0.92 (0.38, 2.24)	1.21 (0.5, 2.94)	0.37	31% (-76, 628)	>0.80
Esterified	Media	DHA	Alcohol	17-HDoHE	15	0.81 (0.33, 2)	0.98 (0.4, 2.4)		20% (-76, 514)	>0.80
Esterified	Media	DHA	Alcohol	17-HDoHE	30	0.83 (0.34, 2.03)	0.92 (0.38, 2.24)		10% (-78, 453)	>0.80
Esterified	Media	DHA	Alcohol	17-HDoHE	60	1.35 (0.56, 3.28)	1.25 (0.51, 3.03)		-8% (-84, 446)	>0.80
NEOx	Media	DHA	Alcohol	17-HDoHE	0	0.83 (0.43, 1.62)	0.76 (0.39, 1.49)	0.67	-8% (-77, 262)	>0.80
NEOx	Media	DHA	Alcohol	17-HDoHE	15	0.76 (0.4, 1.45)	0.73 (0.38, 1.4)		-3% (-71, 225)	>0.80
NEOx	Media	DHA	Alcohol	17-HDoHE	30	0.72 (0.38, 1.38)	0.73 (0.38, 1.4)		1% (-69, 230)	>0.80
NEOx	Media	DHA	Alcohol	17-HDoHE	60	0.76 (0.38, 1.51)	0.85 (0.43, 1.69)		12% (-75, 393)	>0.80
Esterified	Cell	LA	Ketone	9-KODE	0	1.95 (0.68, 5.61)	2.38 (0.83, 6.84)	0.7	22% (-86, 1001)	>0.80
Esterified	Cell	LA	Ketone	9-KODE	15	2.18 (0.98, 4.86)	2.39 (1.07, 5.33)		10% (-78, 441)	>0.80
Esterified	Cell	LA	Ketone	9-KODE	30	2.64 (1.12, 6.24)	2.61 (1.1, 6.15)		-1% (-77, 319)	>0.80
Esterified	Cell	LA	Ketone	9-KODE	60	5 (1.59, 15.78)	3.99 (1.26, 12.59)		-20% (-94, 957)	>0.80
NEOx	Cell	LA	Ketone	9-KODE	0	0.54 (0.09, 3.35)	0.32 (0.05, 1.97)	0.28	-41% (-99, 2548)	>0.80
NEOx	Cell	LA	Ketone	9-KODE	15	0.37 (0.09, 1.55)	0.36 (0.09, 1.52)		-2% (-94, 1595)	>0.80
NEOx	Cell	LA	Ketone	9-KODE	30	0.21 (0.05, 0.96)	0.34 (0.08, 1.58)		64% (-88, 2139)	>0.80
NEOx	Cell	LA	Ketone	9-KODE	60	0.04 (0.01, 0.31)	0.2 (0.03, 1.41)		356% (-95, 37951)	>0.80
Esterified	Media	LA	Ketone	9-KODE	0	0.26 (0.09, 0.72)	0.33 (0.12, 0.9)	0.51	25% (-85, 960)	>0.80
Esterified	Media	LA	Ketone	9-KODE	15	0.34 (0.14, 0.83)	0.36 (0.15, 0.9)		8% (-81, 521)	>0.80
Esterified	Media	LA	Ketone	9-KODE	30	0.42 (0.17, 1.07)	0.39 (0.16, 0.99)		-7% (-82, 389)	>0.80
Esterified	Media	LA	Ketone	9-KODE	60	0.63 (0.21, 1.84)	0.43 (0.15, 1.26)		-32% (-94, 654)	>0.80
NEOx	Media	LA	Ketone	9-KODE	0	0.08 (0.01, 0.47)	0.09 (0.02, 0.58)	>0.80	23% (-97, 5197)	>0.80
NEOx	Media	LA	Ketone	9-KODE	15	0.21 (0.06, 0.76)	0.23 (0.06, 0.84)		10% (-92, 1358)	>0.80
NEOx	Media	LA	Ketone	9-KODE	30	0.4 (0.1, 1.65)	0.39 (0.1, 1.63)		-1% (-90, 860)	>0.80
NEOx	Media	LA	Ketone	9-KODE	60	0.5 (0.07, 3.67)	0.39 (0.05, 2.92)		-20% (-99, 6975)	>0.80
Esterified	Cell	LA	Ketone	13-KODE	0	4.24 (1.32, 13.59)	4.02 (1.26, 12.89)	>0.80	-5% (-91, 870)	>0.80
Esterified	Cell	LA	Ketone	13-KODE	15	6.83 (3.55, 13.15)	6.12 (3.18, 11.77)		-10% (-75, 226)	>0.80
Esterified	Cell	LA	Ketone	13-KODE	30	8.08 (3.6, 18.14)	6.83 (3.04, 15.32)		-16% (-68, 121)	>0.80

Esterified	Cell	LA	Ketone	13-KODE	60	4.48 (1.21, 16.61)	3.37 (0.91, 12.5)		-25% (-96, 1265)	>0.80
NEOx	Cell	LA	Ketone	13-KODE	0	1.6 (0.69, 3.71)	2.41 (1.04, 5.58)	0.06	50% (-72, 708)	>0.80
NEOx	Cell	LA	Ketone	13-KODE	15	1.46 (0.9, 2.35)	1.32 (0.82, 2.13)		-9% (-65, 135)	>0.80
NEOx	Cell	LA	Ketone	13-KODE	30	1.86 (1.04, 3.35)	1.02 (0.57, 1.83)		-45% (-73, 12)	0.13
NEOx	Cell	LA	Ketone	13-KODE	60	8.55 (3.33, 21.97)	1.69 (0.66, 4.35)		-80% (-98, 60)	0.19
Esterified	Media	LA	Ketone	13-KODE	0	1.12 (0.44, 2.87)	1.04 (0.41, 2.68)	0.06	-7% (-87, 561)	>0.80
Esterified	Media	LA	Ketone	13-KODE	15	1.86 (0.94, 3.69)	1.04 (0.53, 2.07)		-44% (-86, 121)	>0.80
Esterified	Media	LA	Ketone	13-KODE	30	3.01 (1.42, 6.35)	1.02 (0.48, 2.15)		-66% (-90, 15)	0.1
Esterified	Media	LA	Ketone	13-KODE	60	7.21 (2.56, 20.29)	0.89 (0.31, 2.49)		-88% (-99, 26)	0.09
NEOx	Media	LA	Ketone	13-KODE	0	1.9 (0.69, 5.19)	1.77 (0.65, 4.83)	0.69	-7% (-89, 659)	>0.80
NEOx	Media	LA	Ketone	13-KODE	15	1.13 (0.53, 2.42)	0.95 (0.44, 2.03)		-16% (-82, 281)	>0.80
NEOx	Media	LA	Ketone	13-KODE	30	0.98 (0.43, 2.22)	0.74 (0.33, 1.67)		-25% (-81, 195)	>0.80
NEOx	Media	LA	Ketone	13-KODE	60	2.25 (0.75, 6.74)	1.36 (0.46, 4.09)		-39% (-95, 616)	>0.80
Esterified	Cell	AA	Ketone	5-KETE	0	1.71 (0.58, 5.02)	0.67 (0.23, 1.97)	0.38	-61% (-96, 259)	>0.80
Esterified	Cell	AA	Ketone	5-KETE	15	2.6 (1.27, 5.32)	1.34 (0.66, 2.74)		-48% (-88, 117)	0.74
Esterified	Cell	AA	Ketone	5-KETE	30	3.52 (1.56, 7.91)	2.38 (1.06, 5.36)		-32% (-80, 130)	>0.80
Esterified	Cell	AA	Ketone	5-KETE	60	4.46 (1.35, 14.78)	5.22 (1.58, 17.28)		17% (-92, 1603)	>0.80
NEOx	Cell	AA	Ketone	5-KETE	0	0.76 (0.14, 4)	0.59 (0.11, 3.11)	0.57	-22% (-97, 2309)	>0.80
NEOx	Cell	AA	Ketone	5-KETE	15	0.57 (0.18, 1.77)	0.34 (0.11, 1.05)		-41% (-94, 485)	>0.80
NEOx	Cell	AA	Ketone	5-KETE	30	0.63 (0.18, 2.25)	0.29 (0.08, 1.02)		-55% (-94, 228)	>0.80
NEOx	Cell	AA	Ketone	5-KETE	60	2.54 (0.4, 16.02)	0.67 (0.11, 4.23)		-74% (-100, 1538)	>0.80
Esterified	Media	AA	Ketone	5-KETE	0	0.33 (0.07, 1.6)	0.85 (0.17, 4.2)	0.39	162% (-91, 7203)	>0.80
Esterified	Media	AA	Ketone	5-KETE	15	0.55 (0.16, 1.9)	1 (0.29, 3.45)		82% (-84, 2000)	>0.80
Esterified	Media	AA	Ketone	5-KETE	30	0.89 (0.24, 3.3)	1.12 (0.3, 4.17)		26% (-86, 1074)	>0.80
Esterified	Media	AA	Ketone	5-KETE	60	1.95 (0.35, 11.04)	1.19 (0.21, 6.73)		-39% (-99, 2892)	>0.80
NEOx	Media	AA	Ketone	5-KETE	0	1.26 (0.41, 3.86)	1.57 (0.51, 4.8)	0.65	24% (-88, 1133)	>0.80
NEOx	Media	AA	Ketone	5-KETE	15	0.7 (0.33, 1.46)	1 (0.48, 2.1)		44% (-68, 540)	>0.80
NEOx	Media	AA	Ketone	5-KETE	30	0.48 (0.21, 1.11)	0.79 (0.34, 1.84)		66% (-54, 494)	>0.80
NEOx	Media	AA	Ketone	5-KETE	60	0.44 (0.13, 1.51)	0.97 (0.28, 3.35)		122% (-86, 3467)	>0.80
Esterified	Cell	AA	Ketone	12-KETE	0	0.45 (0.13, 1.52)	0.56 (0.17, 1.9)	0.71	25% (-90, 1488)	>0.80
Esterified	Cell	AA	Ketone	12-KETE	15	0.55 (0.21, 1.44)	0.62 (0.23, 1.61)		12% (-83, 650)	>0.80
Esterified	Cell	AA	Ketone	12-KETE	30	0.82 (0.3, 2.27)	0.82 (0.3, 2.26)		0% (-83, 473)	>0.80
Esterified	Cell	AA	Ketone	12-KETE	60	3.32 (0.89, 12.34)	2.64 (0.71, 9.8)		-21% (-96, 1422)	>0.80
NEOx	Cell	AA	Ketone	12-KETE	0	0.82 (0.25, 2.7)	0.19 (0.06, 0.61)	0.73	-77% (-98, 160)	0.44
NEOx	Cell	AA	Ketone	12-KETE	15	0.53 (0.24, 1.2)	0.13 (0.06, 0.3)		-75% (-95, 30)	0.13
NEOx	Cell	AA	Ketone	12-KETE	30	0.45 (0.18, 1.12)	0.13 (0.05, 0.32)		-72% (-93, 18)	0.1
NEOx	Cell	AA	Ketone	12-KETE	60	0.73 (0.2, 2.71)	0.26 (0.07, 0.97)		-64% (-98, 578)	>0.80
Esterified	Media	AA	Ketone	12-KETE	0	0.41 (0.17, 0.98)	0.45 (0.19, 1.09)	>0.80	11% (-81, 558)	>0.80
Esterified	Media	AA	Ketone	12-KETE	15	0.28 (0.16, 0.47)	0.3 (0.18, 0.52)		10% (-63, 222)	>0.80
Esterified	Media	AA	Ketone	12-KETE	30	0.23 (0.12, 0.43)	0.25 (0.13, 0.47)		9% (-54, 159)	>0.80
Esterified	Media	AA	Ketone	12-KETE	60	0.31 (0.11, 0.82)	0.33 (0.12, 0.87)		7% (-88, 851)	>0.80
NEOx	Media	AA	Ketone	12-KETE	0	0.23 (0.1, 0.57)	0.45 (0.18, 1.1)	>0.80	91% (-70, 1099)	>0.80
NEOx	Media	AA	Ketone	12-KETE	15	0.17 (0.09, 0.3)	0.31 (0.17, 0.57)		86% (-44, 513)	0.63
NEOx	Media	AA	Ketone	12-KETE	30	0.17 (0.09, 0.33)	0.3 (0.15, 0.59)		80% (-35, 400)	0.5
NEOx	Media	AA	Ketone	12-KETE	60	0.46 (0.17, 1.23)	0.77 (0.29, 2.09)		70% (-82, 1467)	>0.80
Esterified	Cell	AA	Ketone	15-KETE	0	0.15 (0.03, 0.65)	0.4 (0.09, 1.78)	0.49	173% (-88, 6157)	>0.80
Esterified	Cell	AA	Ketone	15-KETE	15	0.21 (0.05, 0.84)	0.46 (0.12, 1.85)		120% (-84, 2980)	>0.80
Esterified	Cell	AA	Ketone	15-KETE	30	0.3 (0.08, 1.23)	0.54 (0.13, 2.18)		78% (-86, 2125)	>0.80
Esterified	Cell	AA	Ketone	15-KETE	60	0.63 (0.13, 3.04)	0.73 (0.15, 3.51)		16% (-96, 3641)	>0.80
NEOx	Cell	AA	Ketone	15-KETE	0	0.08 (0.02, 0.3)	0.05 (0.01, 0.16)	0.52	-46% (-96, 642)	>0.80
NEOx	Cell	AA	Ketone	15-KETE	15	0.08 (0.03, 0.21)	0.03 (0.01, 0.09)		-56% (-94, 198)	0.79
NEOx	Cell	AA	Ketone	15-KETE	30	0.09 (0.03, 0.26)	0.03 (0.01, 0.09)		-65% (-94, 103)	0.47
NEOx	Cell	AA	Ketone	15-KETE	60	0.26 (0.07, 1.02)	0.06 (0.02, 0.24)		-77% (-99, 401)	0.71
Esterified	Media	AA	Ketone	15-KETE	0	0.12 (0.04, 0.37)	0.07 (0.02, 0.22)	0.23	-42% (-95, 537)	>0.80
Esterified	Media	AA	Ketone	15-KETE	15	0.08 (0.03, 0.19)	0.07 (0.03, 0.16)		-16% (-85, 377)	>0.80
Esterified	Media	AA	Ketone	15-KETE	30	0.07 (0.03, 0.17)	0.08 (0.03, 0.21)		23% (-74, 488)	>0.80
Esterified	Media	AA	Ketone	15-KETE	60	0.08 (0.02, 0.28)	0.21 (0.06, 0.72)		160% (-85, 4252)	>0.80
NEOx	Media	AA	Ketone	15-KETE	0	0.1 (0.03, 0.32)	0.03 (0.01, 0.08)	0.21	-74% (-98, 185)	0.53
NEOx	Media	AA	Ketone	15-KETE	15	0.11 (0.04, 0.26)	0.04 (0.02, 0.1)		-62% (-94, 122)	0.56
NEOx	Media	AA	Ketone	15-KETE	30	0.11 (0.04, 0.28)	0.06 (0.02, 0.15)		-45% (-89, 179)	>0.80
NEOx	Media	AA	Ketone	15-KETE	60	0.1 (0.03, 0.35)	0.12 (0.03, 0.41)		18% (-93, 1860)	>0.80
Esterified	Cell	AA	Peroxide	12-HpETE	0	0.33 (0.12, 0.89)	0.38 (0.14, 1.04)	0.61	17% (-85, 818)	>0.80
Esterified	Cell	AA	Peroxide	12-HpETE	15	0.39 (0.19, 0.81)	0.4 (0.19, 0.82)		2% (-76, 339)	>0.80
Esterified	Cell	AA	Peroxide	12-HpETE	30	0.46 (0.21, 1.02)	0.41 (0.19, 0.9)		-11% (-76, 229)	>0.80
Esterified	Cell	AA	Peroxide	12-HpETE	60	0.65 (0.22, 1.91)	0.44 (0.15, 1.3)		-32% (-94, 676)	>0.80
NEOx	Cell	AA	Peroxide	12-HpETE	0	0.33 (0.16, 0.71)	0.24 (0.11, 0.52)	0.56	-28% (-85, 258)	>0.80
NEOx	Cell	AA	Peroxide	12-HpETE	15	0.34 (0.17, 0.66)	0.22 (0.11, 0.43)		-35% (-82, 139)	>0.80
NEOx	Cell	AA	Peroxide	12-HpETE	30	0.38 (0.19, 0.75)	0.22 (0.11, 0.44)		-41% (-83, 101)	0.8
NEOx	Cell	AA	Peroxide	12-HpETE	60	0.64 (0.29, 1.45)	0.31 (0.14, 0.7)		-52% (-92, 194)	>0.80
Esterified	Media	AA	Peroxide	12-HpETE	0	0.17 (0.07, 0.41)	0.29 (0.12, 0.7)	0.46	71% (-72, 958)	>0.80
Esterified	Media	AA	Peroxide	12-HpETE	15	0.25 (0.12, 0.53)	0.37 (0.17, 0.79)		47% (-66, 536)	>0.80
Esterified	Media	AA	Peroxide	12-HpETE	30	0.32 (0.15, 0.69)	0.4 (0.19, 0.87)		27% (-68, 404)	>0.80
Esterified	Media	AA	Peroxide	12-HpETE	60	0.32 (0.13, 0.81)	0.3 (0.12, 0.76)		-6% (-88, 646)	>0.80
NEOx	Media	AA	Peroxide	12-HpETE	0	0.23 (0.14, 0.4)	0.35 (0.21, 0.61)	0.7	52% (-50, 361)	>0.80
NEOx	Media	AA	Peroxide	12-HpETE	15	0.21 (0.15, 0.3)	0.3 (0.21, 0.43)		43% (-30, 192)	0.65
NEOx	Media	AA	Peroxide	12-HpETE	30	0.21 (0.14, 0.31)	0.28 (0.19, 0.42)		35% (-26, 146)	0.66
NEOx	Media	AA	Peroxide	12-HpETE	60	0.25 (0.14, 0.46)	0.3 (0.16, 0.55)		20% (-69, 360)	>0.80
Esterified	Cell	AA	Peroxide	15-HpETE	0	3.27 (1.34, 7.97)	3.03 (1.24, 7.4)	0.36	-7% (-84, 453)	>0.80
Esterified	Cell	AA	Peroxide	15-HpETE	15	3.1 (1.28, 7.55)	2.55 (1.05, 6.21)		-18% (-84, 324)	>0.80
Esterified	Cell	AA	Peroxide	15-HpETE	30	3.17 (1.31, 7.68)	2.31 (0.96, 5.6)		-27% (-85, 265)	>0.80
Esterified	Cell	AA	Peroxide	15-HpETE	60	4.16 (1.69, 10.24)	2.38 (0.97, 5.87)		-43% (-91, 280)	>0.80
NEOx	Cell	AA	Peroxide	15-HpETE	0	2.42 (1.22, 4.8)	1.3 (0.66, 2.59)	>0.80	-46% (-87, 120)	0.78
NEOx	Cell	AA	Peroxide	15-HpETE	15	2.78 (1.78, 4.32)	1.53 (0.98, 2.38)		-45% (-77, 34)	0.34
NEOx	Cell	AA	Peroxide	15-HpETE	30	2.83 (1.7, 4.71)	1.59 (0.95, 2.64)		-44% (-73, 19)	0.2
NEOx	Cell	AA	Peroxide	15-HpETE	60	2.05 (0.95, 4.39)	1.19 (0.56, 2.56)		-42% (-89, 221)	>0.80

Esterified	Media	AA	Peroxide	15-HpETE	0	2.75 (0.8, 9.44)	2.45 (0.71, 8.38)	0.6	-11% (-93, 957)	>0.80
Esterified	Media	AA	Peroxide	15-HpETE	15	1.96 (0.58, 6.67)	1.58 (0.46, 5.38)		-19% (-92, 677)	>0.80
Esterified	Media	AA	Peroxide	15-HpETE	30	1.74 (0.51, 5.88)	1.27 (0.38, 4.31)		-27% (-92, 575)	>0.80
Esterified	Media	AA	Peroxide	15-HpETE	60	2.64 (0.76, 9.22)	1.6 (0.46, 5.57)		-40% (-96, 741)	>0.80
NEOx	Media	AA	Peroxide	15-HpETE	0	2.89 (1.05, 7.94)	1.38 (0.5, 3.8)	0.6	-52% (-94, 279)	>0.80
NEOx	Media	AA	Peroxide	15-HpETE	15	2.71 (1.01, 7.25)	1.42 (0.53, 3.8)		-48% (-92, 231)	>0.80
NEOx	Media	AA	Peroxide	15-HpETE	30	2.55 (0.95, 6.8)	1.46 (0.55, 3.91)		-43% (-90, 245)	>0.80
NEOx	Media	AA	Peroxide	15-HpETE	60	2.26 (0.8, 6.38)	1.56 (0.55, 4.4)		-31% (-93, 546)	>0.80
Esterified	Cell	DHA	Triol	Resolvin D1	0	90 (31, 260)	42 (15, 121)	0.64	-54% (-95, 323)	>0.80
Esterified	Cell	DHA	Triol	Resolvin D1	15	106 (41, 272)	55 (21, 141)		-48% (-92, 218)	>0.80
Esterified	Cell	DHA	Triol	Resolvin D1	30	112 (43, 291)	64 (25, 168)		-42% (-90, 224)	>0.80
Esterified	Cell	DHA	Triol	Resolvin D1	60	89 (29, 272)	64 (21, 194)		-28% (-94, 757)	>0.80
NEOx	Cell	DHA	Triol	Resolvin D1	0	53.47 (16.76, 170.54)	55.79 (17.49, 177.94)	>0.80	4% (-91, 1070)	>0.80
NEOx	Cell	DHA	Triol	Resolvin D1	15	51.01 (17.53, 148.46)	54.05 (18.57, 157.3)		6% (-86, 714)	>0.80
NEOx	Cell	DHA	Triol	Resolvin D1	30	45.91 (15.63, 134.88)	49.4 (16.82, 145.13)		8% (-85, 660)	>0.80
NEOx	Cell	DHA	Triol	Resolvin D1	60	31.24 (9.29, 105.04)	34.67 (10.31, 116.55)		11% (-92, 1520)	>0.80
Esterified	Media	DHA	Triol	Resolvin D1	0	48.47 (12.42, 189.16)	55.97 (14.34, 218.42)	>0.80	15% (-93, 1790)	>0.80
Esterified	Media	DHA	Triol	Resolvin D1	15	36.87 (9.89, 137.39)	41.21 (11.06, 153.59)		12% (-91, 1220)	>0.80
Esterified	Media	DHA	Triol	Resolvin D1	30	33.46 (8.99, 124.5)	36.21 (9.73, 134.73)		8% (-90, 1091)	>0.80
Esterified	Media	DHA	Triol	Resolvin D1	60	46.83 (11.55, 189.85)	47.5 (11.72, 192.56)		1% (-95, 2002)	>0.80
NEOx	Media	DHA	Triol	Resolvin D1	0	76.73 (32.62, 180.48)	55.99 (23.8, 131.69)	0.59	-27% (-88, 339)	>0.80
NEOx	Media	DHA	Triol	Resolvin D1	15	67.45 (32.41, 140.35)	44.21 (21.25, 92)		-34% (-84, 173)	>0.80
NEOx	Media	DHA	Triol	Resolvin D1	30	57.66 (27.14, 122.5)	33.96 (15.98, 72.14)		-41% (-85, 125)	>0.80
NEOx	Media	DHA	Triol	Resolvin D1	60	38.76 (15.58, 96.44)	18.42 (7.41, 45.84)		-52% (-94, 266)	>0.80
Esterified	Cell	LA	Epoxide	9(10)-EpOME	0	2.6 (1.26, 5.35)	2.4 (1.16, 4.94)	0.37	-8% (-79, 311)	>0.80
Esterified	Cell	LA	Epoxide	9(10)-EpOME	15	2.79 (1.41, 5.53)	2.27 (1.14, 4.5)		-19% (-78, 197)	>0.80
Esterified	Cell	LA	Epoxide	9(10)-EpOME	30	3.1 (1.56, 6.15)	2.22 (1.12, 4.42)		-28% (-79, 151)	>0.80
Esterified	Cell	LA	Epoxide	9(10)-EpOME	60	4.23 (2, 8.94)	2.36 (1.12, 4.99)		-44% (-89, 187)	>0.80
NEOx	Cell	LA	Epoxide	9(10)-EpOME	0	0.64 (0.19, 2.17)	0.55 (0.16, 1.85)	0.73	-14% (-93, 891)	>0.80
NEOx	Cell	LA	Epoxide	9(10)-EpOME	15	0.58 (0.17, 1.96)	0.47 (0.14, 1.58)		-20% (-91, 657)	>0.80
NEOx	Cell	LA	Epoxide	9(10)-EpOME	30	0.58 (0.17, 1.94)	0.44 (0.13, 1.47)		-25% (-92, 581)	>0.80
NEOx	Cell	LA	Epoxide	9(10)-EpOME	60	0.75 (0.22, 2.6)	0.5 (0.15, 1.73)		-33% (-95, 799)	>0.80
Esterified	Media	LA	Epoxide	9(10)-EpOME	0	0.75 (0.4, 1.42)	0.56 (0.3, 1.05)	0.42	-26% (-80, 172)	>0.80
Esterified	Media	LA	Epoxide	9(10)-EpOME	15	0.71 (0.39, 1.31)	0.58 (0.32, 1.07)		-18% (-74, 156)	>0.80
Esterified	Media	LA	Epoxide	9(10)-EpOME	30	0.71 (0.39, 1.31)	0.64 (0.35, 1.17)		-10% (-70, 171)	>0.80
Esterified	Media	LA	Epoxide	9(10)-EpOME	60	0.84 (0.44, 1.6)	0.91 (0.47, 1.74)		8% (-74, 344)	>0.80
NEOx	Media	LA	Epoxide	9(10)-EpOME	0	0.51 (0.27, 0.97)	0.34 (0.18, 0.65)	0.24	-33% (-82, 153)	>0.80
NEOx	Media	LA	Epoxide	9(10)-EpOME	15	0.53 (0.32, 0.89)	0.43 (0.26, 0.72)		-19% (-70, 123)	>0.80
NEOx	Media	LA	Epoxide	9(10)-EpOME	30	0.52 (0.31, 0.89)	0.51 (0.3, 0.88)		-2% (-61, 150)	>0.80
NEOx	Media	LA	Epoxide	9(10)-EpOME	60	0.44 (0.22, 0.87)	0.63 (0.32, 1.25)		44% (-69, 568)	>0.80
Esterified	Cell	LA	Epoxide	12(13)-EpOME	0	2.14 (1.1, 4.17)	2.71 (1.39, 5.29)	0.05	27% (-67, 386)	>0.80
Esterified	Cell	LA	Epoxide	12(13)-EpOME	15	2.34 (1.2, 4.54)	2.4 (1.24, 4.65)		3% (-70, 250)	>0.80
Esterified	Cell	LA	Epoxide	12(13)-EpOME	30	2.83 (1.46, 5.48)	2.35 (1.21, 4.54)		-17% (-75, 176)	>0.80
Esterified	Cell	LA	Epoxide	12(13)-EpOME	60	5.62 (2.85, 11.08)	3.05 (1.55, 6.02)		-46% (-87, 127)	>0.80
NEOx	Cell	LA	Epoxide	12(13)-EpOME	0	0.94 (0.39, 2.29)	0.45 (0.19, 1.09)	>0.80	-52% (-93, 206)	>0.80
NEOx	Cell	LA	Epoxide	12(13)-EpOME	15	0.82 (0.39, 1.71)	0.4 (0.19, 0.85)		-51% (-88, 110)	0.69
NEOx	Cell	LA	Epoxide	12(13)-EpOME	30	0.77 (0.36, 1.66)	0.4 (0.18, 0.85)		-49% (-87, 97)	0.67
NEOx	Cell	LA	Epoxide	12(13)-EpOME	60	0.91 (0.35, 2.37)	0.5 (0.19, 1.3)		-45% (-93, 363)	>0.80
Esterified	Media	LA	Epoxide	12(13)-EpOME	0	0.4 (0.18, 0.87)	0.58 (0.27, 1.27)	0.04	45% (-71, 619)	>0.80
Esterified	Media	LA	Epoxide	12(13)-EpOME	15	0.48 (0.23, 1.03)	0.52 (0.24, 1.1)		7% (-74, 340)	>0.80
Esterified	Media	LA	Epoxide	12(13)-EpOME	30	0.65 (0.31, 1.39)	0.51 (0.24, 1.09)		-22% (-80, 210)	>0.80
Esterified	Media	LA	Epoxide	12(13)-EpOME	60	1.65 (0.74, 3.66)	0.69 (0.31, 1.54)		-58% (-93, 137)	0.66
NEOx	Media	LA	Epoxide	12(13)-EpOME	0	0.68 (0.23, 1.95)	0.4 (0.14, 1.16)	0.78	-40% (-93, 410)	>0.80
NEOx	Media	LA	Epoxide	12(13)-EpOME	15	0.52 (0.18, 1.46)	0.32 (0.11, 0.91)		-38% (-91, 333)	>0.80
NEOx	Media	LA	Epoxide	12(13)-EpOME	30	0.46 (0.16, 1.3)	0.3 (0.11, 0.85)		-35% (-90, 334)	>0.80
NEOx	Media	LA	Epoxide	12(13)-EpOME	60	0.58 (0.2, 1.71)	0.42 (0.14, 1.22)		-28% (-93, 616)	>0.80
Esterified	Cell	AA	Epoxide	14(15)-EpETrE	0	0.28 (0.11, 0.72)	0.32 (0.13, 0.84)	0.29	17% (-84, 751)	>0.80
Esterified	Cell	AA	Epoxide	14(15)-EpETrE	15	0.3 (0.14, 0.63)	0.27 (0.13, 0.57)		-10% (-79, 292)	>0.80
Esterified	Cell	AA	Epoxide	14(15)-EpETrE	30	0.35 (0.16, 0.77)	0.24 (0.11, 0.54)		-31% (-82, 166)	>0.80
Esterified	Cell	AA	Epoxide	14(15)-EpETrE	60	0.62 (0.22, 1.74)	0.25 (0.09, 0.71)		-59% (-96, 315)	>0.80
NEOx	Cell	AA	Epoxide	14(15)-EpETrE	0	0.15 (0.09, 0.23)	0.13 (0.08, 0.21)	0.72	-9% (-65, 140)	>0.80
NEOx	Cell	AA	Epoxide	14(15)-EpETrE	15	0.18 (0.13, 0.25)	0.16 (0.11, 0.22)		-13% (-56, 72)	>0.80
NEOx	Cell	AA	Epoxide	14(15)-EpETrE	30	0.19 (0.13, 0.28)	0.16 (0.11, 0.23)		-17% (-55, 53)	>0.80
NEOx	Cell	AA	Epoxide	14(15)-EpETrE	60	0.15 (0.09, 0.26)	0.12 (0.07, 0.19)		-24% (-76, 139)	>0.80
Esterified	Media	AA	Epoxide	14(15)-EpETrE	0	0.12 (0.06, 0.22)	0.1 (0.05, 0.18)	0.15	-19% (-78, 193)	>0.80
Esterified	Media	AA	Epoxide	14(15)-EpETrE	15	0.18 (0.1, 0.32)	0.12 (0.07, 0.22)		-31% (-78, 116)	>0.80
Esterified	Media	AA	Epoxide	14(15)-EpETrE	30	0.22 (0.12, 0.41)	0.13 (0.07, 0.24)		-41% (-81, 78)	0.7
Esterified	Media	AA	Epoxide	14(15)-EpETrE	60	0.22 (0.12, 0.42)	0.09 (0.05, 0.18)		-58% (-89, 70)	0.43
NEOx	Media	AA	Epoxide	14(15)-EpETrE	0	0.15 (0.09, 0.24)	0.12 (0.08, 0.2)	0.3	-17% (-69, 123)	>0.80
NEOx	Media	AA	Epoxide	14(15)-EpETrE	15	0.13 (0.08, 0.21)	0.12 (0.07, 0.19)		-9% (-62, 118)	>0.80
NEOx	Media	AA	Epoxide	14(15)-EpETrE	30	0.12 (0.08, 0.19)	0.12 (0.08, 0.19)		-1% (-58, 133)	>0.80
NEOx	Media	AA	Epoxide	14(15)-EpETrE	60	0.12 (0.07, 0.2)	0.14 (0.09, 0.23)		19% (-59, 245)	>0.80
Esterified	Cell	EPA	Epoxide	8(9)-EpETE	0	0.26 (0.11, 0.61)	0.3 (0.13, 0.7)	0.49	15% (-79, 519)	>0.80
Esterified	Cell	EPA	Epoxide	8(9)-EpETE	15	0.3 (0.13, 0.71)	0.32 (0.13, 0.76)		7% (-78, 422)	>0.80
Esterified	Cell	EPA	Epoxide	8(9)-EpETE	30	0.33 (0.14, 0.77)	0.33 (0.14, 0.77)		0% (-79, 376)	>0.80
Esterified	Cell	EPA	Epoxide	8(9)-EpETE	60	0.33 (0.14, 0.78)	0.29 (0.12, 0.68)		-14% (-85, 400)	>0.80
NEOx	Cell	EPA	Epoxide	8(9)-EpETE	0	0.27 (0.14, 0.52)	0.29 (0.15, 0.55)	0.21	5% (-72, 297)	>0.80
NEOx	Cell	EPA	Epoxide	8(9)-EpETE	15	0.35 (0.19, 0.65)	0.32 (0.17, 0.59)		-9% (-72, 192)	>0.80
NEOx	Cell	EPA	Epoxide	8(9)-EpETE	30	0.42 (0.23, 0.79)	0.33 (0.18, 0.62)		-22% (-75, 144)	>0.80
NEOx	Cell	EPA	Epoxide	8(9)-EpETE	60	0.52 (0.27, 1.02)	0.31 (0.16, 0.59)		-42% (-86, 146)	>0.80
Esterified	Media	EPA	Epoxide	8(9)-EpETE	0	0.37 (0.2, 0.68)	0.36 (0.19, 0.65)	0.07	-4% (-72, 232)	>0.80
Esterified	Media	EPA	Epoxide	8(9)-EpETE	15	0.39 (0.22, 0.72)	0.31 (0.17, 0.57)		-20% (-74, 142)	>0.80
Esterified	Media	EPA	Epoxide	8(9)-EpETE	30	0.43 (0.24, 0.78)	0.28 (0.16, 0.51)		-34% (-78, 94)	>0.80
Esterified	Media	EPA	Epoxide	8(9)-EpETE	60	0.55 (0.3, 1.02)	0.25 (0.13, 0.46)		-55% (-88, 70)	0.45
NEOx	Media	EPA	Epoxide	8(9)-EpETE	0	0.23 (0.15, 0.36)	0.23 (0.15, 0.36)	>0.80	0% (-59, 145)	>0.80

NEOx	Media	EPA	Epoxide	8(9)-EpETE	15	0.3 (0.21, 0.43)	0.31 (0.22, 0.44)		2% (-49, 102)	>0.80
NEOx	Media	EPA	Epoxide	8(9)-EpETE	30	0.35 (0.24, 0.5)	0.36 (0.25, 0.52)		3% (-46, 95)	>0.80
NEOx	Media	EPA	Epoxide	8(9)-EpETE	60	0.32 (0.2, 0.5)	0.33 (0.21, 0.53)		5% (-62, 195)	>0.80
Esterified	Cell	EPA	Epoxide	14(15)-EpETE	0	2.14 (1.4, 3.3)	2.16 (1.41, 3.33)	0.46	1% (-58, 141)	>0.80
Esterified	Cell	EPA	Epoxide	14(15)-EpETE	15	2.18 (1.68, 2.82)	2 (1.54, 2.59)		-8% (-45, 54)	>0.80
Esterified	Cell	EPA	Epoxide	14(15)-EpETE	30	2.22 (1.63, 3.02)	1.85 (1.36, 2.51)		-17% (-45, 26)	0.78
Esterified	Cell	EPA	Epoxide	14(15)-EpETE	60	2.31 (1.42, 3.73)	1.59 (0.98, 2.57)		-31% (-76, 101)	>0.80
NEOx	Cell	EPA	Epoxide	14(15)-EpETE	0	0.98 (0.39, 2.49)	1.13 (0.45, 2.85)	0.34	15% (-84, 701)	>0.80
NEOx	Cell	EPA	Epoxide	14(15)-EpETE	15	1.54 (0.73, 3.27)	1.41 (0.67, 3)		-8% (-79, 302)	>0.80
NEOx	Cell	EPA	Epoxide	14(15)-EpETE	30	1.85 (0.84, 4.06)	1.36 (0.62, 2.98)		-27% (-81, 187)	>0.80
NEOx	Cell	EPA	Epoxide	14(15)-EpETE	60	1.2 (0.44, 3.25)	0.56 (0.21, 1.52)		-53% (-95, 343)	>0.80
Esterified	Media	EPA	Epoxide	14(15)-EpETE	0	0.99 (0.35, 2.8)	2.4 (0.85, 6.76)	0.23	142% (-70, 1865)	>0.80
Esterified	Media	EPA	Epoxide	14(15)-EpETE	15	1.18 (0.64, 2.19)	1.94 (1.05, 3.61)		65% (-52, 466)	>0.80
Esterified	Media	EPA	Epoxide	14(15)-EpETE	30	1.46 (0.7, 3.05)	1.63 (0.78, 3.42)		12% (-58, 197)	>0.80
Esterified	Media	EPA	Epoxide	14(15)-EpETE	60	2.46 (0.77, 7.87)	1.28 (0.4, 4.09)		-48% (-96, 589)	>0.80
NEOx	Media	EPA	Epoxide	14(15)-EpETE	0	1.48 (0.66, 3.32)	0.95 (0.43, 2.14)	0.54	-36% (-88, 245)	>0.80
NEOx	Media	EPA	Epoxide	14(15)-EpETE	15	1.68 (0.91, 3.11)	1.23 (0.67, 2.28)		-27% (-78, 149)	>0.80
NEOx	Media	EPA	Epoxide	14(15)-EpETE	30	1.73 (0.89, 3.34)	1.44 (0.75, 2.79)		-16% (-72, 154)	>0.80
NEOx	Media	EPA	Epoxide	14(15)-EpETE	60	1.37 (0.57, 3.29)	1.49 (0.62, 3.57)		9% (-85, 680)	>0.80
Esterified	Cell	EPA	Epoxide	17(18)-EpETE	0	3.45 (1.25, 9.55)	1.33 (0.48, 3.67)	0.76	-62% (-95, 202)	0.73
Esterified	Cell	EPA	Epoxide	17(18)-EpETE	15	4.32 (2.31, 8.08)	1.82 (0.98, 3.41)		-58% (-88, 48)	0.31
Esterified	Cell	EPA	Epoxide	17(18)-EpETE	30	4.49 (2.15, 9.37)	2.08 (1, 4.34)		-54% (-83, 28)	0.22
Esterified	Cell	EPA	Epoxide	17(18)-EpETE	60	2.77 (0.89, 8.63)	1.55 (0.5, 4.83)		-44% (-96, 603)	>0.80
NEOx	Cell	EPA	Epoxide	17(18)-EpETE	0	5.04 (1.29, 19.76)	2.95 (0.75, 11.57)	0.59	-41% (-96, 868)	>0.80
NEOx	Cell	EPA	Epoxide	17(18)-EpETE	15	2.9 (0.78, 10.82)	1.49 (0.4, 5.56)		-49% (-96, 510)	>0.80
NEOx	Cell	EPA	Epoxide	17(18)-EpETE	30	2.43 (0.65, 9.07)	1.1 (0.29, 4.09)		-55% (-96, 399)	>0.80
NEOx	Cell	EPA	Epoxide	17(18)-EpETE	60	5.32 (1.31, 21.69)	1.85 (0.45, 7.53)		-65% (-98, 629)	>0.80
Esterified	Media	EPA	Epoxide	17(18)-EpETE	0	3.08 (1.29, 7.36)	1.75 (0.73, 4.18)	0.46	-43% (-90, 228)	>0.80
Esterified	Media	EPA	Epoxide	17(18)-EpETE	15	3.02 (1.81, 5.05)	2.08 (1.25, 3.48)		-31% (-75, 92)	>0.80
Esterified	Media	EPA	Epoxide	17(18)-EpETE	30	3.4 (1.83, 6.3)	2.84 (1.53, 5.26)		-16% (-63, 86)	>0.80
Esterified	Media	EPA	Epoxide	17(18)-EpETE	60	6.44 (2.43, 17.1)	7.92 (2.98, 21.03)		23% (-86, 973)	>0.80
NEOx	Media	EPA	Epoxide	17(18)-EpETE	0	3.06 (1.37, 6.85)	3.48 (1.55, 7.78)	0.75	14% (-79, 511)	>0.80
NEOx	Media	EPA	Epoxide	17(18)-EpETE	15	2.35 (1.14, 4.88)	2.83 (1.36, 5.87)		20% (-70, 387)	>0.80
NEOx	Media	EPA	Epoxide	17(18)-EpETE	30	2.17 (1.04, 4.55)	2.76 (1.32, 5.78)		27% (-67, 383)	>0.80
NEOx	Media	EPA	Epoxide	17(18)-EpETE	60	3.2 (1.37, 7.47)	4.55 (1.95, 10.6)		42% (-78, 829)	>0.80
Esterified	Cell	DHA	Epoxide	10(11)-EpDPE	0	1.09 (0.49, 2.4)	1.57 (0.71, 3.45)	0.32	44% (-72, 647)	>0.80
Esterified	Cell	DHA	Epoxide	10(11)-EpDPE	15	2.35 (1.29, 4.27)	2.75 (1.51, 4.99)		17% (-64, 284)	>0.80
Esterified	Cell	DHA	Epoxide	10(11)-EpDPE	30	3.93 (2.07, 7.46)	3.72 (1.96, 7.06)		-5% (-68, 177)	>0.80
Esterified	Cell	DHA	Epoxide	10(11)-EpDPE	60	5.1 (2.16, 12.06)	3.17 (1.34, 7.5)		-38% (-91, 331)	>0.80
NEOx	Cell	DHA	Epoxide	10(11)-EpDPE	0	0.5 (0.23, 1.11)	0.7 (0.32, 1.55)	0.05	40% (-74, 642)	>0.80
NEOx	Cell	DHA	Epoxide	10(11)-EpDPE	15	0.99 (0.49, 2)	0.95 (0.47, 1.91)		-4% (-75, 272)	>0.80
NEOx	Cell	DHA	Epoxide	10(11)-EpDPE	30	1.6 (0.78, 3.27)	1.04 (0.51, 2.14)		-35% (-82, 137)	>0.80
NEOx	Cell	DHA	Epoxide	10(11)-EpDPE	60	2.25 (0.97, 5.22)	0.69 (0.3, 1.6)		-69% (-95, 101)	0.40
Esterified	Media	DHA	Epoxide	10(11)-EpDPE	0	1.72 (0.64, 4.67)	0.62 (0.23, 1.69)	0.45	-64% (-96, 193)	0.69
Esterified	Media	DHA	Epoxide	10(11)-EpDPE	15	1.42 (0.59, 3.45)	0.61 (0.25, 1.48)		-57% (-92, 137)	0.67
Esterified	Media	DHA	Epoxide	10(11)-EpDPE	30	1.26 (0.51, 3.1)	0.64 (0.26, 1.58)		-49% (-90, 157)	>0.80
Esterified	Media	DHA	Epoxide	10(11)-EpDPE	60	1.22 (0.42, 3.5)	0.87 (0.3, 2.51)		-28% (-93, 652)	>0.80
NEOx	Media	DHA	Epoxide	10(11)-EpDPE	0	1.63 (0.54, 4.97)	0.61 (0.2, 1.85)	0.11	-63% (-96, 256)	0.78
NEOx	Media	DHA	Epoxide	10(11)-EpDPE	15	1.18 (0.39, 3.52)	0.59 (0.2, 1.77)		-50% (-93, 286)	>0.80
NEOx	Media	DHA	Epoxide	10(11)-EpDPE	30	0.96 (0.32, 2.84)	0.65 (0.22, 1.93)		-32% (-91, 398)	>0.80
NEOx	Media	DHA	Epoxide	10(11)-EpDPE	60	0.89 (0.29, 2.77)	1.11 (0.36, 3.45)		24% (-89, 1301)	>0.80
Esterified	Cell	DHA	Epoxide	13(14)-EpDPE	0	0.76 (0.2, 2.89)	0.82 (0.22, 3.12)	>0.80	8% (-92, 1414)	>0.80
Esterified	Cell	DHA	Epoxide	13(14)-EpDPE	15	0.83 (0.22, 3.16)	0.86 (0.23, 3.29)		4% (-91, 1114)	>0.80
Esterified	Cell	DHA	Epoxide	13(14)-EpDPE	30	0.97 (0.26, 3.67)	0.97 (0.26, 3.67)		0% (-91, 1025)	>0.80
Esterified	Cell	DHA	Epoxide	13(14)-EpDPE	60	1.65 (0.43, 6.33)	1.53 (0.4, 5.88)		-7% (-94, 1395)	>0.80
NEOx	Cell	DHA	Epoxide	13(14)-EpDPE	0	0.26 (0.15, 0.44)	0.28 (0.16, 0.49)	0.06	11% (-64, 245)	>0.80
NEOx	Cell	DHA	Epoxide	13(14)-EpDPE	15	0.22 (0.13, 0.38)	0.2 (0.12, 0.35)		-8% (-66, 150)	>0.80
NEOx	Cell	DHA	Epoxide	13(14)-EpDPE	30	0.22 (0.13, 0.37)	0.17 (0.1, 0.28)		-24% (-72, 101)	>0.80
NEOx	Cell	DHA	Epoxide	13(14)-EpDPE	60	0.3 (0.17, 0.52)	0.15 (0.09, 0.27)		-49% (-85, 75)	0.57
Esterified	Media	DHA	Epoxide	13(14)-EpDPE	0	0.3 (0.18, 0.5)	0.3 (0.18, 0.5)	>0.80	0% (-65, 185)	>0.80
Esterified	Media	DHA	Epoxide	13(14)-EpDPE	15	0.28 (0.2, 0.4)	0.28 (0.2, 0.39)		-3% (-52, 95)	>0.80
Esterified	Media	DHA	Epoxide	13(14)-EpDPE	30	0.28 (0.19, 0.42)	0.27 (0.18, 0.39)		-5% (-48, 73)	>0.80
Esterified	Media	DHA	Epoxide	13(14)-EpDPE	60	0.34 (0.19, 0.6)	0.3 (0.17, 0.53)		-11% (-75, 215)	>0.80
NEOx	Media	DHA	Epoxide	13(14)-EpDPE	0	0.28 (0.16, 0.48)	0.21 (0.12, 0.36)	>0.80	-25% (-75, 129)	>0.80
NEOx	Media	DHA	Epoxide	13(14)-EpDPE	15	0.26 (0.16, 0.43)	0.2 (0.12, 0.33)		-24% (-71, 100)	>0.80
NEOx	Media	DHA	Epoxide	13(14)-EpDPE	30	0.25 (0.15, 0.42)	0.19 (0.12, 0.32)		-23% (-70, 96)	>0.80
NEOx	Media	DHA	Epoxide	13(14)-EpDPE	60	0.26 (0.15, 0.46)	0.21 (0.12, 0.36)		-21% (-77, 167)	>0.80
Esterified	Cell	DHA	Epoxide	16(17)-EpDPE	0	0.7 (0.36, 1.37)	0.95 (0.49, 1.85)	0.72	35% (-67, 446)	>0.80
Esterified	Cell	DHA	Epoxide	16(17)-EpDPE	15	0.88 (0.52, 1.5)	1.12 (0.66, 1.9)		27% (-56, 263)	>0.80
Esterified	Cell	DHA	Epoxide	16(17)-EpDPE	30	1.07 (0.61, 1.87)	1.27 (0.73, 2.23)		19% (-55, 214)	>0.80
Esterified	Cell	DHA	Epoxide	16(17)-EpDPE	60	1.42 (0.69, 2.92)	1.5 (0.73, 3.09)		6% (-79, 437)	>0.80
NEOx	Cell	DHA	Epoxide	16(17)-EpDPE	0	0.5 (0.34, 0.76)	0.38 (0.25, 0.56)	>0.80	-26% (-67, 69)	>0.80
NEOx	Cell	DHA	Epoxide	16(17)-EpDPE	15	0.47 (0.32, 0.71)	0.35 (0.23, 0.52)		-26% (-65, 56)	>0.80
NEOx	Cell	DHA	Epoxide	16(17)-EpDPE	30	0.46 (0.31, 0.68)	0.34 (0.23, 0.5)		-26% (-64, 53)	>0.80
NEOx	Cell	DHA	Epoxide	16(17)-EpDPE	60	0.47 (0.31, 0.71)	0.34 (0.23, 0.52)		-27% (-70, 76)	>0.80
Esterified	Media	DHA	Epoxide	16(17)-EpDPE	0	0.46 (0.25, 0.88)	0.44 (0.23, 0.82)	0.35	-6% (-74, 240)	>0.80
Esterified	Media	DHA	Epoxide	16(17)-EpDPE	15	0.46 (0.25, 0.87)	0.47 (0.25, 0.89)		3% (-68, 231)	>0.80
Esterified	Media	DHA	Epoxide	16(17)-EpDPE	30	0.46 (0.25, 0.86)	0.52 (0.28, 0.97)		13% (-64, 255)	>0.80
Esterified	Media	DHA	Epoxide	16(17)-EpDPE	60	0.47 (0.24, 0.89)	0.64 (0.33, 1.21)		36% (-66, 439)	>0.80
NEOx	Media	DHA	Epoxide	16(17)-EpDPE	0	0.44 (0.28, 0.71)	0.37 (0.23, 0.58)	0.05	-18% (-67, 105)	>0.80
NEOx	Media	DHA	Epoxide	16(17)-EpDPE	15	0.38 (0.24, 0.61)	0.35 (0.22, 0.56)		-8% (-61, 118)	>0.80
NEOx	Media	DHA	Epoxide	16(17)-EpDPE	30	0.35 (0.22, 0.56)	0.36 (0.22, 0.57)		3% (-56, 141)	>0.80
NEOx	Media	DHA	Epoxide	16(17)-EpDPE	60	0.37 (0.23, 0.59)	0.48 (0.3, 0.76)		28% (-50, 231)	>0.80
Esterified	Cell	DHA	Epoxide	19(20)-EpDPE	0	12.1 (5.6, 26.3)	13.2 (6.1, 28.7)	0.38	9% (-78, 431)	>0.80
Esterified	Cell	DHA	Epoxide	19(20)-EpDPE	15	14.8 (7, 31.4)	14.4 (6.8, 30.4)		-3% (-76, 295)	>0.80

Esterified	Cell	DHA	Epoxide	19(20)-EpDPE	30	17.6 (8.3, 37.3)	15.2 (7.2, 32.1)		-14% (-78, 237)	>0.80
Esterified	Cell	DHA	Epoxide	19(20)-EpDPE	60	23.1 (10.4, 51)	15.6 (7.1, 34.5)		-32% (-88, 274)	>0.80
NEOx	Cell	DHA	Epoxide	19(20)-EpDPE	0	0.09 (0.05, 0.16)	0.07 (0.04, 0.12)	>0.80	-27% (-76, 122)	>0.80
NEOx	Cell	DHA	Epoxide	19(20)-EpDPE	15	0.12 (0.08, 0.19)	0.09 (0.06, 0.14)		-27% (-69, 72)	>0.80
NEOx	Cell	DHA	Epoxide	19(20)-EpDPE	30	0.14 (0.09, 0.22)	0.11 (0.07, 0.17)		-26% (-66, 63)	>0.80
NEOx	Cell	DHA	Epoxide	19(20)-EpDPE	60	0.13 (0.07, 0.23)	0.1 (0.06, 0.17)		-25% (-79, 172)	>0.80
Esterified	Media	DHA	Epoxide	19(20)-EpDPE	0	0.36 (0.19, 0.68)	0.38 (0.2, 0.71)	0.67	4% (-72, 283)	>0.80
Esterified	Media	DHA	Epoxide	19(20)-EpDPE	15	0.36 (0.23, 0.55)	0.35 (0.23, 0.53)		-3% (-59, 127)	>0.80
Esterified	Media	DHA	Epoxide	19(20)-EpDPE	30	0.38 (0.23, 0.61)	0.34 (0.21, 0.54)		-11% (-57, 87)	>0.80
Esterified	Media	DHA	Epoxide	19(20)-EpDPE	60	0.51 (0.25, 1.02)	0.39 (0.19, 0.78)		-23% (-84, 267)	>0.80
NEOx	Media	DHA	Epoxide	19(20)-EpDPE	0	0.12 (0.06, 0.24)	0.08 (0.04, 0.15)	0.69	-38% (-85, 148)	>0.80
NEOx	Media	DHA	Epoxide	19(20)-EpDPE	15	0.14 (0.07, 0.27)	0.09 (0.04, 0.17)		-36% (-82, 127)	>0.80
NEOx	Media	DHA	Epoxide	19(20)-EpDPE	30	0.14 (0.07, 0.27)	0.09 (0.05, 0.18)		-33% (-80, 130)	>0.80
NEOx	Media	DHA	Epoxide	19(20)-EpDPE	60	0.1 (0.05, 0.2)	0.07 (0.04, 0.15)		-27% (-83, 224)	>0.80
Esterified	Cell	LA	Diol	9(10)-DiHOME	0	45 (14.3, 141.2)	46.2 (14.7, 145.1)	0.52	3% (-91, 1021)	>0.80
Esterified	Cell	LA	Diol	9(10)-DiHOME	15	24.7 (8.7, 70.2)	29.8 (10.5, 84.5)		20% (-84, 787)	>0.80
Esterified	Cell	LA	Diol	9(10)-DiHOME	30	18.9 (6.6, 54.2)	26.6 (9.3, 76.4)		41% (-79, 851)	>0.80
Esterified	Cell	LA	Diol	9(10)-DiHOME	60	29.3 (8.8, 97.4)	56.6 (17.1, 188.1)		93% (-87, 2666)	>0.80
NEOx	Cell	LA	Diol	9(10)-DiHOME	0	48.26 (20.95, 111.15)	18.98 (8.24, 43.71)	0.72	-61% (-93, 124)	0.58
NEOx	Cell	LA	Diol	9(10)-DiHOME	15	37.62 (20.17, 70.19)	16.03 (8.59, 29.91)		-57% (-88, 48)	0.31
NEOx	Cell	LA	Diol	9(10)-DiHOME	30	35.49 (18.12, 69.52)	16.39 (8.37, 32.1)		-54% (-85, 41)	0.30
NEOx	Cell	LA	Diol	9(10)-DiHOME	60	55.91 (22.46, 139.17)	30.32 (12.18, 75.46)		-46% (-93, 321)	>0.80
Esterified	Media	LA	Diol	9(10)-DiHOME	0	25.2 (8.87, 71.64)	15.51 (5.46, 44.1)	>0.80	-38% (-93, 416)	>0.80
Esterified	Media	LA	Diol	9(10)-DiHOME	15	20.46 (7.34, 56.99)	12.63 (4.53, 35.18)		-38% (-91, 317)	>0.80
Esterified	Media	LA	Diol	9(10)-DiHOME	30	19.9 (7.17, 55.23)	12.32 (4.44, 34.19)		-38% (-90, 299)	>0.80
Esterified	Media	LA	Diol	9(10)-DiHOME	60	32.37 (11.14, 94.1)	20.15 (6.93, 58.59)		-38% (-94, 511)	>0.80
NEOx	Media	LA	Diol	9(10)-DiHOME	0	28.75 (8.64, 95.69)	27.23 (8.18, 90.66)	0.77	-5% (-92, 997)	>0.80
NEOx	Media	LA	Diol	9(10)-DiHOME	15	18.5 (5.7, 60.08)	18.59 (5.72, 60.36)		0% (-89, 804)	>0.80
NEOx	Media	LA	Diol	9(10)-DiHOME	30	13.94 (4.31, 45.1)	14.86 (4.59, 48.05)		7% (-87, 808)	>0.80
NEOx	Media	LA	Diol	9(10)-DiHOME	60	12.72 (3.72, 43.48)	15.24 (4.46, 52.09)		20% (-91, 1569)	>0.80
Esterified	Cell	LA	Diol	12(13)-DiHOME	0	75 (27.7, 203.1)	61.5 (22.7, 166.5)	0.59	-18% (-90, 561)	>0.80
Esterified	Cell	LA	Diol	12(13)-DiHOME	15	74.5 (33.3, 166.5)	69.8 (31.2, 156.1)		-6% (-81, 357)	>0.80
Esterified	Cell	LA	Diol	12(13)-DiHOME	30	68.9 (29.6, 160)	73.9 (31.8, 171.7)		7% (-75, 364)	>0.80
Esterified	Cell	LA	Diol	12(13)-DiHOME	60	47.6 (16.2, 139.3)	66.8 (22.8, 195.6)		40% (-87, 1471)	>0.80
NEOx	Cell	LA	Diol	12(13)-DiHOME	0	42.94 (16.1, 114.48)	30.73 (11.53, 81.94)	0.21	-28% (-90, 437)	>0.80
NEOx	Cell	LA	Diol	12(13)-DiHOME	15	39.63 (15.4, 101.98)	35.49 (13.79, 91.34)		-10% (-85, 429)	>0.80
NEOx	Cell	LA	Diol	12(13)-DiHOME	30	38.71 (15.05, 99.54)	43.38 (16.87, 111.56)		12% (-80, 528)	>0.80
NEOx	Cell	LA	Diol	12(13)-DiHOME	60	43.77 (15.96, 120.08)	76.81 (28, 210.71)		75% (-80, 1466)	>0.80
Esterified	Media	LA	Diol	12(13)-DiHOME	0	20.88 (6.99, 62.35)	23.62 (7.91, 70.55)	0.31	13% (-89, 1014)	>0.80
Esterified	Media	LA	Diol	12(13)-DiHOME	15	29.55 (10.99, 79.48)	26.19 (9.74, 70.43)		-11% (-87, 492)	>0.80
Esterified	Media	LA	Diol	12(13)-DiHOME	30	35.85 (13.15, 97.69)	24.88 (9.13, 67.81)		-31% (-89, 325)	>0.80
Esterified	Media	LA	Diol	12(13)-DiHOME	60	33.22 (10.52, 104.91)	14.14 (4.48, 44.67)		-57% (-97, 448)	>0.80
NEOx	Media	LA	Diol	12(13)-DiHOME	0	12.79 (2.84, 57.69)	34.52 (7.65, 155.63)	0.25	170% (-88, 5840)	>0.80
NEOx	Media	LA	Diol	12(13)-DiHOME	15	15.27 (3.56, 65.44)	30.12 (7.03, 129.03)		97% (-87, 2925)	>0.80
NEOx	Media	LA	Diol	12(13)-DiHOME	30	17.17 (4.01, 73.42)	24.74 (5.78, 105.82)		44% (-90, 1944)	>0.80
NEOx	Media	LA	Diol	12(13)-DiHOME	60	18.09 (3.85, 85.1)	13.93 (2.96, 65.52)		-23% (-97, 2101)	>0.80
Esterified	Cell	AA	Diol	14(15)-DiHETrE	0	4.7 (2.5, 8.7)	6.8 (3.7, 12.7)	>0.80	46% (-56, 385)	>0.80
Esterified	Cell	AA	Diol	14(15)-DiHETrE	15	4.8 (3.5, 6.5)	6.8 (5, 9.2)		41% (-20, 148)	0.46
Esterified	Cell	AA	Diol	14(15)-DiHETrE	30	5.1 (3.4, 7.7)	6.9 (4.6, 10.4)		36% (-1, 85)	0.06
Esterified	Cell	AA	Diol	14(15)-DiHETrE	60	6.4 (3.2, 12.9)	8.1 (4, 16.3)		27% (-73, 486)	>0.80
NEOx	Cell	AA	Diol	14(15)-DiHETrE	0	3.6 (1.33, 9.71)	3.61 (1.34, 9.73)	>0.80	0% (-87, 701)	>0.80
NEOx	Cell	AA	Diol	14(15)-DiHETrE	15	3.97 (1.64, 9.61)	4.14 (1.71, 10.03)		4% (-81, 474)	>0.80
NEOx	Cell	AA	Diol	14(15)-DiHETrE	30	4.5 (1.83, 11.08)	4.9 (1.99, 12.06)		9% (-78, 450)	>0.80
NEOx	Cell	AA	Diol	14(15)-DiHETrE	60	6.35 (2.23, 18.11)	7.5 (2.63, 21.4)		18% (-89, 1121)	>0.80
Esterified	Media	AA	Diol	14(15)-DiHETrE	0	1.63 (0.61, 4.37)	2.18 (0.81, 5.87)	>0.80	34% (-82, 886)	>0.80
Esterified	Media	AA	Diol	14(15)-DiHETrE	15	1.75 (0.66, 4.66)	2.34 (0.88, 6.24)		34% (-78, 725)	>0.80
Esterified	Media	AA	Diol	14(15)-DiHETrE	30	1.97 (0.74, 5.24)	2.64 (1, 7.01)		34% (-77, 694)	>0.80
Esterified	Media	AA	Diol	14(15)-DiHETrE	60	2.94 (1.08, 8.04)	3.93 (1.44, 10.74)		34% (-84, 1018)	>0.80
NEOx	Media	AA	Diol	14(15)-DiHETrE	0	2.85 (1.51, 5.38)	1.86 (0.98, 3.51)	0.11	-35% (-82, 143)	>0.80
NEOx	Media	AA	Diol	14(15)-DiHETrE	15	1.87 (1.2, 2.91)	1.65 (1.06, 2.57)		-12% (-64, 114)	>0.80
NEOx	Media	AA	Diol	14(15)-DiHETrE	30	1.51 (0.92, 2.47)	1.8 (1.1, 2.94)		19% (-45, 158)	>0.80
NEOx	Media	AA	Diol	14(15)-DiHETrE	60	1.82 (0.9, 3.68)	3.98 (1.97, 8.03)		118% (-55, 955)	0.67
Esterified	Cell	EPA	Diol	8(9)-DiHETE	0	44.5 (12.9, 153.3)	54.8 (15.9, 188.8)	0.69	23% (-91, 1549)	>0.80
Esterified	Cell	EPA	Diol	8(9)-DiHETE	15	45.8 (16, 131.2)	50.2 (17.6, 143.7)		10% (-86, 751)	>0.80
Esterified	Cell	EPA	Diol	8(9)-DiHETE	30	50.8 (17.2, 150.2)	49.5 (16.8, 146.5)		-3% (-86, 566)	>0.80
Esterified	Cell	EPA	Diol	8(9)-DiHETE	60	77.8 (20.8, 291.3)	60 (16, 224.8)		-23% (-96, 1388)	>0.80
NEOx	Cell	EPA	Diol	8(9)-DiHETE	0	31.18 (7.38, 131.72)	24.01 (5.68, 101.46)	0.62	-23% (-96, 1472)	>0.80
NEOx	Cell	EPA	Diol	8(9)-DiHETE	15	29.39 (9.39, 91.95)	18.84 (6.02, 58.96)		-36% (-93, 511)	>0.80
NEOx	Cell	EPA	Diol	8(9)-DiHETE	30	33.56 (10.07, 111.86)	17.92 (5.38, 59.72)		-47% (-93, 323)	>0.80
NEOx	Cell	EPA	Diol	8(9)-DiHETE	60	77.93 (16.37, 370.9)	28.83 (6.06, 137.22)		-63% (-99, 1135)	>0.80
Esterified	Media	EPA	Diol	8(9)-DiHETE	0	25.45 (6.05, 107.02)	10.96 (2.61, 46.1)	0.01	-57% (-98, 657)	>0.80
Esterified	Media	EPA	Diol	8(9)-DiHETE	15	19.52 (4.64, 82.05)	15.17 (3.61, 63.79)		-22% (-94, 997)	>0.80
Esterified	Media	EPA	Diol	8(9)-DiHETE	30	15.1 (3.62, 62.96)	21.19 (5.08, 88.35)		40% (-90, 1790)	>0.80
Esterified	Media	EPA	Diol	8(9)-DiHETE	60	9.29 (2.17, 39.71)	42.47 (9.94, 181.5)		357% (-78, 9377)	0.66
NEOx	Media	EPA	Diol	8(9)-DiHETE	0	12.82 (2.85, 57.75)	13.06 (2.9, 58.81)	0.57	2% (-95, 1968)	>0.80
NEOx	Media	EPA	Diol	8(9)-DiHETE	15	15.6 (3.48, 70.05)	14.03 (3.13, 63.01)		-10% (-94, 1337)	>0.80
NEOx	Media	EPA	Diol	8(9)-DiHETE	30	18.81 (4.23, 83.71)	14.94 (3.36, 66.51)		-21% (-95, 1107)	>0.80
NEOx	Media	EPA	Diol	8(9)-DiHETE	60	26.56 (5.79, 121.83)	16.46 (3.59, 75.52)		-38% (-97, 1406)	>0.80
Esterified	Cell	EPA	Diol	11(12)-DiHETE	0	15.8 (6.6, 38.1)	6.1 (2.5, 14.7)	0.42	-62% (-94, 143)	0.62
Esterified	Cell	EPA	Diol	11(12)-DiHETE	15	9.3 (4.3, 20.1)	4.2 (1.9, 9.1)		-55% (-90, 102)	0.60
Esterified	Cell	EPA	Diol	11(12)-DiHETE	30	7.4 (3.3, 16.3)	3.9 (1.8, 8.7)		-47% (-87, 120)	0.77
Esterified	Cell	EPA	Diol	11(12)-DiHETE	60	11.9 (4.7, 30.2)	8.8 (3.4, 22.3)		-26% (-91, 491)	>0.80
NEOx	Cell	EPA	Diol	11(12)-DiHETE	0	8.67 (3.97, 18.94)	3.11 (1.42, 6.79)	0.36	-64% (-93, 81)	0.40
NEOx	Cell	EPA	Diol	11(12)-DiHETE	15	7.91 (4.55, 13.76)	3.47 (1.99, 6.03)		-56% (-86, 33)	0.23
NEOx	Cell	EPA	Diol	11(12)-DiHETE	30	7.4 (4.02, 13.62)	3.97 (2.16, 7.3)		-46% (-80, 42)	0.39

NEOx	Cell	EPA	Diol	11(12)-DiHETE	60	6.95 (2.94, 16.44)	5.57 (2.36, 13.17)		-20% (-88, 453)	>0.80
Esterified	Media	EPA	Diol	11(12)-DiHETE	0	3.19 (1.24, 8.17)	3.78 (1.47, 9.67)	0.55	18% (-81, 656)	>0.80
Esterified	Media	EPA	Diol	11(12)-DiHETE	15	2.82 (1.72, 4.63)	2.8 (1.71, 4.6)		-1% (-62, 156)	>0.80
Esterified	Media	EPA	Diol	11(12)-DiHETE	30	3.18 (1.69, 6)	2.65 (1.4, 4.99)		-17% (-55, 56)	>0.80
Esterified	Media	EPA	Diol	11(12)-DiHETE	60	8.26 (2.85, 23.95)	4.83 (1.66, 14)		-42% (-94, 506)	>0.80
NEOx	Media	EPA	Diol	11(12)-DiHETE	0	6.8 (3.06, 15.09)	2.42 (1.09, 5.37)	0.05	-64% (-93, 89)	0.42
NEOx	Media	EPA	Diol	11(12)-DiHETE	15	5.68 (2.78, 11.64)	2.9 (1.42, 5.94)		-49% (-87, 102)	0.68
NEOx	Media	EPA	Diol	11(12)-DiHETE	30	5 (2.42, 10.35)	3.66 (1.77, 7.58)		-27% (-80, 172)	>0.80
NEOx	Media	EPA	Diol	11(12)-DiHETE	60	4.51 (1.95, 10.45)	6.8 (2.94, 15.75)		51% (-77, 876)	>0.80
Esterified	Cell	AA	Diol	11(12)-DiHETrE	0	14.3 (6.6, 31.1)	5.8 (2.7, 12.7)	0.63	-59% (-91, 96)	0.52
Esterified	Cell	AA	Diol	11(12)-DiHETrE	15	15.1 (9.5, 24.1)	6.9 (4.4, 11)		-54% (-82, 15)	0.13
Esterified	Cell	AA	Diol	11(12)-DiHETrE	30	14.9 (8.6, 25.9)	7.6 (4.4, 13.3)		-49% (-75, 6)	0.08
Esterified	Cell	AA	Diol	11(12)-DiHETrE	60	11.5 (4.8, 27.5)	7.4 (3.1, 17.7)		-36% (-91, 346)	>0.80
NEOx	Cell	AA	Diol	11(12)-DiHETrE	0	9.9 (3.78, 25.91)	15.29 (5.84, 40.01)	0.01	54% (-78, 969)	>0.80
NEOx	Cell	AA	Diol	11(12)-DiHETrE	15	8.58 (3.3, 22.33)	8.71 (3.35, 22.66)		1% (-83, 496)	>0.80
NEOx	Cell	AA	Diol	11(12)-DiHETrE	30	9.9 (3.82, 25.63)	6.6 (2.55, 17.1)		-33% (-88, 278)	>0.80
NEOx	Cell	AA	Diol	11(12)-DiHETrE	60	31.09 (11.71, 82.51)	8.96 (3.38, 23.78)		-71% (-96, 125)	0.45
Esterified	Media	AA	Diol	11(12)-DiHETrE	0	5.69 (2.3, 14.09)	4.7 (1.9, 11.65)	0.7	-17% (-87, 443)	>0.80
Esterified	Media	AA	Diol	11(12)-DiHETrE	15	6.32 (2.7, 14.81)	5.59 (2.39, 13.1)		-12% (-82, 345)	>0.80
Esterified	Media	AA	Diol	11(12)-DiHETrE	30	6.82 (2.9, 16.03)	6.46 (2.74, 15.18)		-5% (-80, 349)	>0.80
Esterified	Media	AA	Diol	11(12)-DiHETrE	60	7.23 (2.81, 18.56)	7.84 (3.05, 20.14)		9% (-86, 763)	>0.80
NEOx	Media	AA	Diol	11(12)-DiHETrE	0	9.46 (4.55, 19.65)	5.83 (2.81, 12.11)	0.13	-38% (-86, 175)	>0.80
NEOx	Media	AA	Diol	11(12)-DiHETrE	15	5.93 (3.69, 9.52)	5.09 (3.17, 8.18)		-14% (-67, 123)	>0.80
NEOx	Media	AA	Diol	11(12)-DiHETrE	30	4.69 (2.72, 8.07)	5.61 (3.26, 9.67)		20% (-46, 167)	>0.80
NEOx	Media	AA	Diol	11(12)-DiHETrE	60	5.88 (2.61, 13.26)	13.68 (6.07, 30.85)		133% (-62, 1331)	0.73
Esterified	Cell	EPA	Epoxide	11(12)-EpETE	0	0.3 (0.17, 0.55)	0.4 (0.22, 0.74)	0.24	34% (-61, 364)	>0.80
Esterified	Cell	EPA	Epoxide	11(12)-EpETE	15	0.29 (0.16, 0.5)	0.33 (0.19, 0.59)		17% (-60, 239)	>0.80
Esterified	Cell	EPA	Epoxide	11(12)-EpETE	30	0.29 (0.17, 0.51)	0.3 (0.17, 0.52)		1% (-64, 183)	>0.80
Esterified	Cell	EPA	Epoxide	11(12)-EpETE	60	0.37 (0.2, 0.7)	0.29 (0.15, 0.53)		-24% (-80, 199)	>0.80
NEOx	Cell	EPA	Epoxide	11(12)-EpETE	0	0.39 (0.24, 0.64)	0.44 (0.27, 0.71)	0.42	11% (-60, 206)	>0.80
NEOx	Cell	EPA	Epoxide	11(12)-EpETE	15	0.33 (0.23, 0.5)	0.34 (0.23, 0.5)		1% (-54, 119)	>0.80
NEOx	Cell	EPA	Epoxide	11(12)-EpETE	30	0.31 (0.21, 0.47)	0.28 (0.19, 0.43)		-9% (-55, 87)	>0.80
NEOx	Cell	EPA	Epoxide	11(12)-EpETE	60	0.35 (0.21, 0.59)	0.27 (0.16, 0.45)		-25% (-77, 142)	>0.80
Esterified	Media	EPA	Epoxide	11(12)-EpETE	0	0.32 (0.2, 0.52)	0.23 (0.14, 0.37)	>0.80	-29% (-74, 99)	>0.80
Esterified	Media	EPA	Epoxide	11(12)-EpETE	15	0.5 (0.32, 0.77)	0.35 (0.23, 0.54)		-29% (-69, 63)	>0.80
Esterified	Media	EPA	Epoxide	11(12)-EpETE	30	0.59 (0.38, 0.91)	0.41 (0.26, 0.64)		-30% (-68, 55)	0.76
Esterified	Media	EPA	Epoxide	11(12)-EpETE	60	0.35 (0.21, 0.59)	0.24 (0.15, 0.41)		-31% (-78, 118)	>0.80
NEOx	Media	EPA	Epoxide	11(12)-EpETE	0	0.34 (0.2, 0.57)	0.28 (0.16, 0.47)	0.21	23% (-58, 257)	>0.80
NEOx	Media	EPA	Epoxide	11(12)-EpETE	15	0.35 (0.21, 0.58)	0.32 (0.19, 0.53)		9% (-58, 183)	>0.80
NEOx	Media	EPA	Epoxide	11(12)-EpETE	30	0.34 (0.2, 0.56)	0.35 (0.21, 0.58)		-3% (-61, 146)	>0.80
NEOx	Media	EPA	Epoxide	11(12)-EpETE	60	0.26 (0.15, 0.44)	0.33 (0.19, 0.57)		-23% (-76, 145)	>0.80
Esterified	Cell	AA	Epoxide	11(12)-EpETrE	0	0.19 (0.09, 0.41)	0.21 (0.1, 0.46)	>0.80	11% (-77, 446)	>0.80
Esterified	Cell	AA	Epoxide	11(12)-EpETrE	15	0.14 (0.07, 0.25)	0.15 (0.08, 0.28)		13% (-66, 277)	>0.80
Esterified	Cell	AA	Epoxide	11(12)-EpETrE	30	0.12 (0.06, 0.23)	0.14 (0.07, 0.26)		14% (-62, 248)	>0.80
Esterified	Cell	AA	Epoxide	11(12)-EpETrE	60	0.17 (0.08, 0.39)	0.2 (0.09, 0.45)		17% (-81, 637)	>0.80
NEOx	Cell	AA	Epoxide	11(12)-EpETrE	0	0.09 (0.04, 0.18)	0.07 (0.04, 0.15)	0.42	-19% (-82, 261)	>0.80
NEOx	Cell	AA	Epoxide	11(12)-EpETrE	15	0.09 (0.04, 0.17)	0.08 (0.04, 0.16)		-9% (-75, 231)	>0.80
NEOx	Cell	AA	Epoxide	11(12)-EpETrE	30	0.09 (0.05, 0.18)	0.09 (0.05, 0.18)		2% (-71, 254)	>0.80
NEOx	Cell	AA	Epoxide	11(12)-EpETrE	60	0.11 (0.05, 0.23)	0.14 (0.07, 0.29)		27% (-75, 552)	>0.80
Esterified	Media	AA	Epoxide	11(12)-EpETrE	0	0.11 (0.05, 0.22)	0.12 (0.06, 0.25)	0.69	12% (-75, 402)	>0.80
Esterified	Media	AA	Epoxide	11(12)-EpETrE	15	0.1 (0.06, 0.17)	0.1 (0.06, 0.17)		4% (-64, 202)	>0.80
Esterified	Media	AA	Epoxide	11(12)-EpETrE	30	0.1 (0.06, 0.18)	0.09 (0.05, 0.17)		-4% (-63, 150)	>0.80
Esterified	Media	AA	Epoxide	11(12)-EpETrE	60	0.15 (0.07, 0.32)	0.12 (0.06, 0.27)		-18% (-86, 380)	>0.80
NEOx	Media	AA	Epoxide	11(12)-EpETrE	0	0.07 (0.04, 0.14)	0.12 (0.06, 0.22)	0.1	57% (-56, 466)	>0.80
NEOx	Media	AA	Epoxide	11(12)-EpETrE	15	0.11 (0.07, 0.18)	0.13 (0.09, 0.2)		16% (-51, 173)	>0.80
NEOx	Media	AA	Epoxide	11(12)-EpETrE	30	0.15 (0.09, 0.24)	0.13 (0.08, 0.21)		-14% (-59, 80)	>0.80
NEOx	Media	AA	Epoxide	11(12)-EpETrE	60	0.15 (0.08, 0.31)	0.07 (0.04, 0.14)		-53% (-90, 117)	0.67
Esterified	Cell	DHA	Alcohol	11-HDoHE	0	1.69 (0.76, 3.76)	2.21 (0.99, 4.93)	0.26	31% (-75, 601)	>0.80
Esterified	Cell	DHA	Alcohol	11-HDoHE	15	2.13 (1.14, 3.97)	2.2 (1.18, 4.09)		3% (-70, 255)	>0.80
Esterified	Cell	DHA	Alcohol	11-HDoHE	30	2.77 (1.43, 5.36)	2.25 (1.16, 4.36)		-19% (-74, 151)	>0.80
Esterified	Cell	DHA	Alcohol	11-HDoHE	60	5.11 (2.14, 12.21)	2.57 (1.08, 6.15)		-50% (-93, 257)	>0.80
NEOx	Cell	DHA	Alcohol	11-HDoHE	0	0.24 (0.13, 0.42)	0.17 (0.1, 0.31)	0.79	-27% (-78, 147)	>0.80
NEOx	Cell	DHA	Alcohol	11-HDoHE	15	0.27 (0.17, 0.44)	0.21 (0.13, 0.34)		-24% (-70, 96)	>0.80
NEOx	Cell	DHA	Alcohol	11-HDoHE	30	0.3 (0.18, 0.5)	0.24 (0.14, 0.39)		-21% (-67, 91)	>0.80
NEOx	Cell	DHA	Alcohol	11-HDoHE	60	0.32 (0.17, 0.59)	0.27 (0.15, 0.51)		-15% (-79, 245)	>0.80
Esterified	Media	DHA	Alcohol	11-HDoHE	0	0.3 (0.18, 0.49)	0.3 (0.18, 0.51)	0.66	3% (-64, 199)	>0.80
Esterified	Media	DHA	Alcohol	11-HDoHE	15	0.21 (0.14, 0.32)	0.2 (0.13, 0.32)		-2% (-58, 128)	>0.80
Esterified	Media	DHA	Alcohol	11-HDoHE	30	0.2 (0.13, 0.31)	0.18 (0.12, 0.29)		-7% (-58, 106)	>0.80
Esterified	Media	DHA	Alcohol	11-HDoHE	60	0.41 (0.24, 0.7)	0.34 (0.2, 0.59)		-16% (-75, 180)	>0.80
NEOx	Media	DHA	Alcohol	11-HDoHE	0	0.34 (0.21, 0.55)	0.29 (0.18, 0.47)	0.69	-15% (-68, 125)	>0.80
NEOx	Media	DHA	Alcohol	11-HDoHE	15	0.27 (0.17, 0.42)	0.22 (0.14, 0.35)		-18% (-65, 96)	>0.80
NEOx	Media	DHA	Alcohol	11-HDoHE	30	0.23 (0.15, 0.37)	0.19 (0.12, 0.29)		-20% (-66, 85)	>0.80
NEOx	Media	DHA	Alcohol	11-HDoHE	60	0.25 (0.16, 0.41)	0.19 (0.12, 0.31)		-25% (-74, 113)	>0.80
Esterified	Cell	EPA	Diol	14(15)-DiHETE	0	1.5 (0.4, 6)	4 (1, 15.9)	0.1	163% (-85, 4565)	>0.80
Esterified	Cell	EPA	Diol	14(15)-DiHETE	15	5.3 (1.9, 14.8)	7.4 (2.7, 20.6)		39% (-82, 978)	>0.80
Esterified	Cell	EPA	Diol	14(15)-DiHETE	30	12.4 (4.1, 37.4)	9.1 (3, 27.7)		-26% (-88, 363)	>0.80
Esterified	Cell	EPA	Diol	14(15)-DiHETE	60	19.5 (4.3, 88.4)	4.1 (0.9, 18.4)		-79% (-99, 522)	0.74
NEOx	Cell	EPA	Diol	14(15)-DiHETE	0	7.56 (3.37, 16.95)	5.43 (2.42, 12.18)	>0.80	-28% (-86, 261)	>0.80
NEOx	Cell	EPA	Diol	14(15)-DiHETE	15	7.26 (4.6, 11.46)	4.93 (3.13, 7.78)		-32% (-72, 67)	0.8
NEOx	Cell	EPA	Diol	14(15)-DiHETE	30	8.87 (5.06, 15.56)	5.69 (3.24, 9.98)		-36% (-67, 26)	0.35
NEOx	Cell	EPA	Diol	14(15)-DiHETE	60	27.18 (10.94, 67.48)	15.57 (6.27, 38.66)		-43% (-92, 328)	>0.80
Esterified	Media	EPA	Diol	14(15)-DiHETE	0	1.33 (0.37, 4.81)	2.69 (0.74, 9.71)	>0.80	102% (-84, 2469)	>0.80
Esterified	Media	EPA	Diol	14(15)-DiHETE	15	2.75 (1.38, 5.49)	5.06 (2.53, 10.11)		84% (-52, 606)	0.75
Esterified	Media	EPA	Diol	14(15)-DiHETE	30	4.64 (1.93, 11.13)	7.8 (3.25, 18.71)		68% (-34, 328)	0.55
Esterified	Media	EPA	Diol	14(15)-DiHETE	60	7.26 (1.7, 30.96)	10.15 (2.38, 43.32)		40% (-94, 3311)	>0.80

NEOx	Media	EPA	Diol	14(15)-DiHETE	0	7.33 (2.62, 20.51)	7.04 (2.52, 19.7)	0.35	-4% (-89, 729)	>0.80
NEOx	Media	EPA	Diol	14(15)-DiHETE	15	3.99 (1.62, 9.84)	4.78 (1.94, 11.79)		20% (-79, 586)	>0.80
NEOx	Media	EPA	Diol	14(15)-DiHETE	30	2.99 (1.19, 7.51)	4.47 (1.78, 11.24)		50% (-71, 679)	>0.80
NEOx	Media	EPA	Diol	14(15)-DiHETE	60	4.37 (1.47, 13.01)	10.19 (3.42, 30.3)		133% (-80, 2560)	>0.80
Esterified	Cell	AA	Prostanoid	15-deoxy-PGJ2	0	26 (13, 52)	32 (16, 64)	0.56	24% (-71, 436)	>0.80
Esterified	Cell	AA	Prostanoid	15-deoxy-PGJ2	15	39 (23, 67)	43 (25, 75)		11% (-62, 225)	>0.80
Esterified	Cell	AA	Prostanoid	15-deoxy-PGJ2	30	54 (30, 96)	54 (30, 96)		0% (-63, 165)	>0.80
Esterified	Cell	AA	Prostanoid	15-deoxy-PGJ2	60	78 (36, 167)	62 (29, 134)		-20% (-86, 345)	>0.80
NEOx	Cell	AA	Prostanoid	15-deoxy-PGJ2	0	28.74 (12.44, 66.38)	33.29 (14.41, 76.89)	0.55	16% (-80, 571)	>0.80
NEOx	Cell	AA	Prostanoid	15-deoxy-PGJ2	15	22.03 (10.87, 44.64)	28.8 (14.21, 58.36)		31% (-67, 419)	>0.80
NEOx	Cell	AA	Prostanoid	15-deoxy-PGJ2	30	18.07 (8.71, 37.49)	26.66 (12.85, 55.31)		48% (-59, 436)	>0.80
NEOx	Cell	AA	Prostanoid	15-deoxy-PGJ2	60	14.9 (6.09, 36.47)	28.01 (11.44, 68.55)		88% (-75, 1299)	>0.80
Esterified	Media	AA	Prostanoid	15-deoxy-PGJ2	0	50.61 (23.3, 109.91)	41.49 (19.1, 90.11)	0.45	-18% (-84, 315)	>0.80
Esterified	Media	AA	Prostanoid	15-deoxy-PGJ2	15	60.86 (33.41, 110.84)	42.78 (23.49, 77.92)		-30% (-79, 131)	>0.80
Esterified	Media	AA	Prostanoid	15-deoxy-PGJ2	30	69.18 (36.54, 130.95)	41.69 (22.03, 78.93)		-40% (-80, 78)	0.73
Esterified	Media	AA	Prostanoid	15-deoxy-PGJ2	60	75.48 (32.49, 175.39)	33.45 (14.39, 77.71)		-56% (-93, 195)	0.80
NEOx	Media	AA	Prostanoid	15-deoxy-PGJ2	0	31.7 (12.41, 80.95)	22.36 (8.75, 57.09)	0.26	-29% (-90, 400)	>0.80
NEOx	Media	AA	Prostanoid	15-deoxy-PGJ2	15	45.2 (21.9, 93.27)	42.22 (20.46, 87.11)		-7% (-78, 293)	>0.80
NEOx	Media	AA	Prostanoid	15-deoxy-PGJ2	30	45.66 (21.12, 98.73)	56.48 (26.12, 122.13)		24% (-67, 358)	>0.80
NEOx	Media	AA	Prostanoid	15-deoxy-PGJ2	60	16.57 (5.98, 45.91)	35.94 (12.97, 99.62)		117% (-78, 2048)	>0.80
Esterified	Cell	EPA	Alcohol	15-HEPE	0	0.7 (0.35, 1.41)	0.51 (0.26, 1.03)	0.5	-26% (-83, 214)	>0.80
Esterified	Cell	EPA	Alcohol	15-HEPE	15	0.78 (0.47, 1.29)	0.5 (0.3, 0.83)		-35% (-76, 77)	0.79
Esterified	Cell	EPA	Alcohol	15-HEPE	30	0.79 (0.46, 1.37)	0.45 (0.26, 0.78)		-43% (-77, 39)	0.40
Esterified	Cell	EPA	Alcohol	15-HEPE	60	0.61 (0.28, 1.32)	0.27 (0.12, 0.58)		-56% (-92, 147)	0.71
NEOx	Cell	EPA	Alcohol	15-HEPE	0	0.73 (0.31, 1.73)	0.45 (0.19, 1.06)	0.4	-39% (-90, 270)	>0.80
NEOx	Cell	EPA	Alcohol	15-HEPE	15	0.71 (0.31, 1.59)	0.5 (0.22, 1.13)		-29% (-85, 230)	>0.80
NEOx	Cell	EPA	Alcohol	15-HEPE	30	0.72 (0.32, 1.63)	0.59 (0.26, 1.33)		-18% (-81, 260)	>0.80
NEOx	Cell	EPA	Alcohol	15-HEPE	60	0.86 (0.35, 2.12)	0.95 (0.38, 2.32)		9% (-85, 691)	>0.80
Esterified	Media	EPA	Alcohol	15-HEPE	0	0.45 (0.23, 0.87)	0.53 (0.27, 1.04)	0.29	19% (-71, 385)	>0.80
Esterified	Media	EPA	Alcohol	15-HEPE	15	0.43 (0.25, 0.74)	0.43 (0.25, 0.74)		0% (-66, 195)	>0.80
Esterified	Media	EPA	Alcohol	15-HEPE	30	0.46 (0.26, 0.81)	0.38 (0.22, 0.68)		-16% (-69, 130)	>0.80
Esterified	Media	EPA	Alcohol	15-HEPE	60	0.73 (0.35, 1.49)	0.43 (0.21, 0.88)		-41% (-88, 196)	>0.80
NEOx	Media	EPA	Alcohol	15-HEPE	0	1.07 (0.55, 2.07)	0.63 (0.33, 1.22)	0.22	-41% (-85, 134)	>0.80
NEOx	Media	EPA	Alcohol	15-HEPE	15	0.68 (0.4, 1.15)	0.49 (0.29, 0.84)		-27% (-74, 105)	>0.80
NEOx	Media	EPA	Alcohol	15-HEPE	30	0.5 (0.29, 0.87)	0.45 (0.26, 0.78)		-10% (-65, 133)	>0.80
NEOx	Media	EPA	Alcohol	15-HEPE	60	0.43 (0.21, 0.88)	0.59 (0.29, 1.2)		37% (-72, 576)	>0.80
Esterified	Cell	DHA	Alcohol	16-HDoHE	0	1.1 (0.35, 3.43)	0.77 (0.25, 2.41)	0.8	-30% (-93, 576)	>0.80
Esterified	Cell	DHA	Alcohol	16-HDoHE	15	1.51 (0.8, 2.86)	1.16 (0.61, 2.19)		-23% (-78, 169)	>0.80
Esterified	Cell	DHA	Alcohol	16-HDoHE	30	1.74 (0.79, 3.83)	1.47 (0.67, 3.22)		-16% (-67, 113)	>0.80
Esterified	Cell	DHA	Alcohol	16-HDoHE	60	1.38 (0.38, 4.95)	1.39 (0.39, 4.97)		1% (-94, 1594)	>0.80
NEOx	Cell	DHA	Alcohol	16-HDoHE	0	0.12 (0.06, 0.25)	0.05 (0.03, 0.11)	>0.80	-55% (-90, 94)	0.56
NEOx	Cell	DHA	Alcohol	16-HDoHE	15	0.13 (0.09, 0.2)	0.06 (0.04, 0.09)		-56% (-81, 3)	0.06
NEOx	Cell	DHA	Alcohol	16-HDoHE	30	0.14 (0.08, 0.24)	0.06 (0.04, 0.1)		-58% (-78, -16)	0.009
NEOx	Cell	DHA	Alcohol	16-HDoHE	60	0.14 (0.06, 0.31)	0.06 (0.02, 0.12)		-60% (-93, 143)	0.64
Esterified	Media	DHA	Alcohol	16-HDoHE	0	0.11 (0.04, 0.26)	0.06 (0.02, 0.14)	0.2	-46% (-91, 235)	>0.80
Esterified	Media	DHA	Alcohol	16-HDoHE	15	0.08 (0.04, 0.15)	0.06 (0.03, 0.11)		-26% (-80, 172)	>0.80
Esterified	Media	DHA	Alcohol	16-HDoHE	30	0.06 (0.03, 0.12)	0.06 (0.03, 0.12)		0% (-69, 226)	>0.80
Esterified	Media	DHA	Alcohol	16-HDoHE	60	0.05 (0.02, 0.12)	0.09 (0.03, 0.22)		87% (-78, 1507)	>0.80
NEOx	Media	DHA	Alcohol	16-HDoHE	0	0.07 (0.03, 0.15)	0.05 (0.02, 0.11)	0.3	-29% (-85, 244)	>0.80
NEOx	Media	DHA	Alcohol	16-HDoHE	15	0.06 (0.03, 0.13)	0.04 (0.02, 0.08)		-39% (-84, 129)	>0.80
NEOx	Media	DHA	Alcohol	16-HDoHE	30	0.07 (0.03, 0.13)	0.03 (0.02, 0.07)		-48% (-86, 85)	0.62
NEOx	Media	DHA	Alcohol	16-HDoHE	60	0.11 (0.05, 0.23)	0.04 (0.02, 0.09)		-63% (-93, 112)	0.52
Esterified	Cell	EPA	Diol	17(18)-DiHETE	0	152 (63, 369)	197 (81, 477)	>0.80	29% (-79, 680)	>0.80
Esterified	Cell	EPA	Diol	17(18)-DiHETE	15	70 (40, 121)	87 (50, 151)		25% (-58, 277)	>0.80
Esterified	Cell	EPA	Diol	17(18)-DiHETE	30	51 (27, 97)	62 (32, 118)		21% (-51, 198)	>0.80
Esterified	Cell	EPA	Diol	17(18)-DiHETE	60	112 (42, 301)	127 (47, 341)		13% (-87, 923)	>0.80
NEOx	Cell	EPA	Diol	17(18)-DiHETE	0	74.75 (27.51, 203.09)	40.22 (14.8, 109.26)	0.62	-46% (-93, 338)	>0.80
NEOx	Cell	EPA	Diol	17(18)-DiHETE	15	97.79 (42.87, 223.09)	46.57 (20.41, 106.24)		-52% (-91, 140)	0.74
NEOx	Cell	EPA	Diol	17(18)-DiHETE	30	119.32 (50.58, 281.44)	50.3 (21.32, 118.65)		-58% (-91, 90)	0.51
NEOx	Cell	EPA	Diol	17(18)-DiHETE	60	144.11 (49.25, 421.67)	47.61 (16.27, 139.3)		-67% (-97, 268)	0.74
Esterified	Media	EPA	Diol	17(18)-DiHETE	0	29.46 (10.05, 86.41)	11.89 (4.05, 34.88)	0.29	-60% (-96, 285)	>0.80
Esterified	Media	EPA	Diol	17(18)-DiHETE	15	42.65 (17.61, 103.28)	22.93 (9.47, 55.54)		-46% (-91, 205)	>0.80
Esterified	Media	EPA	Diol	17(18)-DiHETE	30	49.19 (19.57, 123.61)	35.24 (14.02, 88.56)		-28% (-86, 259)	>0.80
Esterified	Media	EPA	Diol	17(18)-DiHETE	60	33.12 (10.42, 105.31)	42.12 (13.25, 133.93)		27% (-91, 1609)	>0.80
NEOx	Media	EPA	Diol	17(18)-DiHETE	0	55.5 (24.83, 124.05)	84.09 (37.63, 187.95)	0.74	52% (-71, 703)	>0.80
NEOx	Media	EPA	Diol	17(18)-DiHETE	15	27.46 (15.44, 48.84)	38.66 (21.73, 68.77)		41% (-56, 346)	>0.80
NEOx	Media	EPA	Diol	17(18)-DiHETE	30	19.56 (10.4, 36.79)	25.59 (13.61, 48.14)		31% (-53, 263)	>0.80
NEOx	Media	EPA	Diol	17(18)-DiHETE	60	29.65 (12.24, 71.78)	33.5 (13.84, 81.1)		13% (-84, 723)	>0.80
Esterified	Cell	DHA	Alcohol	20-HDoHE	0	4.94 (2.19, 11.12)	3.96 (1.76, 8.93)	>0.80	-20% (-85, 319)	>0.80
Esterified	Cell	DHA	Alcohol	20-HDoHE	15	6.14 (2.77, 13.61)	5.06 (2.28, 11.23)		-18% (-81, 264)	>0.80
Esterified	Cell	DHA	Alcohol	20-HDoHE	30	7.08 (3.2, 15.65)	6 (2.71, 13.26)		-15% (-80, 261)	>0.80
Esterified	Cell	DHA	Alcohol	20-HDoHE	60	7.5 (3.27, 17.19)	6.71 (2.93, 15.37)		-11% (-85, 428)	>0.80
NEOx	Cell	DHA	Alcohol	20-HDoHE	0	0.16 (0.03, 0.75)	0.04 (0.01, 0.19)	0.77	-75% (-99, 522)	0.79
NEOx	Cell	DHA	Alcohol	20-HDoHE	15	0.11 (0.04, 0.31)	0.02 (0.01, 0.07)		-78% (-97, 82)	0.26
NEOx	Cell	DHA	Alcohol	20-HDoHE	30	0.09 (0.03, 0.31)	0.02 (0.01, 0.06)		-81% (-97, 19)	0.09
NEOx	Cell	DHA	Alcohol	20-HDoHE	60	0.15 (0.03, 0.84)	0.02 (0, 0.12)		-85% (-100, 610)	0.67
Esterified	Media	DHA	Alcohol	20-HDoHE	0	0.14 (0.03, 0.6)	0.1 (0.02, 0.43)	0.24	-28% (-97, 1404)	>0.80
Esterified	Media	DHA	Alcohol	20-HDoHE	15	0.08 (0.02, 0.26)	0.08 (0.02, 0.28)		8% (-90, 1124)	>0.80
Esterified	Media	DHA	Alcohol	20-HDoHE	30	0.05 (0.01, 0.18)	0.08 (0.02, 0.3)		63% (-83, 1499)	>0.80
Esterified	Media	DHA	Alcohol	20-HDoHE	60	0.04 (0.01, 0.21)	0.17 (0.04, 0.78)		271% (-88, 11640)	>0.80
NEOx	Media	DHA	Alcohol	20-HDoHE	0	0.04 (0.01, 0.16)	0.06 (0.01, 0.23)	0.44	45% (-92, 2452)	>0.80
NEOx	Media	DHA	Alcohol	20-HDoHE	15	0.07 (0.02, 0.21)	0.08 (0.02, 0.24)		12% (-88, 933)	>0.80
NEOx	Media	DHA	Alcohol	20-HDoHE	30	0.08 (0.02, 0.24)	0.06 (0.02, 0.21)		-14% (-89, 584)	>0.80
NEOx	Media	DHA	Alcohol	20-HDoHE	60	0.02 (0.01, 0.11)	0.01 (0, 0.05)		-49% (-98, 1288)	>0.80
Esterified	Cell	AA	Alcohol	20-HETE	0	0.37 (0.21, 0.64)	0.34 (0.2, 0.6)	0.3	-6% (-71, 199)	>0.80

Esterified	Cell	AA	Alcohol	20-HETE	15	0.44 (0.28, 0.71)	0.36 (0.22, 0.58)		-19% (-67, 104)	>0.80
Esterified	Cell	AA	Alcohol	20-HETE	30	0.51 (0.32, 0.84)	0.36 (0.22, 0.59)		-29% (-70, 68)	>0.80
Esterified	Cell	AA	Alcohol	20-HETE	60	0.65 (0.36, 1.17)	0.35 (0.19, 0.63)		-46% (-86, 102)	0.72
NEOx	Cell	AA	Alcohol	20-HETE	0	0.33 (0.2, 0.53)	0.27 (0.16, 0.43)	0.61	-18% (-70, 122)	>0.80
NEOx	Cell	AA	Alcohol	20-HETE	15	0.38 (0.24, 0.6)	0.3 (0.19, 0.47)		-22% (-68, 86)	>0.80
NEOx	Cell	AA	Alcohol	20-HETE	30	0.41 (0.26, 0.65)	0.3 (0.19, 0.48)		-26% (-68, 73)	>0.80
NEOx	Cell	AA	Alcohol	20-HETE	60	0.39 (0.23, 0.64)	0.26 (0.16, 0.43)		-32% (-77, 102)	>0.80
Esterified	Media	AA	Alcohol	20-HETE	0	0.36 (0.19, 0.67)	0.32 (0.17, 0.61)	>0.80	-10% (-75, 231)	>0.80
Esterified	Media	AA	Alcohol	20-HETE	15	0.41 (0.22, 0.73)	0.37 (0.2, 0.67)		-9% (-70, 180)	>0.80
Esterified	Media	AA	Alcohol	20-HETE	30	0.43 (0.24, 0.78)	0.39 (0.22, 0.71)		-8% (-69, 172)	>0.80
Esterified	Media	AA	Alcohol	20-HETE	60	0.39 (0.2, 0.75)	0.36 (0.19, 0.7)		-7% (-78, 286)	>0.80
NEOx	Media	AA	Alcohol	20-HETE	0	0.38 (0.18, 0.81)	0.28 (0.13, 0.6)	0.26	-25% (-82, 211)	>0.80
NEOx	Media	AA	Alcohol	20-HETE	15	0.32 (0.15, 0.68)	0.25 (0.12, 0.55)		-20% (-80, 220)	>0.80
NEOx	Media	AA	Alcohol	20-HETE	30	0.3 (0.14, 0.64)	0.26 (0.12, 0.55)		-14% (-78, 241)	>0.80
NEOx	Media	AA	Alcohol	20-HETE	60	0.37 (0.17, 0.79)	0.37 (0.17, 0.78)		-1% (-77, 327)	>0.80
Esterified	Cell	DHA	Alcohol	22-HDoHE	0	0.34 (0.12, 0.97)	0.78 (0.28, 2.23)	0.18	130% (-74, 1921)	>0.80
Esterified	Cell	DHA	Alcohol	22-HDoHE	15	0.59 (0.22, 1.55)	1.01 (0.38, 2.64)		71% (-73, 975)	>0.80
Esterified	Cell	DHA	Alcohol	22-HDoHE	30	0.99 (0.37, 2.62)	1.25 (0.47, 3.32)		27% (-78, 641)	>0.80
Esterified	Cell	DHA	Alcohol	22-HDoHE	60	2.58 (0.87, 7.67)	1.8 (0.61, 5.37)		-30% (-94, 678)	>0.80
NEOx	Cell	DHA	Alcohol	22-HDoHE	0	0.15 (0.07, 0.33)	0.1 (0.04, 0.21)	0.6	-36% (-88, 237)	>0.80
NEOx	Cell	DHA	Alcohol	22-HDoHE	15	0.16 (0.08, 0.31)	0.11 (0.05, 0.22)		-29% (-82, 175)	>0.80
NEOx	Cell	DHA	Alcohol	22-HDoHE	30	0.17 (0.09, 0.36)	0.14 (0.07, 0.28)		-22% (-79, 182)	>0.80
NEOx	Cell	DHA	Alcohol	22-HDoHE	60	0.28 (0.12, 0.64)	0.26 (0.11, 0.6)		-7% (-85, 496)	>0.80
Esterified	Media	DHA	Alcohol	22-HDoHE	0	0.14 (0.05, 0.38)	0.14 (0.05, 0.38)	0.8	-1% (-88, 733)	>0.80
Esterified	Media	DHA	Alcohol	22-HDoHE	15	0.21 (0.08, 0.53)	0.19 (0.08, 0.5)		-6% (-85, 469)	>0.80
Esterified	Media	DHA	Alcohol	22-HDoHE	30	0.28 (0.11, 0.72)	0.25 (0.09, 0.64)		-11% (-84, 401)	>0.80
Esterified	Media	DHA	Alcohol	22-HDoHE	60	0.34 (0.12, 1)	0.27 (0.09, 0.8)		-20% (-92, 746)	>0.80
NEOx	Media	DHA	Alcohol	22-HDoHE	0	0.14 (0.06, 0.32)	0.08 (0.04, 0.18)	>0.80	-44% (-89, 195)	>0.80
NEOx	Media	DHA	Alcohol	22-HDoHE	15	0.17 (0.08, 0.34)	0.1 (0.05, 0.2)		-43% (-85, 125)	>0.80
NEOx	Media	DHA	Alcohol	22-HDoHE	30	0.19 (0.09, 0.39)	0.11 (0.05, 0.23)		-41% (-84, 115)	>0.80
NEOx	Media	DHA	Alcohol	22-HDoHE	60	0.22 (0.1, 0.51)	0.14 (0.06, 0.31)		-38% (-90, 296)	>0.80
Esterified	Cell	AA	Prostanoid	6-keto-PGF1a	0	80 (28, 227)	24 (8, 67)	0.22	-71% (-97, 161)	0.54
Esterified	Cell	AA	Prostanoid	6-keto-PGF1a	15	47 (20, 110)	19 (8, 45)		-59% (-92, 118)	0.59
Esterified	Cell	AA	Prostanoid	6-keto-PGF1a	30	33 (14, 81)	19 (8, 46)		-44% (-88, 167)	>0.80
Esterified	Cell	AA	Prostanoid	6-keto-PGF1a	60	30 (10, 93)	33 (11, 100)		7% (-91, 1226)	>0.80
NEOx	Cell	AA	Prostanoid	6-keto-PGF1a	0	22.26 (5.08, 97.54)	9.42 (2.15, 41.27)	0.51	-58% (-98, 832)	>0.80
NEOx	Cell	AA	Prostanoid	6-keto-PGF1a	15	13.46 (3.61, 50.25)	7.05 (1.89, 26.32)		-48% (-96, 563)	>0.80
NEOx	Cell	AA	Prostanoid	6-keto-PGF1a	30	10.94 (2.86, 41.75)	7.09 (1.86, 27.07)		-35% (-94, 623)	>0.80
NEOx	Cell	AA	Prostanoid	6-keto-PGF1a	60	17.5 (3.68, 83.23)	17.4 (3.66, 82.73)		-1% (-97, 3105)	>0.80
Esterified	Media	AA	Prostanoid	6-keto-PGF1a	0	17.19 (7.67, 38.51)	32.1 (14.32, 71.92)	0.74	87% (-66, 915)	>0.80
Esterified	Media	AA	Prostanoid	6-keto-PGF1a	15	18.62 (9.33, 37.15)	32.65 (16.36, 65.14)		75% (-54, 573)	>0.80
Esterified	Media	AA	Prostanoid	6-keto-PGF1a	30	20.71 (10.18, 42.14)	34.09 (16.75, 69.38)		65% (-53, 482)	>0.80
Esterified	Media	AA	Prostanoid	6-keto-PGF1a	60	27.72 (11.73, 65.49)	40.22 (17.02, 95.04)		45% (-79, 896)	>0.80
NEOx	Media	AA	Prostanoid	6-keto-PGF1a	0	44.55 (17.65, 112.48)	15.81 (6.26, 39.9)	0.25	-65% (-95, 148)	0.59
NEOx	Media	AA	Prostanoid	6-keto-PGF1a	15	40.21 (18.27, 88.48)	18.5 (8.41, 40.7)		-54% (-90, 114)	0.65
NEOx	Media	AA	Prostanoid	6-keto-PGF1a	30	32.37 (14.36, 72.95)	19.31 (8.57, 43.51)		-40% (-86, 152)	>0.80
NEOx	Media	AA	Prostanoid	6-keto-PGF1a	60	14.88 (5.54, 39.97)	14.92 (5.55, 40.08)		0% (-89, 818)	>0.80
Esterified	Cell	DHA	Epoxide	7(8)-EpDPE	0	1.6 (0.74, 3.48)	1.73 (0.8, 3.76)	>0.80	8% (-78, 437)	>0.80
Esterified	Cell	DHA	Epoxide	7(8)-EpDPE	15	1.31 (0.63, 2.73)	1.42 (0.68, 2.96)		8% (-73, 334)	>0.80
Esterified	Cell	DHA	Epoxide	7(8)-EpDPE	30	1.27 (0.61, 2.65)	1.39 (0.67, 2.89)		9% (-71, 315)	>0.80
Esterified	Cell	DHA	Epoxide	7(8)-EpDPE	60	2.01 (0.9, 4.48)	2.21 (0.99, 4.92)		10% (-81, 537)	>0.80
NEOx	Cell	DHA	Epoxide	7(8)-EpDPE	0	0.3 (0.21, 0.44)	0.18 (0.12, 0.26)	0.24	-41% (-73, 30)	0.33
NEOx	Cell	DHA	Epoxide	7(8)-EpDPE	15	0.27 (0.2, 0.37)	0.18 (0.13, 0.24)		-35% (-65, 22)	0.31
NEOx	Cell	DHA	Epoxide	7(8)-EpDPE	30	0.25 (0.18, 0.35)	0.18 (0.13, 0.25)		-27% (-60, 30)	0.57
NEOx	Cell	DHA	Epoxide	7(8)-EpDPE	60	0.24 (0.16, 0.36)	0.21 (0.14, 0.32)		-10% (-64, 122)	>0.80
Esterified	Media	DHA	Epoxide	7(8)-EpDPE	0	0.28 (0.15, 0.53)	0.26 (0.13, 0.49)	>0.80	-8% (-75, 238)	>0.80
Esterified	Media	DHA	Epoxide	7(8)-EpDPE	15	0.22 (0.12, 0.42)	0.2 (0.11, 0.38)		-10% (-72, 193)	>0.80
Esterified	Media	DHA	Epoxide	7(8)-EpDPE	30	0.22 (0.12, 0.42)	0.2 (0.1, 0.37)		-12% (-72, 179)	>0.80
Esterified	Media	DHA	Epoxide	7(8)-EpDPE	60	0.38 (0.2, 0.74)	0.32 (0.17, 0.62)		-16% (-79, 237)	>0.80
NEOx	Media	DHA	Epoxide	7(8)-EpDPE	0	0.27 (0.19, 0.37)	0.22 (0.16, 0.31)	0.46	-16% (-59, 70)	>0.80
NEOx	Media	DHA	Epoxide	7(8)-EpDPE	15	0.24 (0.18, 0.33)	0.22 (0.16, 0.29)		-11% (-50, 57)	>0.80
NEOx	Media	DHA	Epoxide	7(8)-EpDPE	30	0.23 (0.17, 0.31)	0.22 (0.16, 0.29)		-6% (-45, 61)	>0.80
NEOx	Media	DHA	Epoxide	7(8)-EpDPE	60	0.23 (0.16, 0.33)	0.25 (0.17, 0.35)		5% (-53, 136)	>0.80
Esterified	Cell	AA	Diol	8(9)-DiHETrE	0	18.9 (7.4, 47.9)	33.7 (13.3, 85.5)	0.18	79% (-74, 1147)	>0.80
Esterified	Cell	AA	Diol	8(9)-DiHETrE	15	23.6 (11.5, 48.3)	30 (14.6, 61.4)		27% (-69, 427)	>0.80
Esterified	Cell	AA	Diol	8(9)-DiHETrE	30	28.8 (13.4, 61.9)	26.1 (12.1, 56)		-10% (-75, 230)	>0.80
Esterified	Cell	AA	Diol	8(9)-DiHETrE	60	40.3 (14.7, 111)	18.5 (6.7, 50.8)		-54% (-95, 346)	>0.80
NEOx	Cell	AA	Diol	8(9)-DiHETrE	0	26.41 (10.42, 66.89)	13.13 (5.18, 33.27)	0.2	-50% (-93, 249)	>0.80
NEOx	Cell	AA	Diol	8(9)-DiHETrE	15	31.2 (14.2, 68.55)	20.75 (9.44, 45.59)		-33% (-86, 209)	>0.80
NEOx	Cell	AA	Diol	8(9)-DiHETrE	30	34.05 (15.11, 76.74)	30.28 (13.44, 68.24)		-11% (-79, 275)	>0.80
NEOx	Cell	AA	Diol	8(9)-DiHETrE	60	32.02 (11.86, 86.43)	50.91 (18.86, 137.42)		59% (-83, 1373)	>0.80
Esterified	Media	AA	Diol	8(9)-DiHETrE	0	26.62 (11.38, 62.29)	23.24 (9.93, 54.39)	0.77	-13% (-85, 420)	>0.80
Esterified	Media	AA	Diol	8(9)-DiHETrE	15	23.59 (11.47, 48.49)	19.43 (9.45, 39.95)		-18% (-80, 236)	>0.80
Esterified	Media	AA	Diol	8(9)-DiHETrE	30	22.92 (10.9, 48.2)	17.82 (8.47, 37.47)		-22% (-79, 190)	>0.80
Esterified	Media	AA	Diol	8(9)-DiHETrE	60	28.51 (11.5, 70.7)	19.73 (7.96, 48.94)		-31% (-91, 430)	>0.80
NEOx	Media	AA	Diol	8(9)-DiHETrE	0	21.43 (4.95, 92.75)	18.81 (4.35, 81.43)	>0.80	-12% (-96, 1627)	>0.80
NEOx	Media	AA	Diol	8(9)-DiHETrE	15	13.36 (3.17, 56.31)	11.57 (2.74, 48.77)		-13% (-94, 1163)	>0.80
NEOx	Media	AA	Diol	8(9)-DiHETrE	30	10.96 (2.61, 45.95)	9.36 (2.23, 39.26)		-15% (-94, 1069)	>0.80
NEOx	Media	AA	Diol	8(9)-DiHETrE	60	16.82 (3.77, 75.07)	13.99 (3.13, 62.42)		-17% (-97, 1936)	>0.80
Esterified	Cell	AA	Epoxide	8(9)-EpETrE	0	0.34 (0.19, 0.63)	0.35 (0.19, 0.64)	0.64	3% (-71, 268)	>0.80
Esterified	Cell	AA	Epoxide	8(9)-EpETrE	15	0.44 (0.26, 0.73)	0.42 (0.25, 0.7)		-4% (-64, 159)	>0.80
Esterified	Cell	AA	Epoxide	8(9)-EpETrE	30	0.54 (0.32, 0.91)	0.48 (0.28, 0.81)		-10% (-65, 126)	>0.80
Esterified	Cell	AA	Epoxide	8(9)-EpETrE	60	0.68 (0.36, 1.31)	0.53 (0.28, 1.02)		-22% (-82, 236)	>0.80
NEOx	Cell	AA	Epoxide	8(9)-EpETrE	0	0.28 (0.14, 0.53)	0.28 (0.14, 0.53)	0.68	0% (-74, 291)	>0.80
NEOx	Cell	AA	Epoxide	8(9)-EpETrE	15	0.24 (0.14, 0.43)	0.26 (0.14, 0.46)		7% (-65, 225)	>0.80

NEOx	Cell	AA	Epoxide	8(9)-EpETrE	30	0.22 (0.12, 0.39)	0.25 (0.14, 0.44)		13% (-61, 226)	>0.80
NEOx	Cell	AA	Epoxide	8(9)-EpETrE	60	0.18 (0.09, 0.36)	0.23 (0.12, 0.46)		28% (-72, 488)	>0.80
Esterified	Media	AA	Epoxide	8(9)-EpETrE	0	0.19 (0.09, 0.37)	0.19 (0.1, 0.38)	0.45	2% (-76, 330)	>0.80
Esterified	Media	AA	Epoxide	8(9)-EpETrE	15	0.27 (0.15, 0.5)	0.24 (0.13, 0.45)		-10% (-72, 192)	>0.80
Esterified	Media	AA	Epoxide	8(9)-EpETrE	30	0.33 (0.18, 0.62)	0.27 (0.14, 0.5)		-20% (-74, 143)	>0.80
Esterified	Media	AA	Epoxide	8(9)-EpETrE	60	0.31 (0.15, 0.65)	0.2 (0.1, 0.41)		-37% (-88, 222)	>0.80
NEOx	Media	AA	Epoxide	8(9)-EpETrE	0	0.26 (0.12, 0.58)	0.27 (0.12, 0.6)	0.71	3% (-80, 420)	>0.80
NEOx	Media	AA	Epoxide	8(9)-EpETrE	15	0.27 (0.13, 0.57)	0.29 (0.14, 0.62)		8% (-74, 346)	>0.80
NEOx	Media	AA	Epoxide	8(9)-EpETrE	30	0.27 (0.13, 0.56)	0.3 (0.14, 0.64)		14% (-71, 350)	>0.80
NEOx	Media	AA	Epoxide	8(9)-EpETrE	60	0.24 (0.11, 0.54)	0.3 (0.13, 0.68)		28% (-78, 651)	>0.80
Esterified	Cell	EPA	Alcohol	9-HEPE	0	0.84 (0.52, 1.37)	0.55 (0.34, 0.9)	0.59	-34% (-76, 83)	>0.80
Esterified	Cell	EPA	Alcohol	9-HEPE	15	0.93 (0.63, 1.37)	0.57 (0.39, 0.84)		-39% (-71, 32)	0.39
Esterified	Cell	EPA	Alcohol	9-HEPE	30	0.97 (0.65, 1.46)	0.56 (0.37, 0.84)		-43% (-72, 16)	0.18
Esterified	Cell	EPA	Alcohol	9-HEPE	60	0.91 (0.54, 1.55)	0.46 (0.27, 0.77)		-50% (-85, 65)	0.49
NEOx	Cell	EPA	Alcohol	9-HEPE	0	0.63 (0.28, 1.43)	0.44 (0.19, 1)	0.59	-30% (-87, 288)	>0.80
NEOx	Cell	EPA	Alcohol	9-HEPE	15	0.67 (0.34, 1.29)	0.42 (0.21, 0.81)		-37% (-83, 130)	>0.80
NEOx	Cell	EPA	Alcohol	9-HEPE	30	0.74 (0.37, 1.49)	0.42 (0.21, 0.83)		-44% (-83, 87)	0.70
NEOx	Cell	EPA	Alcohol	9-HEPE	60	1.08 (0.45, 2.6)	0.48 (0.2, 1.17)		-55% (-94, 226)	>0.80
Esterified	Media	EPA	Alcohol	9-HEPE	0	0.4 (0.19, 0.84)	0.53 (0.25, 1.1)	0.56	30% (-71, 478)	>0.80
Esterified	Media	EPA	Alcohol	9-HEPE	15	0.38 (0.19, 0.78)	0.53 (0.26, 1.09)		39% (-64, 433)	>0.80
Esterified	Media	EPA	Alcohol	9-HEPE	30	0.38 (0.18, 0.77)	0.56 (0.27, 1.15)		49% (-60, 454)	>0.80
Esterified	Media	EPA	Alcohol	9-HEPE	60	0.42 (0.2, 0.9)	0.73 (0.34, 1.54)		72% (-65, 754)	>0.80
NEOx	Media	EPA	Alcohol	9-HEPE	0	0.55 (0.35, 0.86)	0.51 (0.33, 0.8)	0.61	-7% (-64, 139)	>0.80
NEOx	Media	EPA	Alcohol	9-HEPE	15	0.36 (0.25, 0.53)	0.36 (0.24, 0.52)		-1% (-53, 106)	>0.80
NEOx	Media	EPA	Alcohol	9-HEPE	30	0.3 (0.2, 0.44)	0.31 (0.21, 0.46)		4% (-48, 107)	>0.80
NEOx	Media	EPA	Alcohol	9-HEPE	60	0.38 (0.23, 0.61)	0.44 (0.27, 0.71)		17% (-60, 242)	>0.80
Esterified	Cell	DHA	Diol	Maresin 1	0	88 (44, 177)	29 (14, 58)	0.65	-67% (-92, 35)	0.18
Esterified	Cell	DHA	Diol	Maresin 1	15	91 (59, 142)	33 (21, 51)		-64% (-85, -13)	0.02
Esterified	Cell	DHA	Diol	Maresin 1	30	96 (58, 161)	38 (23, 63)		-61% (-81, -18)	0.008
Esterified	Cell	DHA	Diol	Maresin 1	60	114 (52, 247)	54 (25, 116)		-53% (-92, 166)	0.79
NEOx	Cell	DHA	Diol	Maresin 1	0	24.19 (6.64, 88.12)	23.42 (6.43, 85.29)	0.7	-3% (-94, 1355)	>0.80
NEOx	Cell	DHA	Diol	Maresin 1	15	24.6 (8.54, 70.88)	26.92 (9.34, 77.57)		9% (-86, 775)	>0.80
NEOx	Cell	DHA	Diol	Maresin 1	30	24.7 (8.19, 74.5)	30.56 (10.13, 92.16)		24% (-82, 751)	>0.80
NEOx	Cell	DHA	Diol	Maresin 1	60	23.98 (5.97, 96.34)	37.91 (9.44, 152.31)		58% (-93, 3496)	>0.80
Esterified	Media	DHA	Diol	Maresin 1	0	31.63 (11.61, 86.21)	25.82 (9.48, 70.37)	0.74	-18% (-89, 530)	>0.80
Esterified	Media	DHA	Diol	Maresin 1	15	59.34 (31.43, 112.03)	43.84 (23.22, 82.78)		-26% (-79, 165)	>0.80
Esterified	Media	DHA	Diol	Maresin 1	30	79.3 (37.95, 165.71)	53.03 (25.38, 110.83)		-33% (-77, 93)	>0.80
Esterified	Media	DHA	Diol	Maresin 1	60	51.22 (16.75, 156.63)	28.07 (9.18, 85.82)		-45% (-95, 563)	>0.80
NEOx	Media	DHA	Diol	Maresin 1	0	44.19 (15.63, 124.95)	40.08 (14.18, 113.34)	0.79	-9% (-89, 668)	>0.80
NEOx	Media	DHA	Diol	Maresin 1	15	60.13 (22.08, 163.76)	57.32 (21.05, 156.1)		-5% (-85, 526)	>0.80
NEOx	Media	DHA	Diol	Maresin 1	30	61.97 (22.77, 168.64)	62.08 (22.81, 168.93)		0% (-84, 522)	>0.80
NEOx	Media	DHA	Diol	Maresin 1	60	28.59 (9.81, 83.3)	31.62 (10.85, 92.15)		11% (-89, 1026)	>0.80
Esterified	Cell	AA	Prostanoid	PGD2	0	3.5 (1.8, 6.8)	4.4 (2.2, 8.5)	0.55	24% (-68, 389)	>0.80
Esterified	Cell	AA	Prostanoid	PGD2	15	4 (2.5, 6.3)	4.4 (2.8, 6.9)		11% (-55, 175)	>0.80
Esterified	Cell	AA	Prostanoid	PGD2	30	4.4 (2.6, 7.3)	4.3 (2.6, 7.2)		-1% (-55, 117)	>0.80
Esterified	Cell	AA	Prostanoid	PGD2	60	5.1 (2.4, 10.5)	4 (1.9, 8.3)		-22% (-85, 308)	>0.80
NEOx	Cell	AA	Prostanoid	PGD2	0	3.24 (0.85, 12.39)	2.09 (0.55, 7.99)	0.11	-36% (-95, 714)	>0.80
NEOx	Cell	AA	Prostanoid	PGD2	15	3.08 (0.79, 11.97)	2.41 (0.62, 9.39)		-22% (-93, 813)	>0.80
NEOx	Cell	AA	Prostanoid	PGD2	30	2.72 (0.7, 10.51)	2.59 (0.67, 10.02)		-5% (-92, 992)	>0.80
NEOx	Cell	AA	Prostanoid	PGD2	60	1.71 (0.45, 6.51)	2.41 (0.63, 9.19)		41% (-90, 1799)	>0.80
Esterified	Media	AA	Prostanoid	PGD2	0	2.9 (1.26, 6.68)	3.64 (1.58, 8.39)	0.51	25% (-78, 616)	>0.80
Esterified	Media	AA	Prostanoid	PGD2	15	3.21 (1.69, 6.1)	3.48 (1.83, 6.61)		8% (-70, 289)	>0.80
Esterified	Media	AA	Prostanoid	PGD2	30	3.47 (1.75, 6.89)	3.26 (1.64, 6.46)		-6% (-71, 199)	>0.80
Esterified	Media	AA	Prostanoid	PGD2	60	3.86 (1.56, 9.56)	2.71 (1.09, 6.7)		-30% (-91, 439)	>0.80
NEOx	Media	AA	Prostanoid	PGD2	0	2.99 (1.39, 6.47)	2.08 (0.96, 4.5)	0.23	-30% (-86, 249)	>0.80
NEOx	Media	AA	Prostanoid	PGD2	15	2.51 (1.37, 4.6)	2.23 (1.22, 4.1)		-11% (-73, 196)	>0.80
NEOx	Media	AA	Prostanoid	PGD2	30	2.17 (1.14, 4.13)	2.48 (1.3, 4.7)		14% (-62, 242)	>0.80
NEOx	Media	AA	Prostanoid	PGD2	60	1.81 (0.78, 4.17)	3.37 (1.46, 7.78)		87% (-71, 1122)	>0.80
Esterified	Cell	EPA	Prostanoid	PGD3	0	13.4 (5.1, 35.1)	24.2 (9.2, 63.4)	0.57	80% (-76, 1264)	>0.80
Esterified	Cell	EPA	Prostanoid	PGD3	15	9.5 (4.1, 21.9)	15 (6.5, 34.8)		59% (-69, 708)	>0.80
Esterified	Cell	EPA	Prostanoid	PGD3	30	8.7 (3.7, 20.5)	12.2 (5.2, 28.7)		40% (-70, 550)	>0.80
Esterified	Cell	EPA	Prostanoid	PGD3	60	16.2 (5.8, 45.1)	17.6 (6.3, 48.9)		9% (-89, 972)	>0.80
NEOx	Cell	EPA	Prostanoid	PGD3	0	21.96 (5.76, 83.64)	8.1 (2.13, 30.86)	0.23	-63% (-98, 493)	>0.80
NEOx	Cell	EPA	Prostanoid	PGD3	15	15.16 (4.34, 52.96)	7.74 (2.21, 27.04)		-49% (-95, 450)	>0.80
NEOx	Cell	EPA	Prostanoid	PGD3	30	11.61 (3.3, 40.83)	8.2 (2.33, 28.85)		-29% (-93, 596)	>0.80
NEOx	Cell	EPA	Prostanoid	PGD3	60	9.31 (2.32, 37.42)	12.6 (3.13, 50.63)		35% (-94, 2787)	>0.80
Esterified	Media	EPA	Prostanoid	PGD3	0	6.39 (2.33, 17.55)	10.29 (3.75, 28.25)	0.41	61% (-81, 1234)	>0.80
Esterified	Media	EPA	Prostanoid	PGD3	15	9.99 (4.48, 22.28)	12.95 (5.8, 28.88)		30% (-73, 532)	>0.80
Esterified	Media	EPA	Prostanoid	PGD3	30	13.95 (5.99, 32.51)	14.56 (6.25, 33.93)		4% (-76, 348)	>0.80
Esterified	Media	EPA	Prostanoid	PGD3	60	19.46 (6.52, 58.07)	13.17 (4.42, 39.31)		-32% (-94, 691)	>0.80
NEOx	Media	EPA	Prostanoid	PGD3	0	15.42 (4.5, 52.86)	15.67 (4.57, 53.72)	0.63	2% (-92, 1234)	>0.80
NEOx	Media	EPA	Prostanoid	PGD3	15	15.14 (4.98, 46.03)	13.55 (4.46, 41.2)		-10% (-89, 657)	>0.80
NEOx	Media	EPA	Prostanoid	PGD3	30	13.13 (4.25, 40.55)	10.36 (3.35, 31.97)		-21% (-90, 504)	>0.80
NEOx	Media	EPA	Prostanoid	PGD3	60	6.83 (1.87, 24.96)	4.18 (1.14, 15.27)		-39% (-97, 988)	>0.80
Esterified	Cell	dgLA	Prostanoid	PGE1	0	1.66 (0.59, 4.68)	1.46 (0.52, 4.11)	0.6	-12% (-90, 672)	>0.80
Esterified	Cell	dgLA	Prostanoid	PGE1	15	1.26 (0.54, 2.96)	0.97 (0.41, 2.27)		-23% (-86, 308)	>0.80
Esterified	Cell	dgLA	Prostanoid	PGE1	30	1.03 (0.42, 2.5)	0.69 (0.28, 1.68)		-33% (-86, 216)	>0.80
Esterified	Cell	dgLA	Prostanoid	PGE1	60	0.85 (0.28, 2.6)	0.43 (0.14, 1.33)		-49% (-96, 524)	>0.80
NEOx	Cell	dgLA	Prostanoid	PGE1	0	0.87 (0.28, 2.67)	0.37 (0.12, 1.14)	0.25	-57% (-96, 351)	>0.80
NEOx	Cell	dgLA	Prostanoid	PGE1	15	0.97 (0.37, 2.54)	0.57 (0.22, 1.48)		-42% (-91, 276)	>0.80
NEOx	Cell	dgLA	Prostanoid	PGE1	30	0.99 (0.37, 2.66)	0.79 (0.29, 2.12)		-20% (-86, 358)	>0.80
NEOx	Cell	dgLA	Prostanoid	PGE1	60	0.76 (0.23, 2.53)	1.13 (0.34, 3.76)		49% (-90, 2089)	>0.80
NEOx	Media	dgLA	Prostanoid	PGE1	0	2.82 (1.01, 7.87)	1.54 (0.55, 4.28)	0.59	-46% (-94, 364)	>0.80
NEOx	Media	dgLA	Prostanoid	PGE1	15	1.73 (0.78, 3.82)	1.08 (0.49, 2.4)		-37% (-87, 203)	>0.80
NEOx	Media	dgLA	Prostanoid	PGE1	30	1.32 (0.57, 3.07)	0.96 (0.41, 2.22)		-28% (-83, 204)	>0.80

NEOx	Media	dgLA	Prostanoid	PGE1	60	1.5 (0.49, 4.56)	1.44 (0.47, 4.4)		-4% (-92, 1083)	>0.80
Esterified	Cell	AA	Prostanoid	PGE2	0	14 (6, 32.4)	9.8 (4.2, 22.6)	0.5	-30% (-88, 305)	>0.80
Esterified	Cell	AA	Prostanoid	PGE2	15	15.4 (8.1, 29.4)	9.2 (4.9, 17.6)		-40% (-83, 116)	>0.80
Esterified	Cell	AA	Prostanoid	PGE2	30	16.9 (8.5, 33.7)	8.7 (4.4, 17.4)		-48% (-84, 65)	0.52
Esterified	Cell	AA	Prostanoid	PGE2	60	20.1 (8.1, 50.4)	7.7 (3.1, 19.2)		-62% (-95, 200)	0.72
NEOx	Cell	AA	Prostanoid	PGE2	0	2.53 (0.62, 10.42)	5.48 (1.33, 22.53)	0.33	116% (-89, 4093)	>0.80
NEOx	Cell	AA	Prostanoid	PGE2	15	5.05 (1.59, 16.11)	7.74 (2.43, 24.66)		53% (-84, 1392)	>0.80
NEOx	Cell	AA	Prostanoid	PGE2	30	8.74 (2.61, 29.28)	9.47 (2.83, 31.74)		8% (-87, 796)	>0.80
NEOx	Cell	AA	Prostanoid	PGE2	60	17.07 (3.73, 78.12)	9.28 (2.03, 42.46)		-46% (-98, 1557)	>0.80
Esterified	Media	AA	Prostanoid	PGE2	0	9.12 (2.47, 33.67)	4.02 (1.09, 14.83)	>0.80	-56% (-97, 582)	>0.80
Esterified	Media	AA	Prostanoid	PGE2	15	9.38 (3.14, 28.03)	4.18 (1.4, 12.48)		-55% (-95, 278)	>0.80
Esterified	Media	AA	Prostanoid	PGE2	30	9.47 (3.05, 29.4)	4.26 (1.37, 13.23)		-55% (-94, 232)	>0.80
Esterified	Media	AA	Prostanoid	PGE2	60	9.1 (2.25, 36.86)	4.18 (1.03, 16.94)		-54% (-98, 960)	>0.80
NEOx	Media	AA	Prostanoid	PGE2	0	14.14 (3.78, 52.91)	13.84 (3.7, 51.77)	0.62	-2% (-94, 1455)	>0.80
NEOx	Media	AA	Prostanoid	PGE2	15	9.1 (2.87, 28.8)	10.35 (3.27, 32.77)		14% (-88, 960)	>0.80
NEOx	Media	AA	Prostanoid	PGE2	30	6.81 (2.09, 22.12)	9 (2.77, 29.26)		32% (-84, 990)	>0.80
NEOx	Media	AA	Prostanoid	PGE2	60	5.99 (1.48, 24.3)	10.71 (2.64, 43.44)		79% (-92, 3982)	>0.80
Esterified	Cell	EPA	Prostanoid	PGE3	0	28.7 (11.1, 74.1)	25.8 (10, 66.5)	>0.80	-10% (-88, 548)	>0.80
Esterified	Cell	EPA	Prostanoid	PGE3	15	20.7 (10.2, 41.9)	17.9 (8.8, 36.2)		-14% (-79, 253)	>0.80
Esterified	Cell	EPA	Prostanoid	PGE3	30	17 (7.9, 36.5)	14.1 (6.6, 30.3)		-17% (-76, 194)	>0.80
Esterified	Cell	EPA	Prostanoid	PGE3	60	17.1 (6.1, 48.2)	13.2 (4.7, 37.2)		-23% (-93, 694)	>0.80
NEOx	Cell	EPA	Prostanoid	PGE3	0	17.07 (3.97, 73.47)	14.91 (3.46, 64.2)	>0.80	-13% (-96, 1737)	>0.80
NEOx	Cell	EPA	Prostanoid	PGE3	15	7.48 (1.97, 28.41)	6.96 (1.83, 26.43)		-7% (-93, 1095)	>0.80
NEOx	Cell	EPA	Prostanoid	PGE3	30	5.57 (1.45, 21.47)	5.52 (1.43, 21.26)		-1% (-91, 1040)	>0.80
NEOx	Cell	EPA	Prostanoid	PGE3	60	15.23 (3.3, 70.27)	17.09 (3.7, 78.86)		12% (-96, 3223)	>0.80
Esterified	Media	EPA	Prostanoid	PGE3	0	9.91 (3.41, 28.79)	13 (4.48, 37.76)	0.66	31% (-86, 1098)	>0.80
Esterified	Media	EPA	Prostanoid	PGE3	15	11.65 (5.41, 25.09)	13.4 (6.22, 28.87)		15% (-75, 434)	>0.80
Esterified	Media	EPA	Prostanoid	PGE3	30	12.53 (5.41, 29.02)	12.64 (5.46, 29.28)		1% (-74, 293)	>0.80
Esterified	Media	EPA	Prostanoid	PGE3	60	11.09 (3.44, 35.77)	8.6 (2.67, 27.76)		-22% (-94, 977)	>0.80
NEOx	Media	EPA	Prostanoid	PGE3	0	21.15 (7.85, 57)	7.69 (2.85, 20.74)	0.79	-64% (-95, 184)	0.68
NEOx	Media	EPA	Prostanoid	PGE3	15	18.5 (9.12, 37.53)	7.24 (3.57, 14.69)		-61% (-91, 61)	0.35
NEOx	Media	EPA	Prostanoid	PGE3	30	15.81 (7.27, 34.39)	6.65 (3.06, 14.47)		-58% (-88, 47)	0.30
NEOx	Media	EPA	Prostanoid	PGE3	60	10.76 (3.61, 32.02)	5.24 (1.76, 15.59)		-51% (-96, 463)	>0.80
Esterified	Cell	AA	Prostanoid	PGF2a	0	6.3 (1.8, 22.3)	9.5 (2.7, 33.6)	0.18	51% (-89, 2009)	>0.80
Esterified	Cell	AA	Prostanoid	PGF2a	15	4.6 (1.5, 14.7)	4.8 (1.5, 15.4)		4% (-89, 853)	>0.80
Esterified	Cell	AA	Prostanoid	PGF2a	30	4.9 (1.5, 15.7)	3.5 (1.1, 11.3)		-28% (-91, 499)	>0.80
Esterified	Cell	AA	Prostanoid	PGF2a	60	15.8 (4.2, 59.5)	5.5 (1.5, 20.6)		-65% (-98, 551)	>0.80
NEOx	Cell	AA	Prostanoid	PGF2a	0	10.34 (2.5, 42.76)	5.58 (1.35, 23.08)	0.78	-46% (-97, 893)	>0.80
NEOx	Cell	AA	Prostanoid	PGF2a	15	10.65 (2.69, 42.12)	6.16 (1.56, 24.36)		-42% (-96, 661)	>0.80
NEOx	Cell	AA	Prostanoid	PGF2a	30	9.85 (2.5, 38.85)	6.1 (1.55, 24.07)		-38% (-95, 658)	>0.80
NEOx	Cell	AA	Prostanoid	PGF2a	60	6.07 (1.41, 26.08)	4.31 (1, 18.54)		-29% (-97, 1566)	>0.80
Esterified	Media	AA	Prostanoid	PGF2a	0	16.66 (5.24, 52.93)	7.3 (2.3, 23.19)	0.61	-56% (-96, 395)	>0.80
Esterified	Media	AA	Prostanoid	PGF2a	15	12.33 (4.59, 33.16)	6.22 (2.31, 16.72)		-50% (-93, 246)	>0.80
Esterified	Media	AA	Prostanoid	PGF2a	30	10.32 (3.73, 28.54)	5.99 (2.16, 16.56)		-42% (-90, 254)	>0.80
Esterified	Media	AA	Prostanoid	PGF2a	60	10.4 (3.03, 35.68)	7.99 (2.33, 27.41)		-23% (-95, 1115)	>0.80
NEOx	Media	AA	Prostanoid	PGF2a	0	5.1 (1.49, 17.45)	8.47 (2.48, 28.99)	0.52	66% (-87, 2054)	>0.80
NEOx	Media	AA	Prostanoid	PGF2a	15	5.39 (1.73, 16.78)	7.61 (2.45, 23.66)		41% (-84, 1128)	>0.80
NEOx	Media	AA	Prostanoid	PGF2a	30	6.3 (2.01, 19.79)	7.54 (2.4, 23.67)		20% (-85, 854)	>0.80
NEOx	Media	AA	Prostanoid	PGF2a	60	11.58 (3.2, 41.88)	9.98 (2.76, 36.1)		-14% (-95, 1377)	>0.80
Esterified	Cell	EPA	Prostanoid	PGF3a	0	217 (68, 691)	158 (50, 502)	0.52	-27% (-93, 676)	>0.80
Esterified	Cell	EPA	Prostanoid	PGF3a	15	212 (100, 449)	124 (58, 262)		-42% (-87, 164)	>0.80
Esterified	Cell	EPA	Prostanoid	PGF3a	30	214 (90, 506)	100 (42, 237)		-53% (-87, 67)	0.47
Esterified	Cell	EPA	Prostanoid	PGF3a	60	240 (66, 868)	72 (20, 262)		-70% (-98, 437)	>0.80
NEOx	Cell	EPA	Prostanoid	PGF3a	0	210 (59.09, 746.31)	89.4 (25.15, 317.71)	0.33	-57% (-97, 495)	>0.80
NEOx	Cell	EPA	Prostanoid	PGF3a	15	186.15 (57.24, 605.39)	101.9 (31.33, 331.41)		-45% (-94, 416)	>0.80
NEOx	Cell	EPA	Prostanoid	PGF3a	30	153.83 (46.94, 504.13)	108.29 (33.04, 354.88)		-30% (-92, 508)	>0.80
NEOx	Cell	EPA	Prostanoid	PGF3a	60	85.11 (22.7, 319.1)	99.07 (26.42, 371.45)		16% (-94, 2045)	>0.80
Esterified	Media	EPA	Prostanoid	PGF3a	0	273.07 (82.52, 903.6)	223.08 (67.42, 738.16)	0.69	-18% (-93, 860)	>0.80
Esterified	Media	EPA	Prostanoid	PGF3a	15	184.74 (82.01, 416.18)	173.29 (76.92, 390.37)		-6% (-82, 380)	>0.80
Esterified	Media	EPA	Prostanoid	PGF3a	30	154.63 (62.12, 384.93)	166.54 (66.9, 414.58)		8% (-74, 340)	>0.80
Esterified	Media	EPA	Prostanoid	PGF3a	60	205.15 (54.56, 771.41)	291.31 (77.47, 1095.38)		42% (-93, 2658)	>0.80
NEOx	Media	EPA	Prostanoid	PGF3a	0	298.54 (97.23, 916.67)	154.68 (50.38, 474.94)	>0.80	-48% (-95, 440)	>0.80
NEOx	Media	EPA	Prostanoid	PGF3a	15	188.55 (68.2, 521.3)	96.96 (35.07, 268.07)		-49% (-93, 262)	>0.80
NEOx	Media	EPA	Prostanoid	PGF3a	30	141.58 (50.56, 396.5)	72.26 (25.8, 202.36)		-49% (-92, 228)	>0.80
NEOx	Media	EPA	Prostanoid	PGF3a	60	134.16 (41.29, 435.87)	67.44 (20.76, 219.12)		-50% (-96, 588)	>0.80
Esterified	Cell	DHA	Diol	Protectin D1	0	1.43 (0.45, 4.57)	2.36 (0.74, 7.55)	0.38	65% (-85, 1665)	>0.80
Esterified	Cell	DHA	Diol	Protectin D1	15	1.44 (0.46, 4.51)	2 (0.64, 6.28)		39% (-83, 1069)	>0.80
Esterified	Cell	DHA	Diol	Protectin D1	30	1.62 (0.52, 5.04)	1.89 (0.61, 5.91)		17% (-85, 836)	>0.80
Esterified	Cell	DHA	Diol	Protectin D1	60	2.8 (0.85, 9.2)	2.33 (0.71, 7.66)		-17% (-93, 960)	>0.80
NEOx	Cell	DHA	Diol	Protectin D1	0	2.02 (0.93, 4.39)	0.9 (0.42, 1.97)	0.7	-55% (-91, 128)	0.67
NEOx	Cell	DHA	Diol	Protectin D1	15	2.1 (1.15, 3.85)	1.02 (0.55, 1.86)		-52% (-85, 61)	0.45
NEOx	Cell	DHA	Diol	Protectin D1	30	1.97 (1.03, 3.74)	1.03 (0.54, 1.95)		-48% (-83, 56)	0.47
NEOx	Cell	DHA	Diol	Protectin D1	60	1.25 (0.54, 2.91)	0.76 (0.33, 1.78)		-39% (-91, 307)	>0.80
Esterified	Media	DHA	Diol	Protectin D1	0	2.51 (1.15, 5.48)	1.38 (0.63, 3.01)	0.35	-45% (-88, 160)	>0.80
Esterified	Media	DHA	Diol	Protectin D1	15	1.79 (1.16, 2.77)	1.24 (0.8, 1.91)		-31% (-71, 62)	0.78
Esterified	Media	DHA	Diol	Protectin D1	30	1.47 (0.86, 2.52)	1.27 (0.74, 2.18)		-14% (-54, 61)	>0.80
Esterified	Media	DHA	Diol	Protectin D1	60	1.51 (0.63, 3.63)	2.05 (0.85, 4.93)		36% (-80, 842)	>0.80
NEOx	Media	DHA	Diol	Protectin D1	0	2.12 (0.87, 5.14)	1.26 (0.52, 3.07)	>0.80	-40% (-91, 280)	>0.80
NEOx	Media	DHA	Diol	Protectin D1	15	1.83 (0.82, 4.08)	1.09 (0.49, 2.43)		-40% (-87, 178)	>0.80
NEOx	Media	DHA	Diol	Protectin D1	30	1.79 (0.79, 4.03)	1.07 (0.47, 2.4)		-40% (-86, 159)	>0.80
NEOx	Media	DHA	Diol	Protectin D1	60	2.48 (0.98, 6.29)	1.48 (0.58, 3.75)		-40% (-92, 370)	>0.80
Esterified	Cell	dgLA	Prostanoid	TXB1	0	37 (15, 90)	19 (8, 46)	0.09	-48% (-92, 228)	>0.80
Esterified	Cell	dgLA	Prostanoid	TXB1	15	48 (25, 93)	39 (20, 74)		-20% (-78, 194)	>0.80
Esterified	Cell	dgLA	Prostanoid	TXB1	30	47 (23, 95)	58 (29, 118)		24% (-61, 296)	>0.80
Esterified	Cell	dgLA	Prostanoid	TXB1	60	18 (7, 48)	53 (20, 141)		196% (-67, 2538)	0.67

NEOx	Cell	dgLA	Prostanoid	TXB1	0	17.95 (7.99, 40.33)	6.16 (2.74, 13.84)	0.26	-66% (-94, 87)	0.40
NEOx	Cell	dgLA	Prostanoid	TXB1	15	14.65 (7.27, 29.54)	6.22 (3.08, 12.54)		-58% (-89, 66)	0.40
NEOx	Cell	dgLA	Prostanoid	TXB1	30	10.31 (5.03, 21.17)	5.42 (2.64, 11.12)		-47% (-85, 90)	0.66
NEOx	Cell	dgLA	Prostanoid	TXB1	60	3.28 (1.39, 7.75)	2.64 (1.12, 6.24)		-20% (-88, 451)	>0.80
Esterified	Media	dgLA	Prostanoid	TXB1	0	36.82 (17.49, 77.51)	27.25 (12.94, 57.37)	0.23	-26% (-84, 249)	>0.80
Esterified	Media	dgLA	Prostanoid	TXB1	15	39.49 (22.73, 68.61)	37.35 (21.5, 64.89)		-5% (-69, 185)	>0.80
Esterified	Media	dgLA	Prostanoid	TXB1	30	34.93 (19.22, 63.48)	42.21 (23.23, 76.71)		21% (-55, 225)	>0.80
Esterified	Media	dgLA	Prostanoid	TXB1	60	15.33 (6.79, 34.62)	30.25 (13.4, 68.3)		97% (-68, 1131)	>0.80
NEOx	Media	dgLA	Prostanoid	TXB1	0	11.33 (6.71, 19.13)	10.5 (6.22, 17.73)	0.48	-7% (-68, 172)	>0.80
NEOx	Media	dgLA	Prostanoid	TXB1	15	10.74 (7.54, 15.28)	11.08 (7.78, 15.76)		3% (-49, 110)	>0.80
NEOx	Media	dgLA	Prostanoid	TXB1	30	10.12 (6.8, 15.06)	11.62 (7.81, 17.3)		15% (-38, 111)	>0.80
NEOx	Media	dgLA	Prostanoid	TXB1	60	8.86 (4.96, 15.83)	12.61 (7.06, 22.52)		42% (-61, 422)	>0.80
Esterified	Cell	AA	Prostanoid	TXB2	0	5.2 (2.6, 10.6)	3.7 (1.8, 7.5)	0.68	-30% (-84, 208)	>0.80
Esterified	Cell	AA	Prostanoid	TXB2	15	4.4 (2.5, 7.9)	3.4 (1.9, 6)		-25% (-76, 135)	>0.80
Esterified	Cell	AA	Prostanoid	TXB2	30	4.1 (2.3, 7.6)	3.4 (1.8, 6.1)		-19% (-72, 133)	>0.80
Esterified	Cell	AA	Prostanoid	TXB2	60	4.7 (2.2, 10.1)	4.4 (2.1, 9.5)		-6% (-83, 416)	>0.80
NEOx	Cell	AA	Prostanoid	TXB2	0	4.20 (1.9, 9.29)	1.96 (0.89, 4.33)	0.06	-53% (-91, 146)	0.74
NEOx	Cell	AA	Prostanoid	TXB2	15	3.75 (1.88, 7.48)	2.51 (1.26, 5.01)		-33% (-82, 155)	>0.80
NEOx	Cell	AA	Prostanoid	TXB2	30	3.08 (1.52, 6.25)	2.96 (1.46, 6.01)		-4% (-73, 240)	>0.80
NEOx	Cell	AA	Prostanoid	TXB2	60	1.62 (0.70, 3.77)	3.22 (1.39, 7.49)		98% (-70, 1206)	>0.80
Esterified	Media	AA	Prostanoid	TXB2	0	3.86 (1.84, 8.13)	3.7 (1.76, 7.79)	0.64	-4% (-79, 341)	>0.80
Esterified	Media	AA	Prostanoid	TXB2	15	4.05 (2.49, 6.60)	3.51 (2.16, 5.72)		-13% (-67, 131)	>0.80
Esterified	Media	AA	Prostanoid	TXB2	30	4.04 (2.32, 7.05)	3.17 (1.82, 5.53)		-22% (-66, 80)	>0.80
Esterified	Media	AA	Prostanoid	TXB2	60	3.47 (1.52, 7.94)	2.23 (0.97, 5.09)		-36% (-90, 307)	>0.80
NEOx	Media	AA	Prostanoid	TXB2	0	5.93 (3.19, 11.01)	2.6 (1.4, 4.82)	0.11	-56% (-88, 56)	0.37
NEOx	Media	AA	Prostanoid	TXB2	15	3.87 (2.58, 5.81)	2.29 (1.53, 3.44)		-41% (-74, 34)	0.38
NEOx	Media	AA	Prostanoid	TXB2	30	2.72 (1.71, 4.33)	2.18 (1.37, 3.47)		-20% (-60, 60)	>0.80
NEOx	Media	AA	Prostanoid	TXB2	60	1.7 (0.85, 3.37)	2.49 (1.25, 4.95)		47% (-68, 583)	>0.80
Esterified	Cell	EPA	Prostanoid	TXB3	0	6.9 (2.8, 17.3)	8.5 (3.4, 21.3)	>0.80	23% (-80, 654)	>0.80
Esterified	Cell	EPA	Prostanoid	TXB3	15	7.1 (4.4, 11.5)	8.2 (5.1, 13.3)		16% (-55, 194)	>0.80
Esterified	Cell	EPA	Prostanoid	TXB3	30	7.0 (3.8, 13.1)	7.6 (4.1, 14.2)		9% (-42, 102)	>0.80
Esterified	Cell	EPA	Prostanoid	TXB3	60	6.0 (2.1, 17.0)	5.8 (2.0, 16.3)		-4% (-90, 845)	>0.80
NEOx	Cell	EPA	Prostanoid	TXB3	0	8.36 (3.54, 19.75)	3.33 (1.41, 7.87)	0.56	-60% (-93, 122)	0.59
NEOx	Cell	EPA	Prostanoid	TXB3	15	8.24 (5.08, 13.39)	3.83 (2.36, 6.23)		-53% (-82, 21)	0.17
NEOx	Cell	EPA	Prostanoid	TXB3	30	8.31 (4.57, 15.11)	4.51 (2.48, 8.20)		-46% (-73, 11)	0.12
NEOx	Cell	EPA	Prostanoid	TXB3	60	9.03 (3.43, 23.79)	6.68 (2.54, 17.58)		-26% (-91, 528)	>0.80
Esterified	Media	EPA	Prostanoid	TXB3	0	7.5 (3.31, 17.02)	6.45 (2.84, 14.64)	>0.80	-14% (-85, 379)	>0.80
Esterified	Media	EPA	Prostanoid	TXB3	15	6.78 (3.29, 13.95)	5.6 (2.72, 11.53)		-17% (-80, 233)	>0.80
Esterified	Media	EPA	Prostanoid	TXB3	30	6.5 (3.11, 13.57)	5.16 (2.47, 10.77)		-21% (-79, 197)	>0.80
Esterified	Media	EPA	Prostanoid	TXB3	60	7.14 (3, 17)	5.23 (2.2, 12.45)		-27% (-89, 407)	>0.80
NEOx	Media	EPA	Prostanoid	TXB3	0	11.31 (5.58, 22.92)	9.46 (4.67, 19.18)	>0.80	-16% (-81, 264)	>0.80
NEOx	Media	EPA	Prostanoid	TXB3	15	9.25 (4.79, 17.85)	7.52 (3.9, 14.52)		-19% (-77, 184)	>0.80
NEOx	Media	EPA	Prostanoid	TXB3	30	7.93 (4.09, 15.37)	6.27 (3.24, 12.16)		-21% (-76, 163)	>0.80
NEOx	Media	EPA	Prostanoid	TXB3	60	6.73 (3.22, 14.06)	5.03 (2.41, 10.5)		-25% (-85, 279)	>0.80

Supplemental Table 16: Eigenvalues for each component

PC	Eigenvalue	%
1	16.0	28.6
2	11.0	19.7
3	7.7	13.7
4	2.4	4.2
5	1.9	3.4
6	1.7	3.1
7	1.6	2.8
8	1.5	2.7
9	1.3	2.4
10	1.2	2.2
11	1.2	2.1
12	1.1	1.9
13+	7.4	13.2
Total	**56.0**	



Supplemental Table 17. Principal Components: Loading matrix

	Prin1	Prin2	Prin3	Sum sq (PC 1-3)
18-HEPE	0.626	0.252	-0.702	**0.95**
15-HETE	-0.525	0.773	-0.127	**0.89**
12-HETE	-0.136	0.916	0.154	**0.88**
14(15)-EpETE	0.794	0.451	-0.194	**0.87**
8(9)-EpETrE	0.815	-0.170	-0.413	**0.86**
12(13)-EpOME	0.844	0.304	-0.195	0.84
15-HEPE	-0.587	-0.305	-0.635	0.84
9-HODE	0.766	0.496	0.069	0.84
13-HODE	0.887	0.175	0.135	0.83
17(18)-EpETE	0.608	0.587	-0.344	0.83
9-KODE	0.135	0.886	0.157	0.83
5-KETE	0.301	0.642	-0.563	0.82
8(9)-DiHETrE	0.788	-0.079	0.435	0.82
12(13)-DiHOME	-0.597	0.563	-0.369	0.81
9-HEPE	0.673	-0.349	-0.473	0.80
16(17)-EpDPE	0.834	-0.217	0.228	0.79
9(10)-EpOME	0.872	-0.142	-0.021	0.78
5-HETE	-0.575	0.635	-0.165	0.76
9-HOTrE	0.591	-0.636	-0.034	0.75
15-KETE	0.775	-0.293	0.238	0.74
14(15)-EpETrE	0.342	0.327	0.717	0.74

20-HDoHE	0.622	-0.075	0.585	0.73
17(18)-DiHETE	0.378	0.709	-0.278	0.72
12-KETE	0.663	0.248	-0.464	0.72
11(12)-EpETE	0.717	0.441	0.052	0.71
8(9)-DiHETE	-0.652	0.499	-0.156	0.70
8-HDoHE	0.130	0.407	0.671	0.63
11(12)-DiHETrE	0.629	-0.157	-0.451	0.62
15-HpETE	0.269	-0.704	-0.232	0.62
9(10)-DiHOME	0.188	0.702	-0.300	0.62
19(20)-EpDPE	-0.021	0.221	0.750	0.61
14(15)-DiHETE	0.364	0.398	-0.560	0.60
9-HETE	**-0.520**	**-0.345**	**0.451**	**0.59**
13(14)-EpDPE	0.685	-0.122	0.328	0.59
14-HDoHE	0.156	0.664	0.355	0.59
8-HEPE	0.710	-0.273	0.065	0.58
11-HEPE	0.100	-0.726	-0.192	0.57
8(9)-EpETE	0.301	0.540	0.365	0.52
5-HEPE	0.108	-0.706	0.079	0.52
12-HpETE	0.409	-0.040	0.585	0.51
7-HDoHE	0.686	0.180	-0.080	0.51
13-HOTrE	0.666	-0.094	-0.202	0.49
4-HDoHE	-0.039	-0.188	0.655	0.47
13-KODE	-0.395	0.301	0.434	0.44
17-HDoHE	-0.069	0.459	0.463	0.43
11(12)-EpETrE	0.313	-0.539	-0.155	0.41
7(8)-EpDPE	0.604	0.098	-0.052	0.38
14(15)-DiHETrE	-0.556	0.119	-0.215	0.37
22-HDoHE	0.209	-0.457	0.336	0.37
10(11)-EpDPE	0.561	-0.168	0.077	0.35
10-HDoHE	0.383	0.439	0.007	0.34
12-HEPE	0.497	0.241	0.184	0.34
11(12)-DiHETE	0.204	0.030	0.539	0.33
13-HDoHE	0.043	0.418	0.309	0.27
11-HDoHE	0.251	0.149	0.049	0.09
16-HDoHE	0.116	-0.105	-0.069	0.03